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ABSTRACT 
Increased angiogenesis in the synovium is a hallmark of rheumatoid arthritis (RA), 
and is thought to be driven by the presence of both local regions of reduced oxygen tension 
(hypoxia) and inflammatory cytokines in the synovium. RA fibroblast-like synoviocytes 
(FLS) are the main cell type at the proliferating and invading edge of the pannus, and are 
therefore likely to be exposed to the greatest degree of hypoxia. In culture, RA FLS can 
secrete a plethora of angiogenic factors in response to hypoxia and inflammatory cytokines, 
and these cells are thus potential regulators of synovial angiogenesis. Transcriptional control 
of many hypoxia-inducible genes, including several involved in angiogenesis, occurs via 
hypoxia-inducible factor (HIF)-1α and/or HIF-2α, powerful transcription factors known to be 
induced by hypoxia and cytokines.  
The regulation of HIFs by hypoxia and inflammatory cytokines (tumour necrosis 
factor α, interleukin-1β and transforming growth factor β) was studied in RA FLS. The main 
findings were that HIF-1α mRNA was downregulated in hypoxia (1% oxygen) possibly due 
to a simultaneous upregulation of a natural antisense to HIF-1α, aHIF. HIF-2α was also 
shown to be negatively regulated by hypoxia at the mRNA level but the mechanisms behind 
this were not uncovered in the present study. Cytokines induced HIF-1α mRNA, protein and 
activity but reduced levels of HIF-2α mRNA. The description of regulation of HIF-1α by 
cytokines such as tumour necrosis factor α, supports the concept that HIF transcription factors 
may represent a key convergence point in RA for hypoxia and cytokines. 
In addition to studying the regulation of HIFs by inflammatory cytokines and 
hypoxia, 84 angiogenic genes were investigated for their hypoxia-responsiveness in RA FLS 
by PCR array screening. Two genes, angiopoietin-like 4 (ANGPTL-4) and leptin, were 
strongly induced in response to hypoxia in RA FLS in comparison to cells grown in normoxia 
(21% oxygen). Small interfering RNA technology was used to transiently knock-down HIF-
1α and/or HIF-2α which demonstrated that the hypoxia-inducibility of both ANGPTL-4 and 
leptin was dependent on HIFs, but that ANGPTL-4 induction was mainly HIF-1α dependent, 
compared to leptin which seemed to be regulated predominantly by HIF-2α. The secretion of 
leptin was measured by ELISA, and the functional significance of RA FLS-derived leptin in 
angiogenesis was further investigated using ELISAs and an MTT assay. As leptin has been 
reported to be elevated in the serum and synovial fluid of RA patients, leptin may represent a 
future target for anti-angiogenic therapy in RA. 
The research described in this thesis aimed to gain a better understanding of how 
HIFs are regulated by hypoxia and cytokines in RA FLS, using FLS grown from total 
dissociated human RA synovial membranes, and hereby to understand what governs the 
production of angiogenic factors in the RA synovial milieu. 
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1 INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown aetiology 
affecting approximately 1-3% of the world population. RA fibroblast-like synoviocytes (FLS) 
are thought to contribute to pathological angiogenesis, a key feature of the intra-articular 
destruction in RA, and a process which is thought to sustain inflammation and synovial 
hyperplasia in the arthritic joint. Several of the angiogenic factors present in the rheumatoid 
joint are known to be regulated by hypoxia-inducible factors (HIFs) in RA FLS. These 
transcription factors rapidly accumulate in cells exposed to hypoxia, and coordinate several 
changes in gene transcription aimed at securing cell survival and restoring oxygen levels in 
deprived tissue. Such changes include angiogenesis made possible through the induction of 
HIF-dependent angiogenic genes. 
The present work was aimed at shedding light on the role and regulation of HIFs in 
RA FLS by hypoxia and inflammatory cytokines, which are known to be abundant in the 
synovium and to be involved in RA pathology. The study also aimed at discovering novel 
hypoxia-regulated genes in RA FLS that might contribute to pathological angiogenesis in RA, 
and to determine the involvement of HIFs in their regulation. 
1.1 HYPOXIA IN HEALTH AND DISEASE 
Metazoan organisms are dependent on a continuous supply of oxygen for survival. 
Hypoxia, that is a decrease in the oxygen concentration, is a fundamental physiological 
stimulus that occurs in response to tissue growth during normal development (Krishnan et al. 
2008), physiology (during the female menstrual cycle), as well as in disease states, such as 
anaemia, haemorrhage, pneumonia, wound healing, chronic kidney disease, solid tumours and 
in RA. Common to the state of hypoxia is that there is a deficiency in the amount of oxygen 
reaching tissues. This can either be due to an increase in the distance from tissues to existing 
vasculature, making diffusion distances too great for the proper distribution of oxygen and 
nutrients generating local tissue hypoxia, or through a decreased oxygenation of blood in the 
diseased lungs such as that occurring during systemic hypoxia. Atmospheric oxygen content 
is about 21% (160mmHg), which is much higher than in vivo oxygen levels. Oxygen tensions 
in normal tissues range from approximately 6% to 15% (46mmHg to 114mmHg) depending 
on the tissue type. For instance, arterial blood contains 15% oxygen (114mmHg) and venous 
blood 6% oxygen (46 mmHg). Measurements in joint synovium from healthy individuals has 
shown to range from 8.5% to 13.5% oxygen (65mmHg to 103mmHg) (Sivakumar et al. 
2008), and solid hypoxic tumours have been reported to have a mean oxygen tension of 1.5% 
oxygen (11mmHg) (Jiang et al. 1996). Mean synovial oxygen tension has been reported to be 
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2.4% to 4.4% oxygen (18mmHg to 33mmHg) in RA synovium (Sivakumar et al. 2008), and 
5.7% oxygen (43mmHg) in synovial fluid in osteoarthritis (OA) patients (Lund-Olesen 1970). 
The principal regulator of the adaptive response to hypoxia is HIF-1, which was first 
discovered by Wang and Semenza (Wang and Semenza 1995). HIF-1α protein levels and 
HIF-1 activity have been measured and seen to vary inversely with a range of 0.5% to 21% 
oxygen (4mmHg to 160mmHg) where the hypoxic response was reported to be maximal at 
0.5% (4mmHg) and with an increase in HIF-1α protein commencing at 6% (46mmHg) (Jiang 
et al. 1996). Wiesener et al. reported a much stronger accumulation of both HIF-1α and the 
HIF isoform HIF-2α under anoxic conditions (the absence or near absence of oxygen) 
compared to 1% oxygen (8mmHg) (Wiesener et al. 1998), indicating that cells can respond to 
even further reductions in oxygen levels. If the definition of hypoxia is the oxygen setting in 
which HIFs are activated, hypoxia should be classed as ranging from 0% to 6% oxygen 
(0mmHg to 46mmHg); however hypoxia tolerability and the onset of HIF activation are likely 
to be tissue- and cell type-dependent. 
Hypoxia can occur continuously or intermittently and be either acute or chronic in 
duration. The adaption to low oxygen tension at the cellular and organism level includes the 
initiation of complex biological processes such as erythropoiesis, angiogenesis, and metabolic 
reprogramming with the ultimate aim of reinstating oxygen homoeostasis. In each case, HIF-1 
regulates the expression of multiple genes encoding key components of the response pathway. 
Erythropoiesis represents an adaptive response to systemic hypoxia whereas metabolic 
reprogramming and angiogenesis represents local tissue responses to decreased oxygenation. 
Systemic hypoxia with a reduction in blood oxygen may occur through acute blood loss, 
ascent to high altitude, and diseases of the lung. Subsequently, HIF-1 has been shown to 
orchestrate erythropoiesis by co-ordinately regulating the expression of multiple genes 
encoding proteins responsible for the intestinal uptake, tissue recycling, and delivery of iron to 
the bone marrow for its use in the synthesis of haemoglobin, including the erythropoietin 
(EPO) and the EPO receptor genes (Wang and Semenza 1995). 
Oxygen is fundamental to many metabolic processes including oxidative 
phosphorylation of glucose and fatty acids in the mitochondria in which it functions as an 
electron acceptor during ATP formation. This energy transfer mechanism is very efficient and 
produces 38 ATP molecules per mole of glucose oxidised, in contrast to 2 ATP molecules 
produced when the cells switch to anaerobic glycolysis and decreased rate of aerobic 
respiration under hypoxic conditions. This reduction in ATP synthesis in hypoxia must be 
compensated for by an induced glucose uptake via glucose transporters and increased 
conversion of glucose to lactate by the activity of glycolytic enzymes and lactate 
dehydrogenase A, which are all HIF-dependent target genes (reviewed in (Semenza 2009)). 
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This anaerobic and acidic microenvironment with the presence of low molecular weight 
metabolites in hypoxia has been described using nuclear magnetic resonance spectroscopy 
(Naughton et al. 1993).  
Reactive oxygen species (ROS), such as hydrogen peroxide (H2O2) and superoxide 
anions (O2) are a natural by-product of normal cell metabolism. Another feature of hypoxia 
and ischemia is that the level of ROS production by mitochondria increases through increased 
electron transfer at complex III in the electron transport chain (Bell et al. 2007). ROS at high 
levels are cytotoxic and mutagenic but ROS induced at moderate levels by hypoxia has been 
shown to mediate cell growth, migration, differentiation and gene expression (reviewed in 
(Wu et al. 2008)). The effects of ROS are mediated through the activation of several 
signalling cascades such as the mitogen-activated protein kinases (MAPK) and interestingly 
also through the activation of HIFs (Haddad and Land 2001; Bell et al. 2007; Bonello et al. 
2007). 
In addition to changes in erythropoiesis and cellular metabolism, the process of 
angiogenesis is initiated in response to local tissue hypoxia in most tissues, including the 
hypoxic RA synovium. This is perhaps the most dramatic adaptive responses to hypoxia as it 
requires tissue remodelling and new vessel growth. A more detailed account of hypoxia and 
angiogenesis in the RA synovium is given later in Section 1.3 and 1.4. 
1.1.1 Hypoxia-inducible factor (HIF) structure and function 
When cells are exposed to experimental hypoxia, HIF-1 protein complexes 
accumulate rapidly in the nuclei from nearly undetectable levels and are just as quickly 
degraded upon return to normoxia (Wiesener et al. 1998). In addition to HIF-1α which is 
ubiquitously expressed, two other members of this family, HIF-2α and HIF-3α, have been 
identified. The work which has been done on HIF-2α and HIF-3α is rather limited in 
comparison to work on HIF-1α, but it appears that these isoforms have a more restricted 
tissue expression pattern (Wenger 2002). In the following, the majority of the examples from 
the literature will therefore be concerned with HIF-1α. 
Functional HIFs are composed of the basic helix-loop-helix-Per-Arnt-Sim (bHLH)-
PAS protein HIF-1, -2 or -3α and the aryl hydrocarbon nuclear translocator (ARNT) known 
as HIF-1β. Transactivation of HIF target genes involves dimerisation of the two subunits in 
the nuclei, formation of a transcriptional complex with co-activators, and DNA-binding to the 
enhancer element termed hypoxia response element (HRE) located in HIF target genes 
(Kallio et al. 1998). The core sequence of a HRE HIF-1 binding site is 5’-RCGTG-3’ 
(R=A/G). The HRE elements have been found in a large number of genes believed to be 
regulated by HIFs, including vascular endothelial growth factor (VEGF-A), and the list of 
genes is ever increasing (reviewed (Gaber et al. 2005)). 
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Two transactivating domains have been identified in the C-terminal part of the HIFα 
subunits, namely an N-terminal activation domain (N-TAD) and a more downstream C-
terminal activation domain (C-TAD) (Figure 1.1). The C-TAD in particular has been shown 
to interact with co-activators such as p300/CREB-binding protein (CBP) to activate 
transcription. Between the transactivating domains is the inhibitory domain (IH) which is 
thought to be involved in stability and trans-activation (Hu et al. 2007). Further upstream of 
the transactivating domains, the contiguous bHLH and PAS domains create a functional 
interface for subunit dimerisation and binding to HRE (Kallio et al. 1998). The oxygen-
dependent degradation (ODD) domain which includes the N-TAD domain regulates HIF 
instability through the hydroxylation of specific proline residues (Maxwell et al. 1999). HIF-
1α and HIF-2α have been shown to have many similarities regarding their genomic 
organisation, protein structure, hypoxic protein stabilisation, heterodimerisation with HIF-1β, 
DNA recognition, DNA-binding, and trans-activation of reporter genes (Wenger 2002; Hu et 
al. 2007). 
Figure  1.1 Structure of the HIF-1α and HIF-2α subunits 
HIF-1α and HIF-2α  have several distinct domains which serve different functions e.g. to bind DNA 
via HRE, dimerise with HIF-1β and a domain dedicated to trans-activation and stability. The Figure 
also shows the individual prolines (P) and asparagine (N) sites which are hydroxylated by proline and 
asparaginyl hydroxylases (Hu et al. 2007). 
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The level of HIFα expression is determined by the rates of protein synthesis and 
protein degradation, where synthesis appears to be regulated mainly in an oxygen-
independent fashion and degradation regulated primarily via oxygen-dependent mechanisms. 
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stability (Metzen et al. 2003b; Zhou et al. 2003b; McMahon et al. 2006) (reviewed in 
(Semenza 2003)). The HIF-1α subunit is tightly regulated at multiple levels: transcription, 
translation, post-translational modification, protein-protein interaction and degradation 
(reviewed in (Bardos and Ashcroft 2005)). Post-translational modifications of HIF-1α have 
all been shown to determine its half-life and/or transcriptional activity, and include 
hydroxylation, ubiquitination, acetylation, S-nitrosation and phosphorylation (reviewed in 
(Brahimi-Horn et al. 2005)). Hypoxia-induced HIF-1α changes in protein levels are 
dependent upon both protein translation and degradation. Most of the existing work describes 
the regulatory mechanisms leading to decreased HIF-1α degradation. One study however, 
reports that hypoxia stimulates HIF-1α and -2α translation in pheochromocytoma (PC) 12 
cells and human endothelial kidney 293 cells, and that this translational component accounted 
for 40-50% of HIF-1α accumulation. The mechanism behind this observation was based on a 
hypoxia-induced shift in distribution of HIFα transcripts to a larger polysome fraction, and 
that this effect was mediated through calcium signalling and activation of the classical protein 
kinase (PK) Cα and the mammalian target of rapamycin (mTOR) pathway. Curiously, this 
effect of hypoxia appeared to be selective for HIFα mRNAs, as the mRNA for other hypoxia-
induced genes investigated in the study were not distributed to larger polysomes (Hui et al. 
2006). 
The signal transduction pathways that regulate HIF-1α stability and subsequent 
expression of its target genes are complex and not yet fully unveiled. It is generally accepted 
that the main regulators of HIFα post-translational modifications are specific oxygenases 
named HIF prolyl hydroxylase domain (PHD)-containing enzymes and factor inhibiting HIF 
(FIH)-1. The major oxygen-dependent pathway regulating HIF-1 transcriptional activity is via 
the ODD domain in the α-subunit of HIFs which is the target of the PHDs. These enzymes 
require both oxygen, Fe2+ and ascorbic acid for their activity and they have been considered to 
function as direct cellular oxygen sensors, with no intermediate signalling required for HIF-1 
regulation (Jaakkola et al. 2001) (reviewed in (Hellwig-Burgel et al. 2005)). In the presence 
of oxygen, HIF-1α subunits are prolyl hydroxylated on Pro-402/Pro-564 and HIF-2α on Pro-
405/Pro-530, and these hydroxyl-proline residues are required for the interaction with the von 
Hippel-Lindau tumour suppressor protein (pVHL), which subsequently guides ubiquitin E3 
ligases to polyubiquitinate the HIFα subunits (Ivan et al. 2001; Jaakkola et al. 2001) (Figure 
1.2). Once polyubiquitinated, HIFα-subunits are targeted for proteasomal degradation by the 
26S-proteasome. 
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Figure  1.2 Regulation of HIF-mediated oxygen-dependent gene transcription 
In the presence of oxygen (normoxia), HIF-1α hydroxylation by FIH-1 inhibits p300 co-factor binding 
and HIF-1 trans-activation (1. left panel). Hydroxylation by PHDs targets HIF-1α for ubiquitination 
through an E3 ligase complex via the binding of pVHL and subsequent proteosomal degradation (2. 
left panel). When the oxygen level decreases (hypoxia), these two oxygen-dependent inhibitory 
mechanisms are deterred, allowing HIF-1α accumulation and HIF-1 transcriptional activation (right 
panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PHD enzymes were first described by Epstein et al. in C. elegans and termed 
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after long periods of hypoxia (Marxsen et al. 2004; Pescador et al. 2005).  
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dependent manner through hydroxylation of Asn-803 in the C-TAD using O2 as a co-
substrate. This leads to deactivation of C-TAD by preventing the heterodimerisation with 
HIF-β and co-factor p300/CBP through reduced binding activity and hence reduced HIF 
trans-activation in normoxia (Ema et al. 1999). One property of FIH-1 which contrasts with 
that of the PHD is its ability to function as oxygen levels decline (Koivunen et al. 2004). In 
other words, when the availability of oxygen is low and PHD enzymes can no longer function 
(through a reduction in oxygen substrate), FIH-1 is potentially still able to deactivate HIF that 
has escaped proteosomal degradation. In summary, under hypoxic conditions, the decline in 
oxygen levels decreases the activity of PHDs and FIH-1, thereby preventing proline and 
asparagine hydroxylation of HIFα subunits. Consequently pVHL cannot target HIFα for 
degradation, allowing HIFα to accumulate and dimerise with HIF-1β in the nuclei (Figure 
1.2). Thus proline hydroxylation affects protein accumulation, whereas asparagine 
hydroxylation affects HIF binding to co-factor p300/CBP and subsequent trans-activation. 
Most models suggest that the PHDs are the main hypoxic regulators of HIF-1 
activation, however, it is becoming clear that they are not the sole regulators of HIF-1, and 
that several other signalling pathways are initiated to activate HIF-1 in cells exposed to 
hypoxia. Previous work has shown that members of the MAPK family are activated by 
hypoxia and regulate HIF-1 activity, mainly by augmenting its interaction with its co-
activators and enhancing DNA-binding activity (reviewed in (Hellwig-Burgel et al. 2005)) 
(Jeong et al. 2005). The MAPK that are activated by hypoxia differ according to cell type. For 
example, Conrad et al. reported that exposure of PC12 cells to hypoxia led to a rapid 
activation of p38α and p38γ isoforms and p42/44 MAPK, but had no effect on other p38 
isoforms or c-Jun N-terminal kinase (JNK) (Conrad et al. 1999). This is in contrast to work in 
pulmonary arterial fibroblasts where hypoxia leads to activation of p38 and JNK, but not 
p42/44 MAPK (Scott et al. 1998). Mottet et al. however observed activation of p42/44 
MAPK, but not JNK in HepG2 cells (Mottet et al. 2003). 
The p42/44 MAPK pathway has been shown to be responsible for regulating trans-
activation of HIF-1α in a HeLa cell line and HepG2 cells, but not for DNA-binding and 
protein stabilisation (Hoffer 2001; Mottet et al. 2003). Indeed the p42/44 MAPK pathway, but 
not JNK and p38 MAPK, has been shown to increase the transcriptional activity of the HIF-1 
complex by phosphorylating HIF-1α directly (Richard et al. 1999; Berra et al. 2000; Mottet et 
al. 2003). The phosphorylation site remains to be identified, although Thr-796 is a likely 
candidate, as its phosphorylation leads to increased transcriptional activity and inhibits 
hydroxylation by FIH-1 at Asn-803 (Dery et al. 2005; Emerling et al. 2005). It has been 
proposed that a calmodulin/calcium-dependent pathway links hypoxia to p42/44 MAPK 
phosporylation of HIF-1 (Mottet et al. 2003), whereas mitochondrial ROS generated by 
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hypoxia could be the essential activators of p38 MAPK signalling pathways. As opposed to 
the p42/44 MAPK pathway, activation of p38 MAPK signalling is necessary for both 
stabilisation and increased transcriptional activity of HIF-1α during hypoxia (Emerling et al. 
2005). 
Other major signalling pathways which have shown to regulate HIF-1 activity in 
hypoxia include the phosphatidylinositol 3-kinase (PI3K) and the nuclear factor kappa B 
(NFκB) pathway. Many components of the PI3K/AKT signalling pathway such as PTEN, 
AKT, HDM2 and mTOR have been shown to be involved in positive regulation of HIF-1α 
(Bardos and Ashcroft 2005) (reviewed in (Hellwig-Burgel et al. 2005)), but the exact role of 
PI3K/AKT signalling in HIF-1 activation is still a matter of debate. NFκB plays an important 
role in the induction of a variety of genes involved in immune and inflammatory responses. 
Hypoxia has been demonstrated to activate NFκB in a number of studies and in various cell 
types such as macrophages, myocytes, endothelial cells (ECs) and RA FLS (Chandel et al. 
2000; Han et al. 2003; Zampetaki et al. 2004; Jeong et al. 2005; Cummins et al. 2006; 
Bonello et al. 2007). The signalling mechanisms leading to upregulated NFκB activity in 
hypoxia and the potential links between this pathway and HIFs are under intense 
investigation. In one study, HIF-1α and NFκB were increased in response to the ROS, H2O2, 
and unlike previously described studies, H2O2 induced HIF-1α mRNA in addition to HIF-1α 
protein. Further analyses by the authors led to the discovery that NFκB activated HIF-1α 
mRNA expression via a novel NFκB binding site in the HIF-1α promoter, responsible for 
ROS induced NFκB-mediated transcription of the HIF-1α subunit (Bonello et al. 2007). The 
discovery of an NFκB binding site in the HIF-1α promotor along with the findings that ROS 
can activate NFκB, suggests a sequence of events where hypoxia generates ROS which 
activates NFκB binding to and activation of the HIF-1α promoter. Recently, using IκB kinase 
(IKK)-2-deficient mice, it was shown that NFκB is required for HIF-1α protein 
accumulation, and that absence of IKK-2 results in defective induction of HIF targets such as 
VEGF in hypoxia (Rius et al. 2008). 
Given the importance of HIF and NFκB signalling cascades in the regulation of 
inflammation, further work to clarify the importance of cross talk between these pathways is 
clearly required. 
1.1.3 HIF regulation by inflammatory cytokines 
In parallel to the oxygen-dependent pathway, HIF-1α is also regulated by receptor-
mediated signals under normoxic conditions, although the molecular pathways underlying 
these more subtle changes in HIF gene/protein expression have not been fully characterised. 
Inflammatory cytokines like tumour necrosis factor (TNF) α and interleukin (IL) -1β act via 
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such receptor-mediated pathways and induce changes in HIF-1α levels and/or HIF-1 
transcriptional activity. Furthermore, studies have shown that inflammatory cytokines can 
augment hypoxia-mediated upregulation of HIF activity and VEGF secretion (Berse et al. 
1999; Hellwig-Burgel et al. 1999). As is the case following hypoxic stimuli, the upregulation 
of HIF-1α by cytokines is thought to involve mainly stabilisation of protein, possibly through 
prevention of degradation of ubiquitinated HIFs (McMahon et al. 2006). Very few reports 
describe cytokine induction of HIF-1α through increased HIF-1α steady-state mRNA levels 
and the signalling pathways mediating this effect are largely unknown. 
TNFα is a potent inflammatory cytokine, which exerts its pleiotropic effects through 
ligand-induced cross-linking of specific TNF receptors (TNFR-1 and -2), which are expressed 
ubiquitously (Rothe et al. 1992). TNFα has been shown to upregulate HIF-1α protein levels 
without inducing changes in HIF-1α steady-state mRNA levels (Jung et al. 2003b; Zhou et al. 
2003b). Normoxic TNFα-mediated HIF-1 DNA-binding activity has been reported in several 
cell types including fetal alveolar type II epithelial cells, porcine kidney epithelial cells (LLC-
PK1) and human hepatoma HepG2 cells (Hellwig-Burgel et al. 1999; Haddad and Land 2001; 
Sandau et al. 2001). Several studies have investigated the mechanisms behind TNFα-
mediated HIF-1α regulation and one study found that a non-hypoxic, ROS sensitive pathway 
was involved (Haddad and Land 2001). The authors observed a temporal correlation between 
TNFα induced intracellular accumulation of various ROS and that of HIF-1α 
stabilisation/activation, an effect which was abrogated by a range of antioxidants. Reactive 
nitrogen species, such as the inflammatory mediator nitric oxide (NO), has also been 
implicated in regulation of HIF-1α stability/activity during normoxia (Sandau et al. 2001). 
Two major signalling pathways, NFκB and p38 MAPK, have been shown to play key 
roles in TNFα-mediated HIF-1α protein accumulation. For instance, TNFα-mediated 
stabilisation of HIF-1α in human articular chondrocytes was partially abrogated by the pre-
treatment of cell cultures with NFκB or p38 MAPK inhibitors (Coimbra et al. 2004). In line 
with these findings, another study reported that the observed HIF-1α protein accumulation by 
TNFα in mouse embryonic fibroblasts NIH 3T3 cells, was dependent upon a signalling 
cascade involving TNFR-1, RIP (receptor-interacting protein) and NFκB (Jung et al. 2003a). 
TNFα did not induce HIF-1α mRNA levels in NIH 3T3 cells. Pre-treatment with the 
transcriptional inhibitor actinomycin D abrogated the TNFα-mediated effect on HIF-1α 
protein accumulation. This phenomenon was not observed for other HIF-1α protein stabilisers 
such as hypoxia and cobalt chloride (CoCl2), indicating that TNFα-mediated HIF-1 induction 
is transcription-dependent in these cells (Jung et al. 2003a).  
Similar to HIF-1α activation by TNFα, IL-1β-mediated HIF-1α stabilisation, nuclear 
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translocation and DNA-binding activity may require a ROS-sensitive pathway (Haddad 
2002). IL-1β induced the accumulation of H2O2 and O2 in alveolar epithelial cells, and pre-
treatment with antioxidants could attenuate the effect of the cytokine on HIF-1α protein 
accumulation and activation. It has been suggested that there are two likely sources of ROS 
production following TNFα and IL-1β stimulation: the membrane-bound nicotinamide-
adenine dinucleotide phosphate (NADPH) oxidase and the mitochondrial respiratory chain 
(Haddad and Land 2001; Haddad 2002). IL-1β has also been shown to induce HIF-1α protein 
in a lung epithelial cell line, A549, through an NFκB-dependent pathway as several inhibitors 
of NFκB attenuated the observed induction in HIF-1α protein levels. IL-1β stimulation did 
not alter the steady-state level of HIF-1α mRNA in these cells, but the effect of the cytokine 
on HIF-1α protein induction seemed to require NFκB-mediated transcription. 
Cyclooxygenase (COX)-2 has been reported to be one of the NFκB-transcribed genes 
involved in HIF-1α protein upregulation (Jung et al. 2003b).  
The PI3K pathway has also been shown to be involved in IL-1β-mediated HIF-1α 
protein induction in human lung epithelial cells (Jung et al. 2003a), and HIF-1α protein 
induction and subsequent DNA-binding in HepG2 cells (Stiehl et al. 2002). Other major 
kinase signalling pathways such as p38 MAPK and JNK have been reported to mediate IL-1β 
-induced HIF-1α protein stabilisation. In one study, IL-1β-mediated HIF-1α protein 
stabilisation in chondrocytes from OA patients, was abrogated by inhibitors to the p38 and 
JNK MAPK pathways. This effect was not seen when cells were pre-treated with p42/44 
MAPK inhibitor (Murata et al. 2006).  
Transforming growth factor (TGF) β is expressed as three distinct isoforms TGF-β1, 
-β2 and -β3 in mammalian cells and exerts its biological functions through three classes of 
receptors (TβRI, TβRII and TβRIII) (reviewed in (Massague 1998)). TGFβ has been reported 
to induce HIF-1α accumulation and HIF-1 DNA-binding under normoxic conditions in 
several cell types (Gorlach et al. 2001; Sanchez-Elsner et al. 2001; Shih and Claffey 2001; 
McMahon et al. 2006). In the human fibrosarcoma cell line HT-1080, VEGF production was 
found to be mediated through TGFβ-induced HIF-1α and activating protein (AP) -1 DNA-
binding activity to the VEGF promotor. Hypoxia alone had no effect on AP-1 activity 
whereas a synergistic effect of the two transcription factors was observed when cells were 
treated with both TGFβ and hypoxia, indicating that TGFβ mediates VEGF expression 
through both HIF-1-dependent and HIF-independent signalling pathways (Shih and Claffey 
2001). Interestingly, one study reported a physical interaction between the transcription factor 
Smad3 and HIF-1α in response to TGFβ, demonstrated via co-immunoprecipitation studies in 
HeLa cells (Sanchez-Elsner et al. 2001). Further analysis of this interaction, led to the 
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findings that HIF-1α, Smad3 and DNA forms a ternary complex upstream of HIF-1-regulated 
genes in response to TGFβ. Recent work in the tumour cell lines HepG2 and HT-1080 cells, 
has shown that TGFβ markedly decreases both mRNA and protein levels of PHD-2, leading 
to decreased hydroxylation of the HIF-1α subunit, and thus increased HIF-1α protein stability 
and DNA-binding activity (McMahon et al. 2006). As for the other cytokines described here, 
TGFβ-mediated induction of HIF-1α protein and activity seem to require a ROS sensitive 
pathway. Gorlach et al., found that HIF-1α protein levels, HIF-1 DNA-binding activity and 
ROS levels were induced in vascular smooth muscle cells (VSMCs) in response to TGFβ 
(Gorlach et al. 2001). Pre-treatment of the cell cultures with the antioxidant vitamin C 
completely prevented these TGFβ-mediated effects. ROS sensitive pathways therefore appear 
central to both hypoxia and cytokine-mediated regulation of HIFs in many different cell lines. 
A summary of the signalling pathways which can induce HIFs under normoxic conditions is 
shown in Figure 1.3. 
Figure  1.3 Signalling pathways regulating HIF-1α in normoxia 
A summary of the cytokine-mediated signalling pathways reviewed in the text. These pathways have 
been implicated in cytokine and growth factor-mediated regulation of HIF-1α and subsequent VEGF 
secretion in normoxia. Increased HIF-1α translation, protein stability and HIF-1 activity (DNA-binding 
activity/trans-activation) have all been implicated in the normoxic regulation of HIF-1α. Cytokines can 
also induce VEGF expression via HIF-1-independent pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, cytokines and growth factors appear to mediate their effects on HIFs via 
several of the major signalling pathways, in a cell-type specific manner. Many of these 
pathways are also activated by hypoxia leading to HIF-1α protein stabilisation and increased 
Cytokines &
growth factors
HIF-1α
HRE
VEGF
NFkB
ROS
P38
JNK 
SMAD
PI3K
AP-1
HIF-1α translation
HIF-1α protein
HIF-1 activity
p38
JNK
SMAD
CHAPTER 1                                                                                                             Introduction 
 29
HIF-1 activity. The synovial microenvironment in the RA joint is both hypoxic and expresses 
elevated levels of inflammatory cytokines. As HIFs are able to respond to both stimuli, they 
could represent an important convergence point, where the integrating of cellular responses to 
low oxygen tension and to inflammatory cytokines takes place. 
1.1.4 Differential regulation of HIF isoforms and their distinct roles 
Understanding the differential activity of the HIF isoforms is an important issue in the 
biology of HIF. Both HIF-1 and HIF-2 are thought to recognise the same HRE, but the target 
genes activated by the two isoforms appear to differ. Furthermore, both HIF-1α and HIF-
2α molecules are subject to similar negative regulatory processes under normoxic conditions 
involving the previously described enzymatic hydroxylation of conserved prolyl and 
asparaginyl residues by hydroxylases and proteosomal degradation (Maxwell et al. 1999; 
Epstein et al. 2001). Under hypoxic conditions both subunits escape degradation and thus 
dimerise to HIF-1β and bind to HRE elements in target gene promoters (Wang et al. 1995). 
Moreover, in transfection assays, both transcription factors activate a range of HREs with 
similar efficacy (Wiesener et al. 1998; Ema et al. 1999). In addition to their regulation and 
activation during hypoxia, their structures are also similar (see Figure 1.1) (Kallio et al. 1998; 
Hu et al. 2007). 
Despite these striking similarities, genetic studies have provided firm evidence for 
nonredundant functions of the isoforms alongside common functions. Targeted inactivation of 
HIF-1α and HIF-2α in embryonic stem cells is associated with different patterns of response 
to hypoxia and low glucose stress (Brusselmans et al. 2001) and differential developmental 
effects are observed in HIF-1α -/- and HIF-2α -/- knock-out mouse embryos. These differences 
could be partly due to distinct patterns of cellular expression. In this regard, HIF-1α appears 
to be ubiquitously expressed, whereas HIF-2α is more tissue restricted, being primarily 
expressed in the embryo vasculature and subsequently in the lung, kidney, and liver (Tian et 
al. 1998; Compernolle et al. 2003). The restricted tissue expression of HIF-2α compared to 
HIF-1α is reflected in the ratio of genes regulated by the two isoforms. Aprelikova et al. used 
small interfering RNA (siRNA) technology and microarray analysis to show that HIF-2 
regulates approximately 5% of the hypoxia-responsive genes investigated in a human breast 
adenocarcinoma cell line, MCF7, while the rest were HIF-1-dependent (Aprelikova et al. 
2006). Another study employing affymetrix gene chip analysis of Hep3B cells revealed that 
HIF-2α regulates approximately 13% of genes upregulated by hypoxia, and 17% of 
downregulated genes (Warnecke et al. 2008). In colon cancer cell lines subjected to hypoxia 
and subsequent microarray analysis, the ratio of HIF-1 to HIF-2-regulated genes was 
relatively high in that HIF-1 regulated 21% of hypoxia-inducible genes, whereas HIF-2 
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regulated 9%. Interestingly, a large group of 379 hypoxia-inducible genes were regulated by 
both isoforms suggesting a large overlap in target gene specificity. The remaining genes were 
regulated independently of HIFs (Imamura et al. 2009). 
Interestingly, HIF-1α, but not HIF-2α, is transcriptionally upregulated during 
hypoxia, and the activity of HIF-1α is proportional to its abundance (Wang et al. 1995; Rius 
et al. 2008; Sperandio et al. 2009). Amounts of HIF-2α protein increase modestly during 
hypoxia, but HIF-2-dependent transcription increases markedly, which suggests that 
additional post-translational mechanisms besides oxygen-dependent hydroxylation regulate 
HIF-2 activity (O'Rourke et al. 1999). In accordance with this, a recent study has found that 
Sirtuin1 (Sirt1), can deacetylate and induce HIF-2, but not HIF-1, in hypoxia (Dioum et al. 
2009). Mass spectrometry of HIF-2α has revealed that lysine residues K385, K685 and K741 
within the HIF-2α C-terminus are acetylated by hypoxia. Sirt1, which is known for its role in 
caloric restriction and ageing, is activated by hypoxia as a consequence of the altered redox 
state in hypoxic cells with increased oxidative stress. This effect of Sirt1 on HIF-2α requires 
direct interaction of the proteins and intact deacetylase activity of Sirt1. The process does not 
affect the amount of endogenous HIF-2α protein and occurs independently of known oxygen-
dependent modification of HIF-2α by PHDs and FIH-1. Unlike HIF-1α, HIF-2α is only 
present in higher vertebrates. Thus, HIF-2 signalling conferred through Sirt1/HIF-2α complex 
formation as well as by Sirt1-mediated deacetylation of HIF-2, likely has a specialised role in 
higher metazoans (Dioum et al. 2009). 
An important difference in the regulation of the transcription of HIF-1α and HIF-2α 
include their regulation by the various PHD isoforms. PHD-2 appears to be a primary 
hydroxylase for both HIF-1α and HIF-2α whereas genetic studies indicate that PHD-3 is 
responsible mainly for HIF-2α modification (Berra et al. 2003; Bishop et al. 2008). The 
engagement of different transcription factors by HIF-1α and HIF-2α has also been reported, 
providing a possible explanation to differences in target gene specificity. Interestingly, 
Aprelikova et al. has shown that HIF-2 but not HIF-1 uses the co-transcription factor ELK-1 
to initiate transcription of target genes (Aprelikova et al. 2006). Moreover, the NFκB 
essential modulator, NEMO, has been shown to engage with HIF-2α but not HIF-1α in a 
yeast two-hybrid interaction assay (Bracken et al. 2005). This interaction was shown to 
specifically enhance normoxic activity of HIF-2. Moreover, an iron responsive element (IRE) 
has been detected in the HIF-2α but not HIF-1α promoter and it is thought that iron 
regulatory protein binds to IRE and controls HIF-2α translation in response to cellular iron 
availability (Sanchez et al. 2007). As HIF-2 is the critical isoform regulating EPO under 
physiological and stress conditions, iron levels in the cell provides a feedback system 
modulating EPO expression by HIF-2, thereby adjusting the ratio of blood cell production to 
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iron availability (Warnecke et al. 2004). 
In some situations the functional role of the two HIF isoforms has shown to be 
distinct and isoform-specific with little overlapping and redundancy. In the kidney for 
instance, HIF-1α is expressed in the tubules, whereas HIF-2α is confined to endothelial and 
interstitial cells and studies involving HIF-2α knock-down show that HIF-2 in the 
endothelium exerts a protective effect against ischemia in the kidney by ameliorating 
oxidative stress (Kojima et al. 2007). The HIF isoforms also seem to harbour distinct roles in 
the processes of apoptosis and cell proliferation. In a 2005 study, Raval et al. observed that 
HIF-2α induced an anti-apoptotic response in renal carcinoma cells through its ability to 
downregulate the pro-apoptotic factor, BNIP-3 (BCL2/adenovirus E1B 19 d-interacting 
protein). In contrast, HIF-1α was able to induce BNIP-3 (Raval et al. 2005). Similarly, in a 
breast cancer cell line expressing both HIF isoforms, hypoxic induction of VEGF, BNIP-3, 
carbonic anhydrase 9, the GLUT (glucose transporter) -1 and uPAR (urokinase plasminogen 
activator receptor) was inhibited with HIF-1α, but not HIF-2α siRNA. Likewise, knock-down 
of HIF-1α, but not HIF-2α using siRNA in human umbilical vein endothelial cells (HUVEC) 
ablated the hypoxic induction of BNIP-3, GLUT-1 and uPAR, indicating that HIF-2 does not 
substitute in regulating any of these genes when HIF-1α is inactivated. However, in a breast 
cancer cell line, 786-0, which does not express HIF-1α but only HIF-2α, the transcription of 
GLUT-1 and VEGF has become critically dependent on HIF-2α. Interestingly, HUVEC 
migration was inhibited with siRNA against either isoform (Sowter et al. 2003). c-Myc 
deregulation occurs in most types of human cancers. HIF-1α has been shown to inhibit cell 
cycle progression by counteracting c-Myc transcriptional activity, whereas HIF-2α has the 
opposite effect and activates c-Myc by enhancing its binding to other transcription co-factors 
(Gordan et al. 2007). In SW480 colon cancer cells knock-down of HIF-1α lead to reduced 
proliferation and migration in vitro and a 57% reduction in tumour size when grown as 
xenografts in vivo. In contrast, selective knock-down of HIF-2α had no effect on proliferation 
whereas tumour size was nearly doubled compared to wild-type cells supporting a tumour 
suppressive role for HIF-2α in colon cancer (Imamura et al. 2009). In accordance with these 
findings, cyclin G2 which has been reported to have cell cycle inhibitory functions was 
specifically upregulated by HIF-2 but not by HIF-1 in the SW480 colon cancer cells. In 
general, it is hypothesised that HIF-1α is the major hypoxia-induced transcription factor in 
most breast carcinogenesis and several colon cancer cell lines based on the observations that 
several of these cell lines eventually lose the ability to express HIF-2α (Sowter et al. 2003; 
Imamura et al. 2009). 
Other studies in cancer have assigned specific roles to HIF-2α as compared to HIF-
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1α. For instance, HIF-2α was linked to development of clear-cell renal cell carcinoma (CC-
RCC) in patients with VHL disease in which HIF-1α expression gradually decreases in more 
advanced lesions as HIF-2α expression increases (Mandriota et al. 2002). A non-small cell 
lung cancer analysis of overall survival rate showed that high HIF-2α expression was related 
to poor outcome, while HIF-1α expression was only marginally associated with poor 
prognosis (Giatromanolaki et al. 2001). A high level of HIF-2α has been proposed to promote 
aggressive neuroblastoma phenotype through selective stabilisation of HIF-2α under 
conditions of both chronic hypoxia and physiological levels of oxygen (Holmquist-
Mengelbier et al. 2006). Yet other studies in glioblastomas suggested that overexpression of 
HIF-2α enhances angiogenesis but reduces tumour growth (Acker et al. 2005). Also, 
overexpression of HIF-2α, but not HIF-1α, promotes growth of CC-RCCs (Kondo et al. 
2002; Maranchie et al. 2002), yet inhibited growth of breast cancer cells (Blancher et al. 
2000). Further evidence that HIF-2α plays an important part in tumour progression comes 
from the findings that Oct4, a major transcription factor regulating stem cell maintenance, is a 
direct and selective target of activation and expression by HIF-2 implicating this isoform in 
the dedifferentiation of a number of cell types including cancer cells (Covello et al. 2006). 
Currently, the precise transcriptional mechanisms underlying the differential activity 
of HIF-1α and HIF-2α are largely unknown. The putative mechanisms which have been 
suggested include differential use of co-transcription factors by the isoforms, structural 
differences in the isoforms, or that the differences between HIF-1α and HIF-2-driven 
transcription may be dependent upon the cellular microenvironment, such as duration of 
hypoxic exposure and the degree of hypoxia. Nevertheless, the parallel and divergent role 
which emerges from the literature has important implications for the implementation for HIF 
inhibitors as a therapeutic approach in diseases associated with changes in oxygen tension, 
such as malignancies and, in the context of this study, RA. 
1.2 RHEUMATOID ARTHRITIS 
RA is a chronic systemic inflammatory disease of unknown aetiology. Current 
thinking favours the hypothesis that interplay between genetic factors, sex hormones, and 
possibly an infectious agent or another immune activating factor, initiates an autoimmune 
pathogenic mechanism that culminates in a disease with inflammatory and destructive 
features. It affects approximately 1% of the population worldwide and 1-3% of the population 
in the Western world. However, these figures may be an underestimate, since patients with 
mild disease may never present for a medical opinion. Data point to a multipart interplay 
between environmental and genetic factors. In monozygotic twins, there is a more than 30% 
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concordance for RA development, and 80% of Caucasians with RA express the HLA-DR1 or 
-DR4 subtypes (Goldring 2000). Its financial impact is magnified by the high level of 
functional impairment RA causes: up to 30% of people with RA become permanently work-
disabled within three years of diagnosis if they do not have medical treatment (Sokka 2003; 
Firestein 2005). 
RA principally is a clinical diagnosis. Patients frequently present with pain and 
stiffness in multiple joints, although one third of patients initially experience symptoms at just 
one location or a few scattered sites. In the majority of patients, symptoms appear over weeks 
to months, starting with one joint and often accompanied by prodromal symptoms of 
anorexia, weakness or fatigue. In approximately 15% of patients, onset occurs more rapidly 
over days to weeks. In 8-15% of patients, symptoms commence within a few days of a 
specific inciting event, such as an infectious illness (Maini and Zvaifler 1998). Joints most 
commonly affected are those with the highest ratio of synovium to articular cartilage. Muscles 
near inflamed joints often atrophy, which can lead to weakness that is commonly out of 
proportion to pain on examination. Morning stiffness lasting at least 1 hour after initiating 
movement is common and patients habitually hold joints in flexion to minimize painful 
distension of joint capsules (Akil and Amos 1995a; Akil and Amos 1995b). 
RA may begin at any time from the first few weeks of life until the ninth decade, 
although the peak time of presentation is typically between 30 and 55 years of age, its 
incidence increasing with age (Sweeney and Firestein 2004). Females are affected more 
commonly than males in a ratio of 2.5:1 (Akil and Amos 1995b). The reason for this is not 
fully understood, but it is likely to be hormonal. This is supported by the fact that RA is 
increased in frequency and exacerbated following pregnancy and terminations, while 
remissions are common during pregnancy. However, this female preponderance is greater in 
younger people and the age related incidence is approximately equal in the elderly. Most 
patients have a clinical disability within two decades of the onset of the disease and more than 
half are unemployed after ten years of first diagnosis (Schumacher et al. 1994). 
The disease course of RA is variable. It ranges from a brief, mild, self-limiting 
oligoarticular illness with minimal joint damage, to a sustained polyarticular, synovial 
inflammation resulting in progressive cartilage destruction, erosion of bone and ultimately 
changes in joint integrity with corresponding functional impairment. Up to 90% of patients 
with aggressive synovitis have radiological evidence of bone erosion within two years of 
diagnosis, despite treatment with disease modifying agents such as methotrexate (MTX), 
sulphasalazine and gold. Despite such pharmacological interventions, the majority of patients 
with a more aggressive disease evolution become clinically disabled within 20 years. Indeed 
RA patients of working age are much more likely to stop work on health grounds than 
matched controls. 
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Although in most cases the major manifestation of rheumatoid disease is in the 
synovial joint, there is also evidence of systemic involvement, for example increased acute 
phase markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), 
indicate that patients have systemic inflammation which may involve a wide range of organs. 
Symptoms of systemic involvement include anaemia, weight loss, vasculitis, serositis, 
nodules in subcutaneous, pulmonary and sclera tissues, mono-neuritis multiplex, and 
interstitial inflammation in lungs as well as in exocrine salivary and lachrymal tissue. The 
main cause of the excessive morbidity and mortality observed in RA patients is due to 
cardiovascular manifestations such as pericarditis and vasculitis (Van Doornum et al. 2002; 
Gabriel et al. 2003; Van Doornum et al. 2006). A study from Finland reported that RA 
patients were at increased risk of dying of urogenital, gastrointestinal, respiratory and 
cardiovascular diseases, as well as infections, and cancers, when compared to the general 
population or, more appropriately, to age- and sex-matched controls. More than 40% of 
deaths were due to cardiovascular diseases, including ischemic heart disease and heart failure. 
Young adults with RA appear to have a particular propensity for increased cardiovascular 
disease, compared with individuals without RA (Solomon et al. 2006). RA patients also seem 
to have an increased risk of fatality following myocardial infarction (assessed as the 30 day 
mortality rates following a first acute cardiovascular event) (Van Doornum et al. 2006). 
The mechanism(s) underlying this increased frequency of cardiovascular disease and 
mortality in RA are unclear. Besides the involvement of classical cardiovascular disease risk 
factors, such as an adverse lipid profile seen in RA patients, the inflammatory nature of RA 
may provide a link with accelerated atherogenesis (Gonzalez-Gay et al. 2005). For example, a 
significant correlation has been reported between atherosclerosis, measured as increased 
carotid artery intima-media thickness, and acute phase response markers CRP and ESR (Del 
Rincon et al. 2003; Del Rincon et al. 2006). However a central contributor to the enhanced 
cardiovascular disease seen in RA may be the vasculature. The endothelial lining of blood 
vessels has a critical function in the process of atherogenesis, serving as the site of initial 
injury and leukocyte adhesion/migration and hence playing a central role in development of 
the atherosclerotic plaque (Ross 1999). Maintenance of an intact vascular lining and an 
uninterrupted vascular supply is thus critical in the prevention of the cascade of events which 
trigger acute coronary syndromes such as myocardial infarction. Endothelial dysfunction is 
known to occur in RA, providing a possible link between these seemingly disparate 
pathologies. More particularly, there is evidence that ECs present in the circulation are 
capable of integrating into vessel walls, and that it is these endothelial progenitor cells which 
particularly link RA with increased cardiovascular morbidity and mortality. 
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1.2.1 Pathogenesis of RA 
A key feature of RA is an alteration in the synovial lining component (Figure 1.4). 
Normal synovium provides a protective layer, a few cells thick, over joints and tendons. In 
RA, this synovial lining becomes thickened through hyperplasia of the lining cells and 
infiltration by cells from the circulation, predominantly T-cells, B-cells and macrophages 
(Schumacher et al. 1994). This eventually leads to the formation of a thick multilayered 
granulation tissue, termed a pannus (FitzGerald et al. 1991; Mor et al. 2005; Taylor 2005). 
This tissue is histologically different from any other regions in the synovium, and it has been 
shown to derive from FLS, which normally make up the synovial lining together with 
macrophage-like synoviocytes (MLS) (Lee and Weinblatt 2001; Mor et al. 2005). The pannus 
has the propensity for local invasion at the interface of cartilage and bone, with progressive 
joint and soft tissue destruction mediated principally by matrix degrading metalloprotease 
enzymes. The healthy synovium has a rich vasculature, which is needed in order to supply the 
normally avascular articular cartilage with oxygen and nutrients (Walsh and Pearson 2001). 
The RA synovium experiences upregulated angiogenesis compared to that of control 
individuals, and synovial vascularisation is highly correlated with disease activity in the 
rheumatoid joint (reviewed in (Taylor 2005)). Angiogenesis is detected at an early stage and 
throughout disease, where it contributes to the development and persistence of the pannus by 
supplying the tissue with nutrients and oxygen, in addition to providing the surface for the 
ingress of inflammatory cells and mediators (Clavel et al. 2003). The inflammatory cells are 
activated in situ in the synovial tissue, to secrete a complex variety of cytokines, chemokines 
and antibodies (Jenkins et al. 2002). Much of the research in RA so far has focused solely on 
destruction of synovial lined joints. However, the involvement of soft tissues, primarily 
tendons and ligaments, is also a prominent feature. For example, 50% of patients with RA 
have tendon involvement, and dorsal wrist swelling due to tenosynovitis is often the first 
presentation of the disease (Williamson and Feldon 1995). Proliferation of the synovial lining 
of tendons causes scarring and adhesion formation and 50% of patients with tendon disease 
will also show tenosynovial invasion into the tendon substance itself. This invasion is 
associated with multiple tendon ruptures and a poorer prognosis for long-term hand function 
(Ertel 1989). 
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Figure  1.4 Comparison of normal and rheumatoid joints 
Synovial lining hyperplasia with the ingress of inflammatory cells, inflammation and formation of an 
invasive pannus result in bone and cartilage destruction in RA joints. Hypoxic regions are created as 
the hyperplastic tissue expands which in turn leads to the formation of angiogenesis. A normal joint is 
shown for comparison. Adapted from (Feldmann 2002). 
 
 
 
 
 
 
 
 
 
 
 
1.2.2 Current treatments for RA 
The classic disease-modifying antirheumatic drugs (DMARDs) and small doses of 
glucocorticoids used early, aggressively, alone or in combination in the treatment of RA are 
the cornerstones of the current management of RA disease to suppress inflammation and halt 
disease progression. DMARDs are used as a first line option in newly diagnosed patients with 
RA where they influence disease progress and also slow down joint and bone destruction. 
MTX is the drug of choice for early and established disease or after failure with other 
DMARDs, while other choices include leflunomide, sulfasalazine and cyclosporine A. 
However, current treatment with DMARDs is inadequate, because they only partially control 
disease activity. Only 5-20% of RA patients achieve remission or clinical improvement that 
approaches clinical remission (reviewed in (Blumberg and Fox 2001)). DMARDs also have 
adverse effects that limit their use during course of disease and interfere with prolonged 
administration. Radiological progression continues even in RA patients with clinical 
improvement who take DMARDs (Hulsmans et al. 2000). Moreover, the efficacy of 
DMARDs for the treatment of the extra-articular manifestations of RA (including tendon 
involvement) has not yet been demonstrated.  
The unmet needs in the RA treatment triggered the development of biologic agents 
and more recently etanercept, infliximab and adalimumab, which act by inhibiting TNFα, 
have become available (Table 1.1). These therapeutic agents show impressive clinical effects 
alone or in combination with DMARDs and have proven very effective in patients not 
responding to conventional DMARDs alone (reviewed in (Voulgari 2008)). The TNFα 
inhibitors have shown a quicker onset of action than DMARDs and are now becoming the 
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most prescribed drugs for moderate to severe RA cases. Unfortunately, 30-40% of patients 
with established disease fail to respond to TNFα inhibitors with failure to achieve a 20% 
improvement in the American College of Rheumatology criteria (ACR20) and more lose 
response or experience adverse effects over time (reviewed in (Voll and Kalden 2005)). 
Optimal treatment strategies have yet to be defined for patients who have exhibited an 
inadequate response or were intolerant to an initial TNF inhibitor, because there have been no 
randomised trials comparing the strategies of cycling between TNF inhibitors versus using an 
agent with a different mechanism of action. Some questions have been raised over the short 
and long-term tolerability of these agents and their safety profile. Anti-TNFα treatment has 
been associated with increased risk of tuberculosis (TB), usually reactivation of latent 
infection, making TB screening mandatory before patients can commence treatment 
(reviewed in (Hamilton 2004)). Primary lymphomas have also been reported, but the role of 
TNFα blockade in induction of malignancies is unknown. Other side-effects include 
worsening of pre-existing heart failure, new onset demyelinating disorders and worsening of 
multiple sclerosis (reviewed in (Voulgari 2008)). In addition, it has been suggested that 
tenosynovitis is refractory to novel medical approaches such as anti-TNFα therapy (reviewed 
in (Kaiser et al. 2002)). As a result, surgery remains the mainstay of treatment for tendon 
disease, which contributes significantly to the extra-articular manifestations of RA. 
In recent years therapeutic options in non-responders or patients which experience 
adverse effects to anti-TNFα treatment have increased with the introduction of biologic anti-
rheumatic agents with novel mechanisms of action, such as rituximab, tocilizumab and 
abatacept (Table 1.1). In RA the presentation of an appropriate antigen to CD4+ by an antigen 
presenting cell (APC) is the initial event that leads to T-cell activation. In addition to this first 
event, a second activating event is necessary for T-cell activation, in which co-stimulatory 
molecules, such as CD80 and CD86 on the APC and CD28 on the T-cell, trigger activation. In 
contrast, cytotoxic T lymphocyte-associated antigen (CTLA)-4 on T-cells functions to 
downregulate the immune response by binding to both CD80 and CD86 thereby inhibiting co-
stimulation of T-cells (reviewed in (Voulgari 2008)). The biologic agent, abatacept, is 
developed as a CTLA-4 immunoglobulin (Ig) fusion protein and its therapeutic effect is thus 
to selectively inhibit T-cell co-stimulation and as such is the first of its kind (reviewed in 
(Voll and Kalden 2005)). It was approved in 2006 for the treatment of patients who have 
exhibited an inadequate response to or were intolerant of one or more DMARDs or TNF 
inhibitors in Europe. Superior efficacy of abatacept combined with at least one DMARD 
relative to placebo has been demonstrated in patients exhibiting an inadequate response to 
therapy with TNFα inhibitors (Genovese et al. 2005). 
The activated T-cells in the RA synovium secrete large amounts of inflammatory 
CHAPTER 1                                                                                                             Introduction 
 38
cytokines in addition to activating other cells to do the same. Although both pro- and anti-
inflammatory cytokines are produced, the balance is shifted towards pro-inflammatory 
cytokines (Firestein 1991). This is where the cytokine modulators come in, including the 
above mentioned TNF inhibitors, and also anakinra and tocilizumab, inhibitors of IL-1 and 
IL-6 respectively. The IL-1 receptor antagonist, anakinra, needs to be administered daily 
subcutaneously due to its short half-life, making it a less preferable choice for patients. 
Despite positive pre-clinical studies, anakinra has failed to provide adequate therapeutic value 
in practise as only a small subset of patients show clinical improvement (Konttinen et al. 
2006). Anakinra is not used in combination with TNF antagonists due to increased risk of 
severe infections. Tocilizumab, directed against the IL-6 receptor, is a chimeric monoclonal 
antibody which works to reduce inflammation by blocking IL-6-mediated signal transduction, 
was recently approved by the European Commission for use in patients with inadequate 
response to treatment to TNF inhibitor (Emery et al. 2008). 
B-cells are also important in the pathophysiology of RA as they secrete antibodies 
and cytokines and act as APCs hereby perpetuating inflammation. The monoclonal antibody 
rituximab is directed against CD20 surface antigen and induces C1q complement dependent 
cytotoxicity and antibody-dependent cell-mediated cytotoxicity through natural killer cells, 
macrophages and monocytes. This leads to transient B-cell depletion through cell lysis and 
apoptosis (Edwards et al. 2004). Rituximab was approved in 2006 for treatment of RA 
patients failing TNFα inhibitors. Cohort studies recently suggested that rituximab may be 
more effective than switching to an alternative TNF inhibitor in patients with an inadequate 
response to at least one TNF inhibitor. Rituximab seems well tolerated and adverse effects are 
usually limited to mild to moderate infusion reactions. No opportunistic infections have been 
observed and in a pooled analysis of three randomised trials mean values of IgG and IgM 
remained well above the lower limit of normal (reviewed in (Rubbert-Roth and Finckh 
2009)). 
Table 1.1  Existing biologic therapies in RA 
 
Name Brand 
name 
Biological structure Biological action From: 
Infliximab Remicade Chimeric monoclonal 
antibody  
TNF inhibitor Johnson & 
Johnson 
Adalimumab Humira Human monoclonal 
antibody 
TNF inhibitor Abotts 
Laboratories 
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Continued…. 
Etanercept Enbrel Soluble TNF-R-Fc 
fusion protein 
TNF inhibitor Wyeth 
Rituximab MabThera Monoclonal antibody 
against CD20 surface 
antigen  
Depletes CD20+ B-
cells 
Genentech & 
Roche 
Abatacept Orencia CTL-4 Ig fusion 
protein 
Inhibitor of T-cell 
co-stimulation 
Bristol-Myers 
Squibb 
Company 
Anakinra Kineret Recombinant receptor 
antagonist of IL-1 
Blocks IL-1 
signalling 
Amgen 
Tocilizumab Actemra Chimeric monoclonal 
antibody against IL-6R 
Inhibits IL-6 
signalling  
Roche and 
Chugai 
 
This first generation of biologic anti-rheumatic drugs which include the 
TNFα inhibitors are now in clinical practice showing efficacy and good tolerability and can 
be combined with DMARDs in a more effective treatment regime. As several factors are 
involved in the pathogenesis of RA, blocking one or more of the steps leading to an 
inflammatory cascade seems the way forward. In addition to the above mentioned biologics 
treatments, second generation anti-rheumatic drugs that modulate T-cell activity targeting T-
cell co-stimulatory molecules, B-cells, cytokine inhibitors or agents that modulate kinases 
(including p38 MAPK), RANK/RANKL inhibitors, chemokines, metalloproteinases, 
adhesion molecules and small molecules with various actions in the inflammatory cascade are 
all in development for the management of RA. In parallel to the development of new 
therapeutics it remains important to identify the differences between responders and non-
responders to treatment of the various biologics, such as genetic polymorphisms in genes 
coding for the targeted factors eg. TNFα. Gene profiling studies before and after treatment 
should also supply clues for a better tailoring of treatment to patients. Importantly, more 
patient exposure and long-term safety monitoring are warranted to establish safety profiles of 
all the newer biological anti-rheumatic drugs. 
1.3 ANGIOGENESIS 
Angiogenesis is part of the adaptive response to hypoxia in which tissues attempt to 
restore oxygen tensions back to normal. Angiogenesis is defined as the process by which 
blood vessels form by the sprouting of pre-existing capillary plexuses generated by 
vasculogenesis. Under normal physiological conditions, angiogenesis takes place only during 
maturation of the vascular bed, wound repair and fracture healing and the female reproductive 
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cycle. Otherwise the vascular endothelium is maintained in a state of quiescence which is the 
result of a tightly regulated system of opposing angiogenic regulators (reviewed in (Folkman 
1995)). 
1.3.1 VEGF: a hypoxia-inducible angiogenic factor 
VEGF is known as a very potent and highly EC-specific angiogenic mediator 
(Folkman et al. 1971), but was originally described as a vascular permeability factor produced 
by tumour cells that promoted accumulation of ascites fluid (Senger et al. 1986). VEGF is 
strongly induced by hypoxia but is also upregulated by several cytokines and growth factors 
(Jackson et al. 1997; Sanchez-Elsner et al. 2001; Shih and Claffey 2001). The process of 
angiogenesis is composed of a series of tightly regulated events and it is now evident that 
VEGF plays a pivotal role during most, if not all of these steps, in both normal and 
pathological angiogenesis. VEGF induces proliferation, elongation and movement of EC, 
degradation of the EC basement membrane, remodelling of the extracellular matrix (ECM), 
the formation of capillary tubules and vascular leakage (Peters et al. 1993; Koch et al. 1994; 
Neufeld et al. 1999; Wu et al. 2000). The gene for human VEGF is organized into eight 
exons, and the resultant RNA undergoes alternative splicing events to generate at least five 
transcripts encoding VEGF proteins containing 121, 145, 165, 189 and 206 amino acids. The 
various VEGF isoforms exhibit different heparin-binding properties, which govern whether 
the proteins are secreted or remain cell-associated (Neufeld et al. 1999). VEGF exerts its 
biological effects on blood vessels by binding to two homologous transmembrane receptors, 
VEGF receptor 1 (VEGFR-1/Flt-1) and VEGF receptor 2 (VEGFR-2/Flk-1/KDR), whose 
expression is mainly restricted to ECs (Millauer et al. 1993; Peters et al. 1993). Both VEGF 
and its receptors are intimately involved in regulation of both embryonic vasculogenesis and 
angiogenesis (Neufeld et al. 1999). Angiogenesis is now recognised as a fundamental 
component of disease progression and joint destruction in RA (Afuwape et al. 2002) and 
VEGF is thought to constitute the biggest culprit in pathological synovial angiogenesis. 
1.3.2 Angiogenesis and RA 
At the cellular level, early changes in the RA synovium include angiogenesis, 
inflammatory cell infiltration and synovial hyperplasia (see Section 1.4). Angiogenesis in the 
synovial membrane is considered by many investigators to be an important early step in 
pathogenesis of RA and in the perpetuation of disease (Walsh 1999; Koch 2003). 
Histologically, luxuriant vasculature is a prominent feature of RA synovitis, evident on 
microscopic examination of synovial biopsies from the earliest stages of disease evolution 
(Schumacher et al. 1994; FitzGerald and Bresnihan 1995). Indeed, synovial angiogenesis may 
precede other pathological features of RA. For example, in a patient with very early RA, 
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changes in vascular density were demonstrated without either lining cell proliferation or 
mononuclear cell infiltration (Hirohata and Sakakibara 1999). The number of synovial blood 
vessels has been found to correlate with synovial cell hyperplasia, mononuclear cell 
infiltration and indices of joint tenderness (Rooney et al. 1988). ECs lining blood vessels 
within RA synovium have been shown to express cell cycle-associated antigens, including 
Ki67, as well as integrin αVβ3, which is associated with vascular proliferation (Ceponis et al. 
1996; Walsh et al. 1998). These changes in vascular supply are thought to be necessitated by 
the hyperplastic nature of RA synovial tissue, which as it expands, requires a compensatory 
increase in the number of synovial blood vessels. The new blood vessels supply nutrients and 
oxygen to the augmented inflammatory cell mass. In addition, delivery of inflammatory cells 
and molecules is also maintained, thus perpetuating the synovitis. 
Angiogenesis in the inflamed synovium is driven by a disruption in the balance of 
angiogenic factors in favour of angiogenesis with the upregulation of a variety of angiogenic 
stimulators, including VEGF. VEGF isoforms VEGF165 and VEGF121 appear to be the 
predominant forms expressed (Pufe et al. 2001). VEGF protein levels are elevated in the 
serum and synovial fluids of RA patients (Fava et al. 1994; Koch et al. 1994; Lee and 
Weinblatt 2001), and correlate with levels of CRP (Harada et al. 1998; Kikuchi et al. 1998; 
Paleolog et al. 1998; Lee et al. 2001; Sone et al. 2001b). VEGF levels are increased even in 
RA patients with disease duration of less than two years, and predict subsequent joint 
destruction, further supporting the concept that angiogenesis may be a very early event in RA 
progression (Ballara et al. 2001; Latour et al. 2001; Clavel et al. 2007). Serum VEGF levels 
are also apparently higher in patients with extra-articular manifestations of RA (Kuryliszyn-
Moskal et al. 2006). A potential stimulus known to upregulate expression of VEGF, as well 
as of other genes relevant to RA pathogenesis, is low oxygen tension i.e. hypoxia. 
Many other pro- and anti-angiogenic factors have been reported to be expressed in 
RA synovium (reviewed in (Sivakumar et al. 2004; Sivakumar and Paleolog 2005; 
Bainbridge et al. 2006; Taylor and Paleolog 2006)) in addition to VEGF. Members of the 
fibroblast growth factor (FGF) family, FGF-1 and FGF-2, have been detected in human RA 
synovial tissue (Sano et al. 1990; Sano et al. 1993), as has platelet-derived growth factor, a 
potent mitogen for many cell types including fibroblasts (Remmers et al. 1991). Hepatocyte 
growth factor, or scatter factor, so called due to its ability to disperse cohesive epithelial 
colonies, has been found at significant levels in RA synovial fluids (Yukioka et al. 1994; 
Koch et al. 1996; Feuerherm et al. 2001). Furthermore, expression of both angiopoietin 
(ANGPT)-1 and -2 in RA synovial tissue has been described (Scott et al. 2002; Gravallese et 
al. 2003), together with receptors Tie-1 and Tie-2 (Shahrara et al. 2002; DeBusk et al. 2003). 
Furthermore, placental growth factor (PlGF) is also expressed in RA synovial fluids 
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(Bottomley et al. 2000). PlGF, like VEGF-A and VEGF-B, binds to VEGFR-1 (and to soluble 
VEGFR-1), but in contrast to VEGF, PlGF does not bind VEGFR-2 (Autiero et al. 2003a; 
Tjwa et al. 2003). PlGF not only appears to induce distinct signalling events via VEGFR-1, 
but also to amplify VEGF-driven activation through VEGFR-2 and to complex with 
VEGF/VEGFR-2 forming heterodimeric complexes which trans-phosphorylate each other 
(Autiero et al. 2003b). Interestingly, PlGF-deficient mice are viable, and do not display major 
vascular abnormalities. Moreover, loss of PlGF does not impair reproduction, suggesting that 
this molecule is not essential during physiological angiogenesis, for example during 
development, skeletal bone growth or in the female reproductive cycle (Oosthuyse et al. 
2001). Instead, PlGF may play a more pronounced role in pathological angiogenesis, as 
evidenced by impaired tumour growth and vascularisation in mice lacking this molecule. 
To summarise, a strong pro-angiogenic drive appears to exist in RA synovium. It is 
not yet known which (if any) is the predominant angiogenic stimulus in RA, since blockade 
of many of the above factors appears to decrease angiogenic activity in in vitro assays. 
1.3.3 Anti-angiogenic therapy: prospects for RA 
The proliferative and invasive nature of arthritic synovium has frequently led to 
comparisons with tumour development. Both the arthritic synovium and the growing tumour 
exhibit the apparently paradoxical features of hypoperfusion and concomitant angiogenesis, 
and thus it is possible in theory at least to extrapolate from experience in tumour biology to 
that of angiogenesis blockade in RA. The idea of a therapeutic modality aimed at ‘starving’ a 
tissue of blood vessels, and consequentially of oxygen and nutrients, was born from the 
concept that angiogenesis is central to the progression and maintenance of diseases which 
involve tissue expansion/invasion. Thus many known compounds developed originally for 
angiogenic therapy in cancer are now being tested extensively in various rodent models for 
arthritis with the aim of developing novel therapeutic interventions for RA based on inhibition 
of angiogenesis. 
As was mentioned in the previous Section, several factors including growth factors, 
cytokines, chemokines, proteolytic matrix-degrading enzymes, cell-adhesion molecules and 
others may promote angiogenesis in the RA synovium. In addition to these pro-angiogenic 
factors numerous endogenous angiostatic factors are also produced in the RA synovium, but 
the distribution of pro- and anti-angiogenic factors is balanced in the favour of angiogenesis. 
The existence of naturally engineered angiostatic factors which suppress the induction and 
action of angiogenic mediators opens up for two major strategies to combat excessive and 
pathological angiogenesis in the RA synovium. Firstly, as the synovial level of endogenous 
inhibitors does not appear to be high enough to counterbalance pro-angiogenic factors and 
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stall angiogenesis, a therapeutic regime can be based on the addition of naturally occurring 
inhibitors in excess. Secondly, numerous synthetic compounds currently used in the control of 
inflammation in RA such as TNF inhibitors, corticosteroids and some DMARDs have shown 
to block angiogenesis, further supporting the tight link between angiogenesis and 
inflammation in the synovium. Novel synthetic anti-angiogenic compounds specifically 
directed against angiogenic mediators, such as VEGF, are also being tried out in several 
rodent models for arthritis. 
Suppression of angiogenesis in arthritis using physiological occurring angiostatic 
mediators has been carried out in rodent models. Angiostatic agents which may have future 
therapeutic roles include (1) endostatin, the internal fragment of collagen type 18, (2) 
angiostatin, a cleavage fragment of plasminogen, (3) tumstatin, (4) platelet factor-4, a platelet 
derived chemokine, (5) thrombospondin-1 and (6) a 16-kDa N-terminal fragment of prolactin 
(reviewed in (Tabruyn and Griffioen 2007)). In a study by Kim et al. NIH 3T3 cells carrying 
angiostatin expressing retroviral vectors were transplanted into knees of mice before disease 
onset. This local expression of the human angiostatin gene controlled the outcome of disease, 
which was reflected in the reduction of pannus formation and cartilage destruction (Kim et al. 
2002). The therapeutic effect was also accompanied by a decreased vascularity in the knee 
joints of mice treated with angiostatin compared to knee joints of control mice. Suppression 
of disease has also been demonstrated using virus vector-mediated transfer of angiostatin 
(Kato et al. 2005; Takahashi et al. 2005). Sumariwalla et al. assessed the effect in collagen-
induced arthritis (CIA) of K1-5, protease-activated kringles 1-5, an angiogenesis inhibitor that 
is related to angiostatin but shows enhanced anti-angiogenic activity. Mice received a daily 
treatment with K1-5 when first macroscopic signs of arthritis occurred. Daily treatment with 
K1-5 reduced paw swelling and clinical score compared to untreated animals. Additionally, 
histological assessment of arthritic paws revealed a reduction in joint inflammation and 
destruction (Sumariwalla et al. 2003). Endostatin has been shown to also be effective in both 
murine arthritis models and the rat adjuvant-induced arthritis model by suppressing synovial 
proliferation and joint destruction (Yin et al. 2002; Lainer-Carr and Brahn 2007; Yue et al. 
2007). Kallistatin, another endogenous angiogenesis inhibitor present in the joints of RA 
patients, has been shown to attenuate the progression of arthritis when injected into rat ankles 
(Wang et al. 2007b). Thrombospondin (TSP)-1 and -2 are both angiostatic ECM components 
produced by RA synovial macrophages and fibroblasts. TSPs link connective tissue 
molecules to adhesion receptors, such as integrins. A TSP-1-derived peptide ameliorated 
inflammation and angiogenesis in a rat model of arthritis (Rico et al. 2007), and TSP-2 
inhibited angiogenesis in the SCID (severe combined immunodeficiency) mouse model of 
arthritis (Park et al. 2004). 
Traditional DMARDs and the newer biologics are used to target various components 
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of and control inflammation in RA. However, these compounds also seem to have non-
specific effects on synovial angiogenesis. Treatment of RA, for example with inhibitors of 
TNFα (alone or with MTX), with other DMARDs or IL-6 receptor antibody, significantly 
reduced systemic and synovial release of VEGF resulting in attenuated synovial 
vascularisation in patients (Paleolog et al. 1998; Nagashima et al. 2000; Ballara et al. 2001; 
Nakahara et al. 2003; Aggarwal et al. 2004; Klimiuk et al. 2004; Macias et al. 2005). Anti-
TNFα treatment of RA patients also reduced ANGPT-1-Tie2, but stimulated ANGPT-2 
expression (Markham et al. 2006). Interestingly, the hypoxia-HIF axis has been shown to be 
targeted indirectly by non-specific inhibitor compounds such as 2-methoxyoestradiol and 
taxol (paclitaxel). The main effect of these two drugs, of which paclitaxel is already used in 
human cancer, is to destabilise the cytoskeleton but have shown to have secondary effects of 
blocking HIF-1α expression and activity too. Paclitaxel has been shown to be safe and 
effective in RA patients in a phase I study (Lainer-Carr and Brahn 2007). The endogenous 
oestrogen metabolite 2-methoxyoestradiol, was shown to be a potent inhibitor of EC 
proliferation (Fotsis et al. 1994) and to exhibit anti-angiogenic activity in vivo in tumour 
models (Ireson et al. 2004) and the biologically active oestrogen molecule, 17β-oestradiol, 
has been reported to reduce the severity of murine arthritis (Holmdahl et al. 1987). 
Interestingly, the severity of RA is reduced during pregnancy, supporting a possible role for 
oestrogen in arthritis. This may be of future relevance, since 2-methoxyoestradiol is in clinical 
trials for different malignancies, and trials in RA are being considered. 
TNP-470 is a synthetic analogue of fumagillin, a naturally occurring fungal antibiotic 
from Aspergillus fumigatus and was proven to be effective in the treatment of arthritis in 
different animal models (Peacock et al. 1992; Oliver et al. 1994; Oliver et al. 1995; Peacock 
et al. 1995). The mechanism of action was suggested to be inhibition of angiogenesis since 
peripheral blood VEGF levels were reduced by TNP-470 (Oliver et al. 1995). In the 
SCID/HuRAg model, TNP-470 treatment reduced the number of blood vessels and synovial 
lining cells (Nagashima et al. 2002). Interestingly, TNP-470 and fumagillin both selectively 
and irreversibly inhibited the enzyme methionine aminopeptidase (MetAP) type 2 isoform, 
involved in protein maturation. Bernier et al. have described an irreversible inhibitor of 
MetAP-2 which not only inhibited proliferation of ECs and fibroblasts, but also showed 
significant in vivo activity in a rat model of peptidoglycan-polysaccharide-induced arthritis 
(Bernier et al. 2004; Bernier et al. 2005). Inhibition of MetAP-2 in the CIA model was also 
shown to reduce murine joint inflammation and destruction (Bainbridge et al. 2007). 
As described in Section 1.3.1, VEGF plays a central role in synovial, as well as 
tumour angiogenesis. Thus, VEGF could likewise constitute a primary therapeutic target in 
the RA synovium. VEGF inhibition using synthetic VEGF and VEGFR inhibitors, anti-VEGF 
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antibodies as well as inhibition of VEGF-VEGFR signalling has therefore been the focus of 
considerable clinically-oriented research, and interestingly angiogenesis blockade has been 
shown to be effective in different in vivo rodent models of arthritis. In a study in the CIA 
model, the level of VEGF expression correlated with disease severity and the degree of 
neovascularisation as assessed by the expression of von Willebrand factor (vWf). 
Neutralisation of VEGF activity by administration of anti-VEGF antibody delayed disease 
onset, but appeared less effective when administered during the chronic phase of disease (Lu 
et al. 2000). In another study, application of anti-VEGF treatment in established bovine CIA 
inhibited synovitis, as indicated by a reduction in clinical scores and paw swelling relative to 
untreated mice (Sone et al. 2001a). A soluble form of VEGFR-1 (soluble Flt-1), a naturally 
occurring antagonist of VEGF, has been shown to significantly suppress established arthritis 
in a murine model where reductions in the extent and severity of disease, decreased paw 
swelling and joint destruction was observed. Furthermore, decreased levels of VEGF and vWf 
were found in ankle lysates of these animals (Miotla et al. 2000; Afuwape et al. 2003).  
A different strategy to limit angiogenesis via the VEGF pathway is to target VEGFR 
directly. The group of Carmeliet compared different approaches targeting VEGF (using anti-
VEGFR-1 and anti-VEGFR-2 antibodies) in the murine CIA model. Treatment with anti-
VEGFR-1 reduced the incidence of joint disease by 60%, and suppressed the development of 
clinical symptoms by 85%, whereas anti-VEGFR-2 appeared ineffective (Luttun et al. 2002). 
The VEGFR tyrosine kinase inhibitor PTK787/ZK222584 has also been shown to be effective 
in arthritis models (Grosios et al. 2004). It is interesting to speculate whether targeting VEGF 
or VEGFR-1 actually translates to angiogenesis inhibition in vivo or whether secondary 
effects of VEGF inhibition is taking place. The expression of VEGFR-1 on monocytes has 
been reported, and has been suggested to mediate VEGF-induced monocyte migration (Clauss 
et al. 1996; Sawano et al. 2001). This might imply that part of the observed effects of anti-
VEGF, anti-VEGFR-1 or soluble VEGFR-1 could be mediated by attenuation of monocyte 
migration. In terms of dissecting out the mechanism of action of VEGF blockade in vivo, 
reduced angiogenesis is likely to result in decreased inflammatory cell trafficking, and vice 
versa, further emphasising the strong interdependent link of hypoxia, angiogenesis and 
inflammation in synovial pathology. 
These studies support the role of angiogenesis in RA development and implicate 
angiogenesis and VEGF as being important in this process. It is likely that the blockade of 
angiogenesis holds the potential for considerable therapeutic benefit in the future for RA, and 
many of the above mentioned drugs are already in preclinical or clinical trials. However, there 
may be limitations of angiogenesis inhibition in RA. As there is a complex regulatory 
network of angiogenesis in the synovium consisting of hundreds of mediators, targeting 
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strategies using agents with multiple actions such as that targeting of the VEGF axis, may be 
more effective than targeting a single player in the angiogenic cascade. The future anti-
angiogenic drugs designed and tested for treatment in RA will most likely be prescribed in 
combination with existing anti-inflammatory treatments such as DMARDs or the anti-
cytokine treatments to obtain maximal efficacy against disease activity. 
1.3.4 Anti-angiogenic therapy in cancer and other diseases 
Most of the solid tumours generated in breast, lung, renal, colorectal and liver tissues 
express high levels of VEGF compared to normal tissue due to hypoxic stress and are highly 
vascularised. Over-production of VEGF in tumours increases vascular permeability 
contributing to the formation of ascites tumours. Bevacizumab (avastin) is a recombinant 
humanised anti-human VEGF-A neutralising antibody which has shown to improve 
significantly the disease-free survival rate as well as the overall survival rate in late-stage 
colorectal cancer patients in a phase-III clinical trial. The Food and Drug Administration 
(FDA) has approved bevicizumab in the U.S.A. for use in the treatment of stage-III-IV 
colorectal cancer in combination with conventional therapy, and for the treatment of non-
squamous, non-small cell lung cancers (Hurwitz et al. 2004; Sandler et al. 2006). Moreover, 
bevacizumab is licensed in the European Union for the first-line treatment of patients with 
metastatic cancer of the colon or rectum in combination with fluorouracil (5-FU) and folinic 
acid (leucovorin) with or without irinotecan. Although the original concept was to inhibit 
outgrowth of new tumour vessels, bevacizumab also suppresses tumour growth by causing 
regression and normalisation of existing tumour vasculature and recruitment of bone marrow-
derived progenitor cells (Presta et al. 1997). A clinical study by Willett et al. showed that 
treatment of human rectal cancer with VEGF-specific antibody produced a decrease in 
tumour perfusion, vascular volume, microvascular density, increased pericyte coverage of the 
vasculature and a significant decrease in interstitial fluid pressure (Willett et al. 2004). 
Furthermore, bevacizumab may exert a pro-apoptotic effect by provoking tumour cells to 
enter cell-death pathways as a response to oxygen and nutrient deprivation resulting from 
regression of tumour vasculature (Yao et al. 2005). 
VEGFR small molecule inhibitors sorafenib and sunitinib have been approved for the 
treatment of renal cell carcinoma as these drugs significantly improved the survival of renal 
cancer patients compared with previous therapeutic cytokine strategies. Moreover, sorafenib 
has been approved for hepatocellular carcinoma patients. Although inhibiting VEGF has 
proved very effective in certain cancer types, other cancers such as pancreatic cancers seem 
resistant to anti-VEGF treatment. This is most likely due to the fact that these tumours are less 
vascularised and not as dependent on angiogenesis for their growth as for instance colon 
cancers (reviewed in (Shibuya 2008)). 
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Another disease in which anti-angiogenic therapy has proved beneficial is in age-
related macular degeneration (AMD). It is characterised by elevated levels of VEGF-A in the 
retina, pathophysiological growth of choroidal vessels through the Bruch’s membrane into the 
sub-retinal pigment epithelial (RPE) space, usually leading to accumulation of fluid in the 
sub-RPE space and detachment of the RPE. Two therapeutic inhibitors of VEGF-A, 
pegaptanib sodium (Macugen) and ranibizumab (Lucentis; monoclonal anti-VEGF antibody 
fragment derived from the same parent murine antibody as bevacizumab), are FDA approved 
for the treatment of choroidal neovascularisation secondary to AMD. Bevacizumab has also 
been employed for angiogenesis in AMD. Injection of these antibodies into the eye 
significantly improved visual acuity of AMD patients by arresting VEGF-A induced 
choroidal neovascular growth and reducing vascular permeability (reviewed in (Ciulla and 
Rosenfeld 2009)). 
1.4 INTERPLAY BETWEEN INFLAMMATION, ANGIOGENESIS AND HYPOXIA 
The pro-angiogenic profile that characterises the RA synovium is thought to be the 
result of at least two major driving forces, namely local tissue hypoxia and the presence of 
inflammatory cytokines. Pathophysiological angiogenesis in the synovium in turn allows for 
synovial hyperplasia, leading to increased synovial mass, and further ingress of inflammatory 
cells thus forming a self-perpetuating downward spiral composed of pathological hypoxia, 
angiogenesis, and inflammation (Figure 1.5).  
1.4.1 Relationship between hypoxia and hyperplasia in RA 
The cellular response to hypoxia and the potential role of the hypoxic response in RA 
has been largely extrapolated from studies of tumours. The main consequence of hypoxia is 
the rapid protein stabilisation and accumulation of HIF-1 and HIF-2 which is induced when 
the oxygen levels decrease below 5-6% (see Section 1.1), as has been shown in vitro in a 
variety of cell types (Jiang et al. 1996; Wiesener et al. 1998). The presence of hypoxic 
regions in the RA synovium has been confirmed by immunohistochemical studies showing 
expression of HIFs in RA synovial tissue subjected to 1% oxygen, where the staining 
appeared to be confined to the hyperplastic FLS in the synovial lining of RA tissue (Hollander 
et al. 2001; Hitchon et al. 2002). In an animal model of arthritis, HIF-1α was shown to be 
associated with areas of hypoxia in inflamed joints (Kung et al. 2004). In a different study, 
significant cytoplasmic and nuclear overexpression of both HIF-1α and HIF-2α was found in 
synovial lining and stromal cells of RA patients relative to healthy synovium (Giatromanolaki 
et al. 2003). 
Hypoxic RA synovial fluids were first described in 1970 by Lund-Olesen, who found 
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that the mean synovial fluid oxygen tension in RA patients was 27mmHg (3.6% oxygen), 
compared to 63mmHg (8% oxygen) in controls and 43mmHg (5.6% oxygen) in OA patients 
(Lund-Olesen 1970). Since this publication, no further reports on synovial pO2 measurements 
in humans were released for many years. A similar study, however, was conducted in a 
murine arthritis model, which showed that the pO2 measured with microelectrodes in the hind 
limb knee joints was significantly lower in arthritic animals compared to control animals 
(Etherington et al. 2002). In a recent publication, in vivo oxygen measurements were taken 
intra-operatively in RA patients undergoing elective hand surgery. Measurements were 
performed in the inflammatory and invasive synovial tissue (rather than fluid) using a 
microelectrode, and oxygen tensions of 2.4%-4.4% oxygen (18 to 33mmHg) were observed 
(Sivakumar et al. 2008). By comparison, control measurements from healthy individuals 
showed a pO2 range of 8.5%-13.5% (65mmHg to 103mmHg) oxygen in the same study, thus 
supporting the notion that RA synovitis is characterised by the presence of hypoxia.  
Figure  1.5 The pathological processes leading to intra-articular joint destruction in RA 
Synovial hyperplasia leads to an increased demand for oxygen and a simultaneous increase in distance 
from the expanding tissue to the existing synovial vasculature. This in turn leads to areas of 
hypoperfusion and local tissue hypoxia. Cells in a tissue exposed to hypoxia respond by upregulating 
HIFs which in turn upregulate pro-angiogenic factors, such as VEGF, and angiogenesis is initiated in 
an attempt to restore oxygen tension back towards normal. The increase in blood vessel content in the 
synovium leads to a larger vessel surface area for further ingress of inflammatory cells and synovial 
hyperplasia. The activated inflammatory cells secrete many types of cytokines, growth factors and 
angiogenic factors, further exacerbating synovial inflammation and joint destruction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Local tissue hypoxia is thought to arise in the RA synovial lining when the resident 
fibroblast population expands in a hyperplastic fashion as is characteristic for RA. The ingress 
of highly activated inflammatory cells into the hyperplastic tissue further increases oxygen 
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consumption and the metabolic demand of the tissue. As the arthritic tissue expands and 
invades the intra-articular space, the tissue furthest from the underlying synovial vessels is 
thought to experience perfusion insufficiency and thus hypoxia. The generation of a hypoxic 
synovial microenvironment in RA is also driven by the accumulation of synovial fluid, which 
is thought to apply pressure on existing vessels, thereby further compromising oxygen flow to 
the synovium. In support of this, Richman et al. have shown that oxygen tensions in the 
synovial fluid vary inversely with volumes of synovial fluid (Richman et al. 1981). A recent 
study assessed whether synovial proliferation (assessed by ultra-sonography as visible 
synovial thickening and nodular or villous appearance) differentially affects hypoxia in RA 
and OA. No difference was found between the OA patients with and without synovial 
proliferation in terms of synovial fluid pO2, whereas RA patients had both increased 
proliferation and significantly lower synovial fluid pO2 levels (Lee et al. 2007b). 
Other factors promoting raised intra-articular pressures as high as 300mmHg include 
movement and accumulation of synovial fluid in involved joints (Jawed et al. 1997). This 
further compromises the vasculature and thus exacerbates hypoxia in an already ischemic 
environment. On completion of movement, intra-articular pressure normalises and small 
vessels refill. However a high proportion of vessels in RA synovium expresses neovascular 
markers, and appears to lack the accessory cells associated with mature vasculature that in 
health permit auto-regulation of blood flow in response to tissue demand. It has been 
demonstrated that in involved joints of mice with CIA, tissue oxygenation is dysregulated in 
response to movement in comparison with healthy non-arthritic mice (Etherington et al. 
2002). Similarly, dysfunctional vasculature in the RA joint fails to maintain adequate tissue 
oxygen homeostasis, and the joint may be susceptible to hypoxic-reperfusion injury, thus 
favouring a redox environment in which cell systems generate ROS via NADPH (Simonini et 
al. 2001). As described previously, ROS present in high concentrations can lead to tissue 
damage. 
To date a lot of research effort has focused on understanding the mechanisms driving 
synovial hypercellularity, and there is evidence for the involvement of at least three individual 
factors: 1) dysregulated proliferation, 2) dysregulated apoptosis of fibroblasts, and 3) 
increased migration into the tissue of inflammatory cells. Increased proliferation of RA FLS 
is a concept supported by the increased presence of growth factors and markers of 
proliferation in the synovial fluids, such as FGF-2 and TGFβ (Qu et al. 1995; Salvador et al. 
2006). Regulators of the cell cycle and of transcription are also abundantly expressed in the 
RA synovium, such as c-Fos, Ras, Myc and macrophage inhibitory factor (MIF) (Trabandt et 
al. 1990; Dooley et al. 1996; Lacey et al. 2003). MIF is found in synovial fluid and has been 
shown to induce RA FLS proliferation in vitro at concentrations similar to those found in 
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synovial fluids (Lacey et al. 2003). More recent contributions include serum amyloid A 
(SAA), a major acute phase reactant and a marker for a variety of inflammatory diseases. 
SAA is present in the synovial fluid and synovium of RA patients and has been shown to 
induce RA FLS proliferation in vitro by increasing levels of intracellular calcium and 
subsequent activation of P42/44 MAPK and AKT, leading to expression of Cyclin D1 (Lee et 
al. 2006).  Similar to various malignant cells, the RA FLS are characterised by being resistant 
to apoptosis. This phenomenon could be explained by an increased expression of anti-
apoptotic molecules by the RA fibroblasts such as Bcl (B-cell lymphoma)-2, NFκB and 
FLICE (Miagkov et al. 1998; Schedel et al. 2002; Kim et al. 2006; Lee et al. 2006). Other 
alterations in genes and gene expression in RA FLS relevant for apoptosis includes PTEN and 
p53 (Pap et al. 2000a; Pap et al. 2000b). Amongst the most recent publications on the subject 
however, is one on SUMO-1 which was shown to alter the resistance of RA FLS to Fas-
induced apoptosis by increasing the recruitment and retention of the pro-apoptotic adaptor 
molecule DAXX to nuclear bodies whereby its effects are inhibited (Meinecke et al. 2007). 
Interestingly, VEGF165 is also reported to act as an inhibitor of fibroblast apoptosis, and is 
reported to do so by binding to neuropillin-1 thus inducing P42/44 MAPK and AKT 
signalling and expression of Bcl-2 (Kim et al. 2006). Controversial findings, however, raise 
questions about the relative contribution of proliferation and apoptosis of RA FLS to synovial 
hyperplasia. First of all, some studies have shown that RA FLS do not proliferate more in 
vitro than normal fibroblasts (Seemayer et al. 2003), and that there are low mitotic counts in 
the synovial lining as assessed by 3H-thymidine incorporation into cultured synovial explants 
(Mohr et al. 1975). Similarly, in vitro experiments have shown a considerable variability in 
the sensitivity of RA FLS to apoptosis (Baier et al. 2003). 
Whether the expansion of the RA synovium occurs via decreased apoptosis and/or 
increased proliferation in addition to the incorporation and retention of inflammatory cells, 
the highly metabolically active tissue is consuming oxygen at a high rate, leading to the 
generation of a hypoxic environment in the RA joint. Low oxygen tensions in conjunction 
with inflammatory cytokines activate HIFs and ensure the production of angiogenic factors 
with concomitant angiogenesis. The pathological process involving tissue hypoxia, 
inflammation, angiogenesis and synovial invasion is set in train, where each step in the 
process sustains the next in a cyclical fashion, eventually leading to joint destruction in RA 
(Figure 1.5). 
1.4.2 FLS – a key cell population in RA pathogenesis 
Several cell types are actively involved in the pathogenesis of RA, but increasing 
attention has been directed toward the non-T-cell elements as potential therapeutic targets. 
FLS are responsible for maintaining normal joint function and homeostasis and are the 
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primary source of articular hyaluronic acid and lubricin amongst other glycoproteins 
(Yamanishi and Firestein 2001). However, due to the high degree of hypoxic exposure at the 
edge of the pannus, FLS are potential inducers and perpetuators of pathological synovial 
angiogenesis, hyperplasia and inflammation in the affected RA synovium. The synovial 
microenvironment is also characterised by elevated levels of inflammatory cytokines, and 
changes in the gene and protein expression profiles in RA FLS are likely to be the result of a 
combination of the effect of both hypoxia and cytokines. 
As the synovial membrane in RA becomes inflamed, the microenvironment changes. 
Consequently this results in changes in the morphology and the biological property of the RA 
FLS. Interestingly, it seems that the change occurring is a stable phenotypic change, rather 
than a feature which can be reversed upon removing the cells from their micro-environmental 
stimuli into cell culture (Pap et al. 2000b). The changes represent alterations in the 
transcription of disease genes and alterations in intracellular signalling pathways. 
Characteristic features of RA FLS are their ability to attach to and invade articular cartilage 
(Muller-Ladner et al. 1996; Pap et al. 2000a) and to grow in an anchorage independent 
manner (Lafyatis et al. 1989). This aggressive behaviour, coined partial-transformation, is 
specific to FLS activated by RA and is not observed in normal FLS, OA or dermal fibroblasts 
(Muller-Ladner et al. 1996). The acquired ability can in part be explained by observations that 
RA FLS have an enhanced expression of cathepsins, matrix metalloproteinases (MMPs) and 
cell surface adhesion molecules. In addition, activated RA FLS can secrete large amounts of 
osteoclast differentiation factor, which further contributes to progressive resorbtion of bone 
and cartilage in the joint (Pap et al. 2000b). Activated RA FLS are also directly involved in 
the propagation of synovial inflammation, as they secrete increased amount of growth factors, 
chemokines and inflammatory cytokines which attracts inflammatory cells to the synovium 
exacerbating ongoing inflammation (Franz et al. 1998; Berse et al. 1999; Berckmans et al. 
2002; Kasperkovitz et al. 2005). 
RA FLS from late stage RA have been reported to constitutively express elevated 
levels of ANGPT-1 and -2 (Scott et al. 2002). However, when the RA FLS were cultured in 
hypoxia the mRNA levels of both angiopoietins were downregulated. In contrast, TGFβ and 
TNFα induced ANGPT-1 but had no effect on ANGPT-2 mRNA expression (Scott et al. 
2002). Stromal cell-derived factor (SDF) -1 is a chemokine of the CXC family involved in 
inflammation and angiogenesis. In the RA synovium, the source of the elevated level of SDF-
1 is thought to be the stromal and lining FLS (Hitchon et al. 2002). This is supported by 
observations that RA FLS cultures are capable of secreting large amounts of SDF-1 in 
response to hypoxia but not in response to TGFβ, IL-1β and TNFα (Hitchon et al. 2002). The 
RA synovial tissue is characterised by abundant infiltration of mononuclear cells and 
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monocyte chemotactic protein (MCP) -1 is significantly elevated in RA synovial fluid and 
tissue (Koch et al. 1992). While hypoxia was reported to have a suppressive effect on both 
MCP-1 mRNA and protein in RA FLS, IL-1β could induce MCP-1 expression (Safronova et 
al. 2003). The level of MCP-1 secretion by RA FLS in the synovium may thus be determined 
by the composition of the stimuli affecting the RA FLS. 
It is now commonly accepted that RA FLS contribute significantly to the cartilage 
and bone degradation observed in the rheumatoid joint. The family of MMPs and the serine 
proteases cathepsins are all matrix-degrading enzymes thought to contribute to this 
destruction (Pap et al. 2000b). MMPs are synthesised by several cell types in the synovium, 
including FLS which have been reported to secrete MMP-1 and -3 in response to hypoxia. 
Interestingly, hypoxia also decreased tissue inhibitor of metalloproteinase (TIMP)-1 in the 
same study, potentially enhancing the activity of MMPs and joint destruction (Cha et al. 
2003). Demasi et al. discovered that IL-1β stimulation of RA FLS in normoxia increased 
MMP activity significantly and that this activity was greatly potentiated by co-stimulating the 
cells with hypoxia (Demasi et al. 2004). 
Adhesion molecules are involved in RA disease and it is thought that resident synovial 
cells expressing elevated levels of adhesion molecules, may contribute to the recruitment of 
inflammatory cells (Pap et al. 2000b; Han et al. 2003). Of particular interest is intercellular 
adhesion molecule (ICAM)-1 which has been shown to be upregulated in a hypoxia-
dependent manner in RA FLS. Interestingly, this increased ICAM-1 expression by RA FLS 
following hypoxia/re-oxygenation was shown to induce hyperadhesion of lymphocytes to the 
RA FLS and involve NFκB activity (Han et al. 2003). Other adhesion molecules 
overexpressed by RA FLS include β1 integrins (Pap et al. 2000b). 
The transformed-like phenotype of RA FLS induced by the hypoxic and inflamed RA 
synovium is thought to explain hyperproliferation of synovial tissue in affected joints. 
Extensive studies of the characteristics and behaviour of RA FLS are needed in order to 
understand these phenotypic changes that FLS undergo in RA, as these changes potentially 
contribute to all aspects of RA pathogenesis, such as angiogenesis, synovial fluid 
accumulation, synovial hyperplasia, matrix degradation and inflammation. 
 
1.5 HYPOTHESIS 
The RA synovium is both hypoxic and has high local concentrations of inflammatory 
cytokines and therefore constitutes a milieu tailored to drive angiogenesis. RA FLS in 
particular are likely to be exposed to the greatest degree of hypoxia at the edge of the invasive 
pannus and therefore may secrete large amounts of angiogenic factors in response to hypoxia 
CHAPTER 1                                                                                                             Introduction 
 53
and inflammatory cytokines. The hypothesis underlying this study was therefore that RA FLS 
are likely contributors to several pathological processes in RA including synovial 
angiogenesis, in part as a result of hypoxia-induced changes in their gene/protein profile. 
1.6 RESEARCH OBJECTIVES 
RA FLS are exposed to both hypoxia and inflammatory cytokines in the RA joint. 
These two types of stimuli are known to regulate HIFs which are potent transcription factors 
known to coordinate the cellular response to hypoxia including the angiogenic response. In 
order to investigate the impact of hypoxia and cytokines on HIF regulation and its 
downstream target genes in RA, FLS from RA patients, as well as total RA synovial 
membrane cells, were cultured under hypoxia alone and/or in the presence of cytokines and 
the following objectives were identified: 
1 To examine the effects of hypoxia and cytokines on the regulation of HIFs in RA FLS at 
the gene and protein level 
2 To identify novel hypoxia-induced angiogenic mediators in RA FLS and determine if 
these are regulated by HIF-1α and/or HIF-2α 
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2 MATERIALS AND METHODS 
2.1 PATIENT SELECTION AND CONSENT 
Full ethical approval was granted for the project before starting the research work 
(Local Ethics Research Committee EC2003-35). The practice and implications of tissue 
donation were discussed with the patients using an information sheet prepared by Dr 
Mohammed Akhavani (Royal Free Hospital, London) and approved by the Ethics Committee. 
Pre-operative informed consent was obtained in all cases. The RA patients were recruited at 
Royal Free Hospital, Hampstead, London, and all had clinically significant rheumatoid hand 
disease at the time of surgery and met the ACR 1987 criteria for RA. Patients were 
predominantly female (81%), and ranged in age from 38 years to 80 years (median age 60 
years, no difference between male and female cohorts). Duration of RA was 7 years or more, 
and patients were on a range of treatments, including MTX, TNFα inhibitors and other 
DMARDs. The FLS used for the for the Human Angiogenesis RT2 ProfilerTM PCR Arrays 
gene expression studies were taken from 5 RA patients, all of whom were female and >70 
years of age, and receiving treatment with methrotrexate and either sulphasalazine or 
diclofenac. 
2.2 CELL CULTURE TECHNIQUES 
Adherent synovial tissue from RA joint synovium was enzymatically dispersed to 
yield a mixture of RA synovial membrane cells (Brennan et al. 1989; Sivakumar et al. 2008). 
This mixture of synovial membrane cells was either used in experiments directly or left to 
grow until confluent and then they were passaged. Over several passages, the subset of FLS 
expands in the culture and at passage 3 the culture is a relatively homogenous population of 
FLS (Figure 2.1a). FLS undergo phenotypic changes with repeated passaging (Zimmermann 
et al. 2001) and gradually become senescent after passages 10-12 (Firestein 1996). The 
primary FLS cultures were therefore used between passage 3 and 6 only, to ensure a minimal 
change in phenotype. Cells were used only if they appeared to be a homogenous fibroblast 
culture as assessed by microscopy and by staining cells (see Section 2.3). Moreover, the 
flasks where cells were growing in an unorderly fashion and not as a uniform monolayer were 
discarded. For comparison, a human lung fibroblast cell line, CCD-19Lu (ATCC, VA, USA) 
and human skin fibroblasts (HSFs, a gift kindly donated by the Cell Signalling Group at 
Kennedy Institute of Rheumatology) were used in parallel to the studies in RA FLS (Figure 
 2.1). 
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Figure  2.1 Fibroblasts used in the study 
The following fibroblasts were used in the study: (a) human RA FLS, (b) HSFs and (b) human 
CCD19Lu. The fibroblasts were cultured as described in the text. The pictures were taken with a digital 
camera attached to a light microscope (Nikon Diaphot, Optech Microscopes, Bolton, UK). 
 
 
 
 
 
 
 
2.2.1 Preparation of RA FLS and whole synovial membrane cell cultures 
The RA tissue was obtained on the day of the operation and was processed 
immediately upon receipt. The tissue was washed in sterile Dulbecco’s Modified Eagle’s 
Medium (DMEM; PAA Laboratories, Coelbe, Germany) and cut into small pieces using 
sterile scissors and surgical forceps. These smaller pieces of tissue were then digested in 
DMEM containing heat-inactivated 10% foetal calf serum (FCS; PAA Laboratories, Coelbe, 
Germany), 1g/L collagenase A (Boehringer, Mannheim, Germany), and 0.15g/L DNAse 
(Sigma, Poole, UK) for up to 1 hour at 37°C. The disaggregated cells were nylon mesh 
filtered to remove undigested tissue and were plated in DMEM medium containing 10% FCS, 
100U/mL penicillin and 100μg/mL streptomycin (BioWhittaker, Verviers, Belgium), at 4x106 
cells per 24cm2 culture dish (BD Falcon, Leuven, Belgium) for use directly in experiments as 
whole synovial membrane cell cultures. Alternatively, 4x106 cells were seeded per 25cm2 
culture flasks (BD Falcon, Leuven, Belgium) for FLS propagation. These were incubated 
overnight after which non-adherent cells were removed by changing the media and cells were 
cultured for at least 3 passages before they were used in experiments. 
2.2.2 Fibroblast culture 
RA FLS and HSFs were grown in DMEM with 10% FCS and 100U/mL penicillin 
plus 100μg/mL streptomycin. The RA FLS were passaged 1:2 to 1:3 depending on their 
growth rate and the HSFs were passaged 1:6. CCD19Lu fibroblasts were grown in Eagle’s 
Minimum Essential Medium (EMEM, BioWhittaker, Verviers, Belgium) with 10% FCS, 
2mM L-glutamine, 100U/mL penicillin and 100μg/mL streptomycin, and passaged 1:5 when 
confluent. All cell types were cultivated in 75cm2 culture flasks in 10mL of media, kept in a 
humidified atmosphere of 5% CO2 in air at 37°C and the medium was replaced twice a week. 
Trypsin-ethylenediaminetetraacetic acid (EDTA) 0.25% 1X (25g/L Trypsin with EDTA 4Na) 
(Invitrogen, Paisley, UK) was used to passage the cells when confluent. The medium was 
(a) (b) (c)
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removed, 4mL of trypsin was added and the flask swirled briefly before 2mL of trypsin was 
removed and the cells left to trypsinise in 2mL at 37°C for 5 minutes. The relevant media 
were added to the flask of trypsinised cells, and the cells were split into an appropriate 
number of 75cm2 culture flasks. 
2.2.3 HUVEC culture 
HUVECs were isolated from human umbilical cord veins, obtained with the 
necessary ethical approval (REC2948 granted Feb 2002) and informed patient consent from 
Chelsea and Westminster Hospital, London. Following isolation of the HUVECs from cords 
with Collagenase A (0.25mg/mL; Boehringer-Mannheim, Germany), cells were propagated in 
gelatin-coated 75cm2 culture flasks containing 10mL of Roswell Park Memorial Institute 
medium (RPMI 1640, PAA Laboratories, Coelbe, Germany) with 10% heat inactivated FCS, 
10% newborn calf serum (Invitrogen, Paisley, UK), 15μg/mL endothelial growth factor 
supplement (Sigma, Poole, UK), 15U/mL heparin (Charing Cross Hospital, Hammersmith, 
UK), 100U/mL penicillin and 100μg/mL streptomycin. The HUVECs were passaged when 
confluent by incubating a 75cm2 culture flask with 3mL of Trypsin-EDTA 0.25% 1X (2.5g/L 
Trypsin with EDTA 4Na) for 3 minutes at 37°C and upon detachment the cells were split at 
1:3 into gelatin-coated 75cm2 culture flasks with growth medium.  
2.3 STAINING OF RA FLS AND SYNOVIAL TISSUE  
To confirm that the isolated cells were of fibroblast origin, the cultures were stained 
with monoclonal anti-human-Fibroblast-Surface Protein (FSP)-1 antibody (Abcam, 
Cambridge, UK) and the antigen was visualised using two staining methods as described 
below. Anti-FSP-1 recognises a surface protein on human fibroblasts and fibroblast cell lines, 
namely an antigen found in coated pits and in endosomal and lysosomal structures of these 
cells. The antigen is also found on tissue macrophages and 95% of peripheral blood 
monocytes. It is absent on human epithelial cells and lymphocytes (Ronnov-Jessen et al. 
1992). 
RA synovial tissue paraffin sections were stained with antibodies against leptin 
(Abcam, Cambridge, UK). 
 
2.3.1 Immunohistochemistry (IHC) for FSP-1 and leptin  
IHC refers to the process of localising proteins in cells of a tissue section or cells 
grown on a slide by exploiting a chemical reaction between an enzyme and its substrate. The 
ABC (Avidin: Biotinylated enzyme Complex) Peroxidase Immunostaining Technique 
(Vector, Burlingame, CA, USA) was used for detecting FSP-1 and leptin on RA FLS or 
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synovial tissue sections. The ABC technique employs a biotinylated secondary antibody and a 
preformed Avidin: Biotinylated enzyme Complex. The secondary antibody will bind to the 
primary antigen specific antibody on the cell surface and the Avidin:Biotinylated enzyme 
Complex can then bind to the secondary antibody via the biotin molecule. Visualising the 
antibody-antigen interaction is accomplished by adding an appropriate substrate that catalyses 
a colour-producing reaction.  
Lab Tech 4-chamber slides (Lab-Tek Nunc, Roskilde, DK) were coated overnight 
with 100% FCS. The serum was removed and RA FLS were seeded at 80% confluence in 
DMEM, and left to grow to confluency for 1 to 2 days. The media was removed, and the cells 
were washed twice in PBS. The synovial tissue sections were deparaffinised prior to staining 
by heating the slides to 60°C, followed by incubation in 2 changes of xylene, followed by 
incubation in 2 changes of absolute EtOH and a final rinse in tap water. Following these 
procedures, the sections with cells and the synovial tissue sections were treated the same. 3% 
hydrogen peroxide (R&D Systems, Minneapolis, USA) in methanol (BDH, Poole, UK) was 
used to quench endogenous peroxidase enzyme activity in the cells and tissue. Sections were 
then washed in Tris-Buffered Saline (TBS, 6.4g Tris, 44 mL 1M HCl, 80g NaCl, 10L distilled 
water) and blocked in normal horse serum (Serotec, Oxford, UK), 1:10 in TBS. The primary 
antibodies to FSP-1 or leptin were used at 1:500 and 1:100 respectively. A mouse IgM 
isotype antibody (Abcam, Cambridge, UK) was used as a negative control for FSP-1 staining 
and a mouse IgG isotype control antibody (Abcam, Cambridge, UK) was used as a control for 
leptin staining on tissue sections. Both were diluted in TBS and applied to the slides at the 
same concentration as the primary antibodies and incubated at room temperature for 1 hour. 
Sections were washed twice in TBS and biotinylated human polyclonal anti-mouse IgM 
antibody (Vector, Burlingame, CA, USA) diluted 1:400 in TBS was then added to sections 
and incubated at room temperature for 30 minutes. Sections were washed twice and ABC 
peroxidase in TBS was added for 30 minutes at room temperature. Following another round 
of washing, 3-3’diaminobenzidine (DAB; DakoCytomation, Glostrup, DK), a substrate for 
ABC peroxidase, was added for 5 minutes. Finally, the sections were counterstained with 
Harris’s Haematoxylin (Surgipath Europe Ltd., Peterborough, UK) for 1 minute, blued using 
tap water then rehydrated in graded alcohols (BDH, Poole, UK), cleared in xylene (Genta 
Medical, York, UK) and mounted with pertex slide mounting medium (HistoLab, 
Gothenburg, Sweden). IHC staining of FSP-1 is shown in Figure  2.2. 
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Figure  2.2 IHC staining of RA FLS with antibody against FSP-1 
FLS stained with an antibody against FSP-1 (a) or with an isotype control (b) using DAB as a substrate. 
 
 
 
 
 
 
 
 
 
 
2.3.2 Immunofluorescence (IF) analysis for the expression of FSP-1 
Indirect IF staining was likewise used to detect FSP-1 on RA FLS. This method 
employs a secondary antibody labelled with a fluorochrome that recognises a primary 
antibody bound to the antigen of interest. Immunofluorescence stained samples are examined 
under a fluorescence microscope, by illuminating the fluorescent dye with laser light. The 
fluorochrome absorbs the light, becomes excited, and emits light which is visible and can be 
photographed. The colour of the emitted light varies according to which fluorchrome is used, 
where Alexa-488, used in the current study, emits light in the green part of the colour 
spectrum. A goat anti-mouse secondary antibody with Alexa-488 fluorescent dye covalently 
attached (Molecular Probes, Invitrogen, Paisly, UK) was used to detect the mouse anti-FSP-1 
primary antibody.  
Lab Tech 4-chamber slides were coated overnight with 100% FCS. The serum was 
removed and RA FLS were seeded at 80% confluence in DMEM, and left to grow for 1 to 2 
days. The media was removed, and the cells were washed twice in PBS and then fixed for 6 
minutes at room temperature in 4% paraformaldehyde in PBS (VWR, Batavia, IL, USA). 
Following two washes in PBS, 5 minutes each, the samples were blocked for 1 hour with 
500μL/chamber PBS containing 3% bovine serum albumin (BSA) and 5% goat serum 
(Serotec, Oxford, UK). Following two washes in PBS as before, 500μL/chamber primary 
anti-human-FSP-1 antibody used at 1:500 in PBS with 5% goat serum or mouse IgM isotype 
control antibody (Abcam, Cambridge, UK) was added at the same concentration and left to 
incubate overnight at 4°C. 
The following day, the cells were washed twice as described before, and 500μL of 
fluorchrome-coupled secondary goat anti-mouse antibody 1:1000 along with propidium 
iodide at 1:1000 in PBS with 5% goat serum was added for 2 hours at room temperature. 
Following two 5 minute washes with PBS, the chambers were removed, the slides were 
(a) (b)
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mounted with cover slips using 50% glycerol in PBS and nail polish was used to seal the 
cover slip to the slide. The slides were then examined and pictures taken under the 
fluorescence microscope (Olympus BH-2, Optech Microscopes). IF staining of FSP-1 is 
shown in Figure  2.3. 
Figure  2.3 IF staining of RA FLS with antibody against FSP-1 
FLS stained with an antibody against FSP-1 (a) or with an isotype control (b) and a fluorchrome-
coupled secondary antibody. Cells were counterstained with propidium iodide which stains nucleic 
acids (red). 
 
 (a) (b)
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2.4 EXPERIMENTAL PROTOCOLS 
2.4.1 Stimulation of cells 
Prior to experimentation, cells were plated on 50cm2 petri dishes (BD Falcon, 
Leuven, Belgium) and used when cells were approximately 80% confluent. Cells were 
starved in serum-free DMEM (FLS and HSF) or EMEM (CCD19Lu) at 21% oxygen for 24 
hours prior to their stimulation with leptin (R&D Systems, Minneapolis, USA), 
Dimethyloxalylglycine (DMOG, Enzo Lifesciences, Exeter, UK), IL-1β, TNFα, TGFβ 
(PreproTECH, London, UK), and/or 1% oxygen. DMOG is a non-specific inhibitor of PHDs 
and FIH and works by chelating the iron molecules necessary for the hydroxylase function of 
these enzymes. Concentration- and time-response curves were done for all the cytokines 
assayed and the concentration and time-point which showed maximal induction of HIF-1α 
mRNA were used in subsequent experiments. The cultures were incubated in 21% oxygen or 
at the specified oxygen tension for the indicated periods. Controls were included for every 
time-point and depending on the experiment, dimethyl sulfoxide (DMSO) or serum-free 
medium was added in place of test stimulant. Actinomycin D (Sigma, Poole, UK; dissolved in 
DMSO) in the RNA chase experiments was used at 1mM and was added to cells following 
incubation in 21% oxygen or 1% oxygen for 6 hours. Total RNA was then harvested 0 to 240 
minutes after actinomycin D addition. 
Effects of hypoxia were studied in cultures placed in an air tight cell incubator with 
inflow and outflow valves (Wolf Laboratories Limited, York, UK). A hypoxic gas mixture 
(1% O2, 5% CO2, and 94% N2) was delivered to the cell cultures for the desired length of 
time. Oxygen concentration within the incubator was continuously measured with a built-in 
oxygen sensor and the percentage of oxygen delivered to the incubator was adjusted as 
needed. Cells which were treated with hypoxia only, were taken from 21% oxygen where 
they were serum-starved, and transferred directly to the hypoxic incubator. 
2.4.2 RNA silencing of HIF-1α and HIF-2α 
Sequence-specific gene silencing using siRNA technology is a widely used technique, 
to uncover regulation of down-stream targets of silenced genes. Briefly, the process known as 
RNA interference or RNA silencing, involves the transfection of cells with synthetically 
produced small non-coding RNAs, also known as siRNAs. Once present in the cytoplasm the 
siRNA is incorporated into a protein complex called RNA-induced silencing complex (RISC). 
Argonaute 2, a protein contained within RISC, then unwinds the siRNA and cleaves the sense 
strand. The activated RISC, now containing only the antisense strand, finds and degrades 
mRNA complementary to the antisense strand, thereby preventing its expression (reviewed in 
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(Whitehead et al. 2009)). This technique, based on a fundamental pathway in eurokaryotic 
cells, allows researchers to silence genes of interest, either to study downstream processes, or 
as part of therapeutic intervention. siRNA delivery into the cells can be carried out using 
several different transfection reagents, but in the present study I used lipofectamine 2000. 
Lipofectamine forms liposomes containing the siRNA and fuses with the lipid bilayered cell 
membrane, releasing the siRNA into the cytoplasm. 
FLS were seeded in 24cm2 plates at approximately 80% confluency and transfected 
with siRNA oligonucleotides at a final concentration of 10nM (MWG, Ebersberg, Germany). 
Two different siRNA nucleotides were tested per isoforms, and compared with scrambled 
siRNA (scr). The oligonucleotides used are shown in Table 2.1.  
 
Table  2.1 The siRNA oligonucleotides used in the study 
siRNA Sense sequence 
siHIF-1α #1 5’ [agcaguaggaauuggaacauu]RNA [tt]DNA 3’ 
siHIF-1α #2 5’ [cugaugaccagcaacuuga]RNA [tt]DNA 3’ 
siHIF-2α #1 5’ [gcgacagcuggaguaugaauu]RNA [tt]DNA 3’ 
siHIF-2α #2 5’ [cagcaucuuugauagcagu]RNA [tt]DNA 3’ 
scrHIF-1α 5’ [gaugaguaugacgaacaugau]RNA [tt]DNA 3’ 
scrHIF-2α 5’ [ggguuauggcucggaaucaaa]RNA [tt]DNA 3’ 
siLuc 5’ [cguacgcggaauacuucga]RNA [tt]DNA 3’ 
 
Just prior to transfection of cells, DMEM was replaced by 2mL Opti-MEM (modified 
eagles’s medium) I Reduced Serum Medium (Invitrogen, Paisley, UK). Oligonucleotides and 
5μL lipofectamine 2000 (Invitrogen, Paisley, UK) were diluted individually in 250µl of Opti-
MEM I and left for 5 minutes. The two solutions were then mixed and left for 20 minutes at 
room temperature to form liposome complexes. The 500μL transfection solution was then 
added slowly dropwise to the cell culture to a final volume of 2.5mL and the plates were 
carefully tilted back and forth to ensure even distribution of the liposomes in the media. The 
cell cultures were then incubated for 5 hours at 37°C after which the transfection mixture was 
replaced with 10% FCS/DMEM and cells were left for 24 hours. Total RNA or protein was 
then isolated and quantitative-polymerase chain reaction (Q-PCR), Western Blotting (WB) 
and HIF-1α ELISA was performed to monitor gene knock-down.  
I used an siRNA oligonucleotide complementary to luciferase mRNA (siLuc), which 
is not expressed in mammalian cells as a negative control, in addition to siRNAs made up of 
the scrambled sequence of siHIF-1α (scrHIF-1α) or siHIF-2α (scrHIF-2α). The siRNA 
uptake by cells was visualised using a fluorescent labelled oligonucleotide, siGLO at 10nM 
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(Perbio Sciences, Northumberland, UK), in transfection reactions performed in parallel to the 
knock-down reactions. This is a widely used technique to monitor transfection efficiency and 
was performed with the assistance of my colleague Barbara Muz (Figure  2.4). 
Figure  2.4 RA FLS transfected with siGLO 
FLS co-transfected with siGLO, a fluorescent labelled oligonucleotide, and siHIF-1α confirming the 
uptake of oligonucleotides into the cells. 
 
 
 
 
 
 
 
 
2.5 MTT CELL VIABILITY ASSAY 
The MTT (3-(4,5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) 
colorimetric assay was used to measure cellular viability in the treated cell cultures. MTT is 
modified into a dye by enzymes associated with metabolic activity in the mitochondria in live 
cells. The amount of yellow MTT reduced to purple formazan by mitochondrial reductase 
enzymes is measured spectrophotometrically and is directly related to the number of viable 
cells (Mosmann 1983). 
Cells were treated equivalently to cells in the experimental setups, such that they 
were starved for 24 hours in serum-free medium, cultured for 24 hours with DMOG or in 
21% oxygen or 1% oxygen with or without the addition of cytokines in 96-well plates. Each 
condition was set up in triplicate wells. Following 24 hours of stimulation with the agents of 
interest, the supernatant was removed and 100μL 10% MTT in DMEM media was added and 
the plates were left to incubate at 37°C for 4-6 hours. The following day 100μL MTT lysis 
buffer containing 10% Sodium Dodecyl Sulphate (SDS, BDH, Poole, UK) and 0.01M 
hydrochloride (HCl, Sigma, Poole, UK) were added to each well. The plates were incubated 
for an additional 24 hours at 37°C before being read at 620nm on the spectrophotometer 
(ELISA Multiskan, Ascent Scanner Thermo Lab systems, Finland). Typical graphs of cell 
viability following various treatment conditions are shown (Figure 2.5). Likewise, the 
influence of IL-1β and TGFβ on cell viability was tested (data not shown). Neither of the 
cytokines nor DMOG had any effect on cell viability when tested at concentrations of up to 
40ng/mL for 24 hours (Figure 2.5a, b). Hypoxia as a single stimulus, however, was able to 
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significantly increase cell proliferation (Figure  2.5a). The effect of leptin on cell viability will 
be addressed in Chapter 6. 
Figure  2.5  MTT assay for cell survival 
RA FLS were serum-starved for 24 hours prior to incubation in 21% or 1% oxygen with or without up 
to 40ng/mL TNFα (a) or DMSO or 1mM DMOG for 24 hours (b). The data represent mean ± standard 
error of mean (SEM) of 3 independent experiments with samples assayed in triplicate. * p<0.05, ns: not 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6 GENE EXPRESSION STUDIES 
In order to quantify specific mRNA changes in RA FLS and CCD19Lu fibroblasts in 
response to cytokines, leptin, hypoxia, DMOG and transient knock-down of HIF-1α and/or 
HIF-2α, I used Q-PCR. Total RNA was isolated and reverse transcribed and cDNA synthesis 
was performed prior to the Q-PCR reaction.  
2.6.1 Total RNA isolation 
RNA was isolated using the Total RNA E.Z.N.A™ EaZy Nucleic Acid Isolation kit 
(VWR, Batavia, IL, USA) according to manufacturer’s protocol. The media was removed 
from the cultures and the adherent RA FLS, HSFs or CCD19Lu grown on 50cm2 petri dishes 
were scraped and lysed in 350µL of the provided TRK lysis buffer with 20μL β-
mercaptoethanol added per 1mL of lysis buffer. An equal amount of 70% ethanol was added 
to the lysate which was then vortexed thoroughly, applied to HiBind®RNA Spin Columns 
and centrifuged at 10,000 x g for 1 minute. Following appropriate washing of the column 
using buffers supplied in the kit, RNA was eluted with 40µL nuclease-free water. In order to 
remove any potential DNA contamination, the RNA sample was DNAse treated using 2μL 
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10U/μL DNAse and 5μL 10x DNAse buffer (Ambion Ltd, Cambridgeshire, UK) with 1μL of 
40U/μL RNasin (Mammalian RNase inhibitor, Promega, Southampton, UK). This mixture 
was incubated at 37°C for 30 minutes before adding additionally 1μL DNAse and leaving the 
sample at 37°C for 30 more minutes. To inactivate DNAse enzyme, 0.2 volume of DNAse 
inactivation reagent was mixed with the RNA (Ambion Ltd, Cambridgeshire, UK), and then 
removed after 2 minutes by centrifugation at 10,000 x g. 
Quantification of the RNA yield from each sample was carried out at 260nm on a 
spectrophotometer (Genova, Jenway, Dunmow, UK) using the formula A260 reading x 40 x 
dilution factor = μg/mL of RNA. Prior to cDNA synthesis the RNA samples were analysed by 
PCR with a set of house keeping gene (HKG) primers for the presence of any possible DNA 
contamination. This PCR reaction was performed as outlined in Table  2.2 with 1μL of RNA 
in place of cDNA. 
2.6.2 cDNA synthesis: Reverse transcription (RT) 
This technology exploits the ability of reverse transcriptase enzymes to produce a 
DNA strand that is complementary to an mRNA strand by reverse transcription (RT). The 
reaction is primed by random primers that anneal to the mRNA, and the resultant cDNA 
product can be amplified and analysed using conventional PCR or Q-PCR.  
The purified RNA from stimulated fibroblast cell cultures was used at 500-1000ng 
per RT-PCR reaction with 1μL of 50ng/mL random primers (Invitrogen, Paisley, UK) and 
DEPC-treated water to a total volume of 12μL. This mixture was heated to 70°C for 10 
minutes and then placed on ice for 5 minutes. A master mix was prepared as shown in Table 
 2.2 with reverse transcriptase buffer, RNasin, dNTPs (deoxyribonucleotide triphosphates), 
Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase (all from Promega, 
Southampton, UK), and nuclease-free water and 8μL of this mix was added per RNA sample. 
The mixtures were kept at room temperature for 10 minutes and then incubated at 42ºC for 60 
minutes followed by a denaturing step at 70ºC for 10 minutes and 5 minutes on ice to keep 
RT products single stranded. The finished cDNA was diluted 5 times with nuclease-free 
water, used immediately or stored at -70ºC. 
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Table  2.2 Reagents used in the RT-reaction 
Reagent Concentration Final concentration Volume (μL) 
RNA+random 
primers 
  12 
RT buffer 5x 1x 4 
Nuclease-free water   1.5 
RNasin 40U 2U 1 
dNTPs 10mM 0.5mM 1 
Reverse 
transcriptase 
200U/μL 0.5U/μL 0.5 
Total volume 20μL 
 
2.6.3 Primer design 
Primer 3 Software (http://frodo.wi.mit.edu/) (Whitehead Institute for Biomedical 
Research, Cambridge, MA) and UCSC (University of California, Santa Cruz) Genome 
Bioinformatics (http://genome.ucsc.edu/) were used to design PCR primers (MWG, 
Ebersberg, Germany). In addition to DNAse treatment of the isolated RNA, PCR primers 
were designed to span one or more exons to eliminate the risk of amplifying products from 
any remaining genomic contamination. Four sets of primers were used for VEGF 
amplification, and as described in Chapter 5, each set was designed to amplify one of the four 
isoforms of interest. All primer sets were analysed by conventional PCR prior to performing 
Q-PCR to ensure that single bands of the expected molecular size were amplified. The 
sequences of the primers used are given below (Table  2.3). 
 
 
 
 
 
- 
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Table  2.3 Primers used for conventional PCR and Q-PCR 
Gene amplified 
# accession number 
Primer sequence (forward & reverse) Product size (kb) 
VEGF121 
AF_214570 
GCC ATC CAA TCG AGA CCC TG 
CTC GGC TTG TCA CAT TTT TC 
283 
VEGF165 
AB_021221 
CCC TGA TGA GAT CGA GTA CAT CTT 
AGC AAG GCC CAC AGG GAT TT 
283 
VEGF165b 
AF_430806 
GAG ATG AGC TTC CTA CAG CAC 
TCA GTC TTT CCT GGT GAG AGA TCT GCA 
240 
VEGF189 
NM_003376 
GCC ATC CAA TCG AGA CCC TG 
CAA GGC CCA CAG GGA ACG CT 
355 
VEGFtotal 
NM_003376 
CTT GCC TTG CTG CTC TAC CT 
CTG CAT GGT GAT GTTG GAC T 
282 
HIF-1α 
NM_001530 
CAC CTC TGG ACT TGC CTT TC 
GGC TGC ATC TCG AGA CTT TT 
194 
HIF-2α 
NM_001430 
CCT TCA AGA CAA GGT CTG CA  
TTC ATC CGT TTC CAC ATC AA 
190 
aHIF 
U85044 
TTT GTG TTT GAG CAT TTT AAT AGG C 
CCA GGC CCC TTT CAT CAG CTT 
279 
Leptin 
NM_000230 
GGC TTT GGC CCT ATC TTT TC 
GGA ATG AAT GAA GTC CAA ACC GGT G 
170 
ANGPTL4 
NM_016109 
CCA CTT GGG ACC AGG ATC AC 
CGG AAG TAC TGG CCG TTG AG 
115 
ObRb 
NM_002303 
CCT GGG CAC AAG GAC TTA AT 
ACC ACA GTT GTT GGC ATC AT 
175 
GLUT-1 
NM_006516 
TGGCATGGCGGGTTGT 
CCAGGGTAGCTGCTCCAGC 
63 
ARP 
NM_053275 
CGA CCT GGA AGT CCA ACT AC 
ATC TGC TGC ATC TGC TTG 
378 
18SrRNA 
X03205 
GTA ACC CGT TGA ACC CCA 
CCA TCC AAT CGG TAG TAG CG 
152 
 
 
2.6.4 Polymerase chain reaction (PCR) 
PCR is a technique for amplifying DNA sequences in vitro by separating the DNA into 
two strands and incubating it with oligonucleotide primers and DNA polymerase. This 
technique can amplify a specific sequence of DNA by as many as one billion times, where the 
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product of interest increases exponentially with cycle number. The resulting PCR product can 
then be analysed for size and amount of product on an agarose gel. A PCR master mix 
(Invitrogen, Paisley, UK) was made up prior to each analysis (Table  2.4). 
 
Table  2.4 The protocol used for PCR amplification of cDNA 
Reagent Concentration Final concentration Volume (μL) 
PCR buffer  10 x 1 x 2.5 
dNTP mix  10mM 200μM 0.5 
Forward primer 6.25μM 125nM 0.5 
Reverse primer 6.25μM 125nM 0.5 
MgCl2  50mM 1.5mM 0.75 
Taq DNA polymerase 5U/μL 0.02U/μL 0.1 
cDNA or RNA   1 
Nuclease-free water   19.15 
Total volume  25μL 
 
All PCR reactions were carried out in a Peltier Thermal Cycler (MJ Research, 
Watertown, Massachusetts, USA) with the program outlined below. Annealing temperatures 
and cycle numbers were modified as necessary. 
Program: 
1. 94°C  5 minutes denaturation 
2. 94°C  30 seconds denaturation    
60°C  30 seconds annealing   step 2 x 36 cycles 
72°C   40 seconds extension 
3. 72°C   5 minutes final extension 
4. 4°C  Finished 
 
 
 
 
2.6.5 Q-PCR and data analysis 
There are two common ways to analyse data from Q-PCR; absolute and relative 
quantification. Relative quantification describes the fold change in expression of the gene of 
interest relative to a reference group such as an untreated control. For the purpose of the 
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studies shown in this report, results were analysed using a relative quantification approach 
and the 2 -∆∆ Ct method (Livak and Schmittgen 2001). 
SYBR Green I was used as the fluorescent dye of choice. SYBR Green I is a double-
stranded DNA-binding dye, which has an undetectable fluorescence in its free form, but starts 
to emit fluorescence once bound to double-stranded DNA. Therefore, the accumulation of 
fluorescence is proportional to the amount of amplification product. The data is analysed by 
determining a threshold cycle (Ct) value which represents the PCR cycle where the product 
amplification and thus fluorescence crosses a threshold line set by the user. The threshold line 
is placed above background fluorescence and early in the exponential phase to ensure that the 
Ct values are representative of initial template difference, and not just changes in reaction 
kinetics. Ct values are lower for the samples with more mRNA of interest in the initial cDNA 
reaction, as these accumulate PCR product and start to emit fluorescence at an earlier PCR 
cycle. An example of this is shown in Figure  2.6. 
Figure  2.6 Q-PCR demonstrating IL-1β induced HIF-1α mRNA 
RA FLS were stimulated with IL-1β (1ng/mL) for 6 hours and the amount of HIF-1α mRNA was 
determined relative to an equivalent untreated control. The graph depicts fluorescence emission against 
the number of PCR cycles. As the IL-1β stimulated cells have increased levels of HIF-1α mRNA, the 
fluorescence signal from the corresponding cDNA is detectable at an earlier PCR cycle and have lower 
Ct values (represented by the green curves) compared to the control cDNA (blue curves). Samples are 
run in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
During data analysis, it is necessary to normalise the amount of input target mRNA to 
an endogenous reference gene, to ensure that both the amount of RNA added to the RT-
reaction, and the efficiencies in the RT-reaction, are corrected for. The HKGs acidic 
ribosomal protein (ARP) and 18SrRNA ribosomal RNA (18S) were used as these specific 
mRNAs do not vary with the experimental conditions used here. For analysis of the PCR 
array data, a selection of the HKGs provided on the array was used for normalisation. Finally, 
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the changes in the mRNA of interest were set relative to an untreated control calibrator. These 
above notions are all given by the 2 -∆∆ Ct mathematical model, where ∆∆Ct = ∆Ct (target)-∆Ct 
(calibrator), and ∆Ct is the Ct of the target gene subtracted from the Ct of the HKG. The ∆Ct 
values were calculated for each mRNA by taking the mean Ct of triplicate reactions and 
subtracting the mean Ct value of a reference HKG mRNA (or an average of the mean Ct 
values for several HKGs in the case of the PCR array analyses) measured on an aliquot of the 
same RT-reaction. Rotor-Gene 6000, a 72-tube centrifugal thermal cycler designed by Corbett 
Research (Mortlake, Sydney, Australia) was used in these experiments to amplify, detect and 
quantify the gene products and Rotor-Gene Software version 6.0 (Corbett Research, 
Mortlake, Sydney, Australia) was used to analyse the data. Genes were considered to be up- 
or downregulated by hypoxia if there was a fold change ≥ 2.0 or ≤ -2.0 compared to normoxic 
controls. 
SYBR Green Jumpstart TM Taq Ready Mix TM (2x PCR Buffer) (Sigma, Poole, 
UK) was used in the PCR reactions and contains 20mM Tris-HCl (pH 8.3), 100mM KCl, 
7mM MgCl2, 0.4mM of each dNTP (dATP, dCTP, dGTP, and dTTP), 0.5U/mL Taq DNA 
Polymerase, Jumpstart Antibody and SYBR Green I dye. A master mix of SYBR Green, 
cDNA and primers was made up as shown in Table  2.5. 
Table  2.5 PCR reagents used in the Q-PCR reaction 
Reagent Concentration Final 
concentration 
Volume (μl) 
cDNA   3 
SYBR Green I 2x 1x 6.25 
Forward primer 6.25µM 120nM 0.25 
Reverse primer 6.25µM 120nM 0.25 
Nuclease-free water   3.25 
Final volume 13μl 
 
 
Every sample was run in triplicate along with a set of non-template controls. The 
following PCR program was used: 
 
Program: 
1. 50°C  2 minutes  
2. 95°C  5 minutes denaturation    
3. 95°C  10 seconds denaturation   
4. 60°C  30 seconds annealing   step 3 x 40 cycles 
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5. 72°C   30seconds extension 
6. 72°C  20 seconds final extension 
 
2.6.6 Human Angiogenesis RT2 ProfilerTM PCR Arrays 
The quantitative Human Angiogenesis RT2 ProfilerTM PCR Arrays (Tebu-Bio, 
Peterborough, UK) are based on the same principles as those described in the previous section 
for single samples and were used to screen for hypoxia or DMOG-induced changes in RA 
FLS relative to untreated controls. The PCR arrays come in a 96-well format with each well 
coated with a set of lyophilized primers designed to amplify a gene that has previously been 
reported to be angiogenic in other settings. 
A list of the 84 angiogenic genes which were screened on the array is shown in 
Chapter 5 (Table 5.1), followed by 5 HKG genes. Several HKGs for which the specific 
mRNA did not vary with experimental conditions were chosen to normalise samples by 
taking an average of the Ct values of the chosen HKGs for each condition tested. The fold 
change in gene expression in response to hypoxia was determined using the 2-∆∆ Ct 
mathematical model. Genes were considered to be up- or downregulated by hypoxia if there 
was a fold change ≥ 2.0 or ≤ -2.0 compared to normoxic controls. 
A mixture of 1173μL nuclease free water, 1275μL 2x RT2 SYBR Green/ROX qPCR 
Master Mix (Tebu-Bio, Peterborough, UK) and 102μL cDNA (prepared as described in 
Section  2.6.2) was made up per 96-well plate and 25μL was added to each well with an eight-
channel pipettor. The 96-well PCR array plate was sealed and run on an ABI 7900 HT 
sequence detector which contains a built-in thermocycler and the ability to process 96-well 
microplates (Applied Biosystems, Warrington, UK). The CT values were obtained using 
Sequence Detection Software version 1.9.1 for MAC (Applied Biosystems, Warrington, UK). 
 
The following PCR program was used: 
Program: 
1. 50°C  2 minutes 
2. 95°C  10 minutes denaturation    
3. 95°C  15 seconds denaturation   
4. 60°C  1 minute annealing   step 3 x 40 cycles 
5. 78°C   20 seconds extension 
6. 78°C  20 seconds final extension 
 
 
2.6.7 Primer validation 
The reaction kinetics of the PCR reaction are not ideal meaning that the PCR product 
concentration does not double during every cycle as would be expected during the 
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amplification process. This is due to factors such as depletion of PCR components, and 
competition for PCR components. The amplification efficiency thus declines with increasing 
cycle number. As the PCR results are determined very early in the exponential phase of the 
reaction, these differences in amplification efficiency cause very little differences in Ct 
values. Many current mathematical models include an inherent correction for this non-ideal 
amplification efficiency which is true for the 2 -∆∆ Ct model as well. In order to use the 2 -∆∆ Ct 
model to analyse the PCR results however, the amplification efficiencies of the primer for the 
HKG and the gene of interest need to be equal. A validation assay to monitor the difference in 
amplification efficiency for the HKG and that of the genes of interest was therefore always 
performed prior to Q-PCR analysis (Livak and Schmittgen 2001). 
Validation of the 2 -∆∆ Ct method was carried out by analysing the changes in ∆Ct with 
changes in input cDNA concentration, assuming that if the primer efficiencies are close to 
equal, ∆Ct should be almost identical with different cDNA concentrations. To do this a 
template dilution over a 100-fold range was made and the average Ct was then calculated 
from the triplicate PCR reactions for each gene, and then the ∆Ct was determined. A plot of 
the log cDNA dilution versus ∆Ct was made and if the absolute value of the slope was close 
to zero i.e. less than 0.1, it was assumed that the efficiencies of the target and reference gene 
were similar and that it was appropriate to use the ∆∆Ct model for calculating the relative 
amount of input mRNA from the initial samples. If the absolute value of the slope was greater 
than 0.1, primers were re-designed and validated again. 
2.6.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was used as a tool to analyse PCR amplification 
products. As previously described SYBR Green binds to double-stranded DNA and can be 
visualised in ultraviolet light. 1-2% agarose gels were prepared by dissolving 1-2g of agarose 
in 100mL 1x TAE buffer (40mM Tris, 20mM acetic acid, 1M EDTA) by boiling. Then 10μL 
SYBR Green was added and gels were cast in a chamber in an electrophoresis apparatus 
(BioRad, CA, USA). The gel was left to polymerize for 15 minutes, the PCR chamber filled 
with TAE buffer and then 10μL PCR product was loaded together with 2μL 10x loading 
buffer (250mg bromphenol blue (VWR, Batavia, IL, USA), 60mL glycerol (VWR, Batavia, 
IL, USA), 40mL H2O). DNA MW 1KB ladder (Invitrogen, Paisley, UK) was used as a size 
marker. The samples were electrophorised for 30-45 minutes at 100 volt and pictures were 
taken while the gel was exposed to ultraviolet light. 
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2.7 PROTEIN EXPRESSION STUDIES 
Protein concentrations of HIF-1α, leptin, IL-6, IL-8 and VEGF were measured by 
Enzyme-Linked Immunoadsorbent Assays (ELISA), and in addition HIF-1α protein was 
visualised by WB. HIF-1 and HIF-2 activity were measured by analysing nuclear extracts 
from stimulated cells using a DNA-binding assay.  
2.7.1 HIF-1α, leptin, IL-6, IL-8 and VEGF ELISA 
ELISA is an enzyme immunoassay for antigen measurements, and in this report 
measuring total VEGF, leptin, IL-6, IL-8 or HIF-1α was done using a so-called sandwich 
ELISA. This method employs a capture antibody bound to a polystyrene well in a 96-well 
plate to which the antigen to be measured is added, in the form of either cell culture 
supernatant for secreted proteins such as VEGF and leptin or as a total cell lysate when the 
protein of interest is located in the cytoplasm or in the nuclei such as HIF-1α. A second 
antibody conjugated to biotin (termed a detection antibody) is then added to the wells where it 
binds the antigen-antibody complex. Biotin has a strong affinity for streptavidin, and 
subsequently when streptavidin conjugated to horseradish peroxidase enzyme (HRP) is added 
to the reaction, the enzyme becomes attached to the immune complex and therefore the 
antigen of interest. Next a stable colorimetric substrate based on 3,3´,5,5´-
tetramethylbenzidine (TMB) is added to the enzyme conjugate, to enable visualization of the 
captured antigen. TMB is oxidized during the enzymatic degradation of H2O2 by HRP and 
this oxidized product has a deep blue colour, which turns into a rich yellow when the reaction 
is stopped with acid stop solution (1M H2SO4 acid). The optical density (OD) can now be 
read at 450nm, and the concentration of the antigen determined against a standard curve based 
on a serial dilution of a standard protein solution of known concentration.  
A total human/mouse HIF-1α ELISA (R&D Systems, Minneapolis, USA) was used 
to determine hypoxic and cytokine-induced stabilisation of total HIF-1α protein in the 
fibroblast cultures. Cells were grown on 50cm2 petri dishes and serum-starved for 24 hours as 
described Section 2.4. HIF-1α is a very labile protein and all work generating the cell lysate 
was performed quickly and on ice. Cell lysates were generated by washing each petri dish in 
1mL ice cold 1x PBS after which cells were scraped with a rubber policeman in 250μL ice-
cold lysis buffer containing 50mM TRIS, 300mM NaCl, 3mM EDTA, 1mM MgCl2, 25mM 
NaF, 20mM β-glycerophosphate, 1% Triton-X (Sigma, Poole, UK) and 10% glycerol. 
Lysates were transferred to pre-chilled 1.5mL eppendorf tubes and vortexed briefly. Before 
use, lysates were centrifuged at 2,000 x g for 5 minutes and the supernatant transferred to a 
new test tube. 
A flat bottomed microtitre 96-well plate (Nunc, Roskilde, DK) was coated with 
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100μL of mouse anti-human HIF-1α capture antibody at a working concentration of 4μg/mL 
in PBS. The plate was then covered with a plate sealer and incubated overnight at 4°C. The 
following day the plate was washed 3 times with wash buffer (0.05% Tween 20 in PBS pH 
7.2-7.4). After the last wash, any remaining wash buffer was removed by blotting the plate 
against clean paper towels. The plate was subsequently blocked for unspecific binding with 
300μL blocking buffer (5% BSA in 0.05% Tween 20 in PBS) for 1-2 hours. The washing 
procedure was repeated as before. 
A 7-point standard curve of HIF-1α protein using a 2-fold serial dilution and a 
protein range of 125-8000pg/mL was used in the assay and 100μL of sample and standards 
was loaded per well in triplicate. Lysis buffer was also added in triplicate wells to serve as 
blanks. Following 2 hours of incubation at room temperature on a rocking platform the 
washing procedure was repeated. Next 100μL of the detection antibody was added per well at 
a concentration of 400ng/mL in blocking buffer, and the plate was left to incubate for 2 hours 
at room temperature. The washing steps were repeated as before prior to the addition of 
Streptavidin diluted 1:200 in blocking buffer, 100μL per well for 20 minutes. The washing 
steps were repeated as before followed by the addition of 100μL TMB: H2O2 substrate (1:1) 
(Kirkegaard and Perry Laboratories, Gaithersburg, Maryland, USA) to each well. The plate 
was incubated until a blue colour appeared or for a maximum of 20 minutes before the 
addition of 50μL acid stop solution (50μL of 2M H2SO4). The plate was read at 450nm on the 
spectrophotometer and the amount of HIF-1α determined in relation to the standard curve.  
VEGF ELISA was carried out on cell supernatants, using the same procedure as 
described above for HIF-1α with the same washing steps and incubation times. Plates were 
coated with capture antibody at a working concentration of 1μg/mL (R&D Systems, 
Minneapolis, USA) in PBS. The plate was blocked in 300μL PBS containing 2% BSA. The 
assay was performed in triplicate using 100μL supernatant per well. A 7-point standard curve 
of VEGF protein using a 2-fold serial dilution in DMEM and a high standard of 10,000pg/mL 
was used in this assay and 100μL standards were loaded per well in triplicate. DMEM was 
also added in triplicate wells to serve as blanks.  Anti-human VEGF detection antibody was 
used at 200ng/mL in PBS containing 0.5% BSA carrier protein and 100μL of the detection 
antibody was added per well. The ELISA was developed as described above for the HIF-1α 
ELISA, and the plate was read at 450nm on the spectrophotometer and the amount of VEGF 
determined in relation to the standard curve. 
Leptin ELISA was likewise carried out on cell supernatants using a DUO set (R&D 
Systems Minneapolis, USA), and the general ELISA procedure was carried out as described 
for HIF-1α and VEGF. More specifically, plates were coated with 4ug/mL capture antibody 
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in PBS, the plate blocked in 300μL PBS containing 1% BSA. The assay was performed in 
triplicate using 100μL cell supernatant per well. A 7-point standard curve of leptin protein 
using a 2-fold serial dilution in DMEM and a high standard of 2,000-4,000pg/mL was used in 
this assay and 100μL standards were loaded per well in triplicate. Anti-human leptin detection 
antibody was used at 12.5ng/mL in PBS containing 1% BSA carrier protein and 100μL of the 
detection antibody mix was added per well. The ELISA was developed and the plate was read 
as previously described. 
IL-6 ELISA was also carried out on cell supernatants using individual reagents 
(Becton Dickinson, Oxford, UK), and the general ELISA procedure was carried out as before. 
More specifically, plates were coated with 1ug/mL capture antibody in PBS, the plate blocked 
in 300μL PBS containing 2% BSA. The assay was performed in triplicate using 100μL cell 
supernatant per well. A 7-point standard curve of IL-6 protein using a 2-fold serial dilution in 
DMEM and a high standard of 10,000pg/mL was used in this assay and 100μL standards 
were loaded per well in triplicate. Anti-human IL-6 detection antibody was used at 500ng/mL 
in PBS containing 0.5% BSA carrier protein and 100μL of the detection antibody mix was 
added per well. The ELISA was developed and the plate was read as described before. 
IL-8 ELISA was performed with cell supernatants using individual reagents (Becton 
Dickinson, Oxford, UK), and the general ELISA procedure was carried out as before. More 
specifically, plates were coated with 2μg/mL capture antibody in PBS, the plate blocked in 
300μL PBS containing 2% BSA. The assay was performed in triplicate using 100μL cell 
supernatant per well. A 7-point standard curve of IL-8 protein using a 2-fold serial dilution in 
DMEM and a high standard of 10,000pg/mL was used in the assay and 100μL standards were 
loaded per well in triplicate. Anti-human IL-8 detection antibody was used at 500ng/mL in 
PBS containing 0.5% BSA carrier protein and 100μL of the detection antibody mix was 
added per well. The ELISA was developed and the plate was read as described previously. 
2.7.2 Nuclear extract preparation for assessment of HIF DNA-binding 
HIF DNA-binding was determined in nuclear extracts from treated RA FLS and 
HSFs. All reagents were from Sigma, Poole, UK unless otherwise indicated. Two 50cm2 petri 
dishes with cells were used for each condition. Following the specific stimulation of the 
cultures, the cells were washed with 5mL ice-cold PBS/phosphatase inhibitor buffer (PIB) per 
dish (125mM NaF, 250mM β-glycerophosphate, 250mM para-nitrophenyl phosphate and 
25mM NaVO3). The buffer was discarded and the cells were removed by scraping and pooled 
using 10mL fresh PBS/PIB in total per pair of petri dishes. The cells were transferred into 
pre-chilled 15mL tubes and centrifuged at 300 x g for 5 minutes at 4°C. Cells were 
resuspended in 1.3mL hypotonic buffer (HB) (20mM Hepes, pH 7.5, 5mM NaF, 10μM 
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Na2MoO4 and 0.1mM EDTA) and transferred into pre-chilled 1.5mL tubes. The cells were 
left to swell on ice for 15 minutes and then 65μL 10% Nonidet P-40 (0.5% final 
concentration) was added and the tubes vortexed for 10 seconds. The homogenate was then 
centrifuged for 1 minute at 4,000 x g at 4°C and the resultant nuclear pellet was resuspended 
in 67μL lysis buffer (Active Motif, Carlsbad, CA, USA) and left to incubate on a rocking 
platform at 4°C for 30 minutes. Following a centrifugation step of 14,000 x g for 10 min at 
4°C, the nuclear extracts were used immediately or stored at 80°C. The protein concentration 
was determined using the BCA method (described below). 
2.7.3 DNA-binding assay for HIF-1 and HIF-2 
The TransAM HIF-1 method from Active Motif is an ELISA-based kit which can 
detect and quantify HIF-1 transcription factor DNA-binding. The kit is based on a 96-well 
plate coated with immobilised HRE-oligonucleotides. HIF-1α/ARNT1 dimers in nuclear 
extracts bind specifically to this oligonucleotide and are detected through the use of a primary 
antibody directed against HIF-1α. As HIF-2α/ARNT1 binds to the same HRE sequences, I 
modified this assay to also detect HIF-2α simply by substituting the primary anti-HIF-1α 
mouse antibody with anti-HIF-2α primary mouse IgG antibody (Autogen Bioclear, Wiltshire, 
UK). The following addition of a secondary antibody conjugated to HRP provides a 
colorimetric read-out which can be measured by spectrophotometry at 450 nm. This assay 
therefore provides information about the degree of HIF-1α/ARNT1 and HIF-2α/ARNT1 
dimer formation, nuclear translocation and the subsequent DNA-binding activity which takes 
place in vitro in response to stimuli such as low oxygen levels and/or inflammatory cytokines. 
The specificity of HIF-1 and HIF-2 binding to the HRE coated wells can be confirmed by 
competition experiments where either free wild-type or mutated HRE-oligonucleotides are 
added to the wells along with the nuclear extracts to be tested. The specificity of HIF-1 or 
HIF-2 DNA-binding is confirmed when the wild-type HRE but not the mutated HRE-
oligonucleotide, is able to inhibit the hypoxia and/or cytokine induced increase in absorbance 
at 450nm.  
The nuclear extracts prepared as described in the previous Section were tested with 
the TransAM kit. All reagents were included in the kit and prepared according to 
manufacturer’s protocol unless otherwise stated. Each sample to be assayed for HIF-1 or HIF-
2 DNA-binding was tested in duplicate wells. Nuclear extracts corresponding to 2-10μg 
protein were diluted to 10μL per well in complete lysis buffer and the samples were incubated 
on a rocking platform for 1 hour at room temperature. A washing step using wash buffer was 
repeated three times, and for each wash the inverted plate was tapped 3 times on absorbent 
paper towel. Next, 100μL of HIF-1 antibody (1:1000) or HIF-2α antibody at the same 
CHAPTER 2                                                                                            Materials and Methods 
 77
concentration diluted in antibody-binding buffer was added per well and the plate was 
incubated at room temperature for 1 hour without agitation. The plate was then washed 3 
times in washing buffer before adding a secondary anti-mouse HRP-conjugated antibody 
(1:1000) diluted in antibody-binding buffer. Following another washing step, 100μL of 
developing solution was added to each well and the plate was incubated at room temperature 
for 8-12 minutes protected from direct light. Finally, 100μL stop solution was added to each 
well, and the plate was read at 450nm on a spectrophotometer.  
2.7.4 Protein extraction and Western Blotting (WB) 
SDS-Polyacrylamide Gel Electrophoresis (PAGE) separates proteins according to 
size. Negatively charged SDS-coated proteins migrate in polyacrylamide gels towards the 
lower positive anode. The gel consists of a separation gel and a stacking gel, the latter serves 
to concentrate the applied sample. Following gel electrophoresis, the proteins can be analysed 
by WB by transferring them from the polyacrylamide gel to a polyvinylidene fluoride 
membrane (Perkin Elmer, Boston, MA, USA). Proteins become bound to the surface of the 
membrane and become accessible to immunodetection by primary antibodies. Secondary 
antibodies are directed against the Fc part of the primary antibody and can be conjugated with 
enzymes such as HRP. For detection of HIF-1α, HRP-conjugated secondary antibody was 
used and protein was visualised with an enhanced chemiluminescence system (ECL plus, GE 
Healthcare, Buckinghamshire, UK). HRP catalyses the oxidation and excitation of luminol in 
the presence of H2O2. Luminol decays to its ground state via a light emitting pathway and this 
is detected by exposure to hyper-film ECL (GE Healthcare, Buckinghamshire, UK).  
After incubation with DMOG, cytokine and/or hypoxia, cells were washed with ice-
cold PBS and lysed for 2 minutes on ice in 300μl extraction buffer (8M urea in distilled water 
containing 30μL glycerol, 15μL 20% SDS, 1μL 1M dithiothreitol, 3μL 1M Tris pH6.8, 
Merck AnalaR), and 500μM phenylmethylsulfonyl fluoride (Sigma, Poole, UK) per 50cm2 
petri dish and scraped and transferred into 1.5mL tubes. NuPAGE Novex Tris-Acetate pre-
cast gels 3-8% (Invitrogen, Paisley, UK) were used to fractionate protein extracts. Each 
protein sample was measured by the BCA (bicinchoninic acid) method and adjusted to 
contain the same concentration of total protein ≥ 20μg, and 4x loading buffer (Invitrogen, 
Paisley, UK) was added to each sample. The samples were boiled for 5 minutes to denature 
proteins, centrifuged briefly and then kept on ice. A pre-stained protein standard SeeBlue 
Plus2 (Invitrogen, Paisley, UK) was run on each gel to visualise protein molecular weight 
ranges. The NuPAGE Electrophoresis System (Invitrogen, Paisley, UK) was used with a Tris-
Acetate buffer (50mM Tricine, 50mM Tris Base, 0.1% SDS).  
Prior to transferring proteins onto the membrane, the membrane was activated by 
placing it in methanol for 20 seconds, then in water for 2 minutes and finally into transfer 
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buffer (200mL methanol, BDH, Poole, UK, 800mL distilled water, 12g Tris base, and 57.6g 
glycine; Sigma, Poole, UK) for 10 minutes. The proteins were transferred using the BioRad 
system (BioRad, Herts, UK) at 4°C for 1 hour and 30 minutes at 100mA using transfer buffer. 
The membrane was blocked with 0.01% tween/PBS/5% non-fat milk at room temperature. 
Membranes were incubated with P-STAT3 (signal activator of transcription) rabbit polyclonal 
antibody 1:1000 (New England Biolabs, Herts, UK), leptin receptor either mouse monoclonal 
1:1000 or rabbit polyclonal antibody 1:2000 (Abcam, Cambridge, UK) or anti-HIF-1α mouse 
monoclonal antibody 1:250 (Becton Dickinson, Oxford, UK) overnight at 4°C. After 3 
washes with PBS/0.01% Tween (Sigma, Poole, UK), the membrane was incubated with a 
secondary goat anti-mouse or anti-rabbit antibody at 1:5000 (Dakocytomation, Cambridge, 
UK) for 2 hours and ECL plus was used for detection. Equal loading and transfer efficiency 
were verified by incubation with STAT3 mouse monoclonal at 1:2500 (New England Biolabs, 
Herts, UK) or α-tubulin mouse monoclonal (Sigma, Poole, UK). 
2.7.5 Total protein quantification using BCA-200 Protein Assay 
The amount of total protein in the cell lysates or nuclear extracts was determined 
using the BCA-200 Protein Assay kit (Perbio Sciences, Northumberland, UK). The method 
combines the reduction of Cu2+ to Cu+ by proteins in an alkaline medium, with a colorimetric 
detection of Cu+ using a reagent containing BCA. The colour reaction is formed by the 
chelation of two molecules of BCA with one Cu+. Briefly, 10μL of the protein sample was 
incubated for 30 minutes at 37°C with 200μl of the working reagent (50:1, Reagent A: B). 
Reagent A contains sodium carbonate, sodium bicarbonate, BCA detection reagent and 
sodium tartarate in 0.1M NaOH, and reagent B contains 4% CuSO4 5H2O. The colour 
reaction was measured at 560nm on the spectrophotometer, and the amount of protein in each 
sample was determined using a standard curve with BSA ranging from 2000mg/ml to 
25mg/ml. 
2.8 MATRIGEL TUBULE FORMATION ASSAY 
In the present study, Growth Factor Reduced Matrigel Matrix (Marathon, London, 
UK) was used to set up an in vitro angiogenesis assay with HUVECs, in which the angiogenic 
potential of the supernatants from hypoxia and DMOG-stimulated RA FLS was measured. 
Basically, the number of interbranches formed by HUVECs in the matrigel is a measure of 
the angiogenic potential of the solution added to the wells. The matrigel matrix is a soluble 
basement membrane extract of the Engelbrecht-Holm-Swarm mouse tumour that gels at room 
temperature to form a genuine reconstituted basement membrane, of which the major 
components are laminin, collagen IV, entactin and heparin sulphate proteoglycan. The level 
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of growth factors has been reduced in this particular type of matrix ensuring minimum 
interference with the functional studies performed in the assay.  
In the present study, HUVECs were starved overnight in 10mL RPMI 1640 with 5% 
FCS, 5% newborn calf serum, 7.5μg/mL endothelial growth factor supplement and 7.5U/mL 
heparin. The next day, the HUVEC medium was changed to 10mL of RPMI 1640 with 2.5% 
FCS, 2.5% newborn calf serum, 3.75μg/mL endothelial growth factor supplement and 
3.75μg/mL heparin and the cells underwent a final starvation step for 3 hours prior to the 
experiment. Meanwhile, 65μL matrigel matrix was added per well in a 96-well plate and left 
to solidify at 37°C for at least an hour. HUVECs were then plated at 10,000 cells/well in the 
final starving medium. The supernatants of RA FLS grown in serum-free DMEM with 
DMSO or 1mM DMOG, under normoxia or hypoxia for 24 hours were then added 100μL per 
well where each sample was assayed in duplicate. Serum-free DMEM was used as a negative 
control and 25ng/mL of the well-described angiogenic factor VEGF in serum-free DMEM 
was used as a positive control. Following 6-8 hours of incubation in 37°C, the cells were 
washed twice with chilled PBS and then fixed in 100μL 4% paraformaldehyde in PBS per 
well for 10 minutes. Following two careful washes in cold PBS, the cells were stained in 
crystal violet solution (Sigma, Poole, UK) for 5 minutes. The numbers of interbranches 
formed by the HUVECs were counted in a blinded fashion using a Nikon light microscope. 
 
2.9 STATISTICAL ANALYSES 
Graph Pad Prism software package (Graph Pad Software, CA, USA) was used in the 
analyses of the data. For comparing two groups of data, a paired two-tailed t-test was used for 
normally distributed paired data. For three or more normally distributed groups of data, 1-way 
analysis of variance (ANOVA) with Bonferroni’s Multiple Comparison Test was used. A P 
value of > 0.05 was considered significant. 
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3 REGULATION OF HIFS IN HUMAN FIBROBLASTS BY 
HYPOXIA 
3.1 INTRODUCTION 
The pro-angiogenic profile that characterises RA synovium is thought to be the result 
of at least two major driving forces, namely local tissue hypoxia and the presence of abundant 
inflammatory cytokines. Local tissue hypoxia is thought to arise in the synovial lining when 
the resident fibroblast population expand in a hyperplastic fashion as is characteristic for RA. 
As the arthritic tissue expands and invades the intra-articular space, the metabolically active 
tissue furthest from the underlying synovial vessels is thought to experience perfusion 
insufficiency and hence hypoxia. The cellular response to hypoxia and the potential role of 
the hypoxic response in RA has been largely extrapolated from studies of solid tumours. The 
main feature of hypoxia is the rapid protein stabilisation and accumulation of hypoxia-
inducible factors HIF-1α and HIF-2α which together with HIF-1β form HIF-1 and HIF-2 
heterodimers. HIF-1α protein levels and HIF-1 activity has been shown to be maximally 
induced at 0% oxygen (anoxia) in cells exposed to a range of oxygen tensions (Jiang et al. 
1996), demonstrating that cells can respond to even further reductions in oxygen levels than 
the 1% oxygen (8mmHg) used throughout my study. At the other end of the scale, the 
accumulation of HIFs first appear when oxygen levels decrease below 5-7%, as has been 
shown in vitro in a variety of cell types (Jiang et al. 1996; Wiesener et al. 1998). Hypoxia 
tolerability and the onset of HIF activation are likely to occur in a tissue- and cell type-
dependent however. PHDs and FIH-1 are the main oxygen-dependent regulators of HIFs 
which are inactivated with declining oxygen tensions thus allowing for accumulation of HIFs 
in the cell nuclei, formation of heterodimers with HIF-1β and binding to HRE with activation 
of target genes, including VEGF (Ivan et al. 2001; Jaakkola et al. 2001). 
The objective of the present work was to characterise the regulation of HIFs by hypoxia 
in human RA FLS. The effect of hypoxia on the HIF system was investigated at three levels, 
namely (1) at the mRNA level by Q-PCR, (2) at the protein level by ELISA and WB and (3) 
at the activity level by monitoring HIF activity using a DNA-binding assay. To examine the 
potential contribution of hypoxia and RA FLS to the angiogenic component of RA I assessed 
the expression of VEGF by Q-PCR and ELISA. The data presented in my thesis emphasise 
that HIFs are the subject of tight regulation enforced at multiple levels, with activating and 
inhibitory mechanisms operating in parallel. In the present Chapter, I will present the data 
from in vitro studies, demonstrating the effect of hypoxia on the HIF system in RA FLS, and 
in Chapter 4 I will describe the regulation of HIFs by cytokines. 
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3.2 RESULTS 
3.2.1 Characterisation of HIFα protein regulation by hypoxia in fibroblasts 
The first part of the study focused on determining the effects of hypoxia on HIF-1α 
and HIF-2α protein in fibroblasts. It has been extensively published that HIF-1α is regulated 
post-translationally by hypoxia through increased stabilisation of HIF-1α, and that hypoxia 
has little or no effect on HIF-1α mRNA levels. To investigate the effect of hypoxia on HIF-
1α protein in RA FLS, I incubated cells in 21% oxygen (normoxia) or 1% oxygen (hypoxia) 
for 24 hours. As expected, hypoxic cells produced significantly more HIF-1α protein 
compared to the basal levels produced by normoxic cells (Figure  3.1a). In a series of 
experiments, hypoxia increased HIF-1α protein levels to 215pg/mL from basal normoxic 
levels. In most cases, HIF-1α protein was undetectable in normoxic cell extracts when 
assayed by ELISA. 
DMOG is a non-specific inhibitor of PHDs and FIH-1 leading to HIFα accumulation 
and trans-activation as the subunits no longer become hydroxylated and targeted for 
proteosomal degradation. In response to hypoxia and DMOG, HIF-1α accumulated and 
migrated on a polyacrylamide gel as a broad band with an apparent molecular mass of 
approximately 120kDa (Figure  3.1b). Stimulation of RA FLS with 1mM DMOG for 24 hours 
induced a greater increase in HIF-1α protein levels in comparison to the induction seen when 
cell cultures were stimulated with 1% oxygen for the same length of time. 
Figure  3.1 Hypoxia and DMOG stabilise HIF-1α protein in RA FLS 
Human RA FLS were cultured in 21%, 1% oxygen or in the presence of DMSO or DMOG (1mM) for 
24 hours. Total cell extracts were prepared and (a) HIF-1α protein was measured by ELISA. Data are 
presented as mean ± SEM of ≥ 5 independent experiments performed in triplicate, and were analysed 
using paired Student’s t-test ** p<0.01. (b) Nuclear extracts from RA FLS were analysed by WB for 
HIF-1α protein. α-tubulin was used as a loading control.  
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To investigate whether the increased HIF-1α protein level induced by hypoxia was 
paralleled by an increase in HIF-1 DNA-binding activity, I performed an enzyme-linked, 
colormetric DNA-binding immunosorbent assay for HIF-1. HIF-1 DNA-binding activity 
increased 9.2-fold when RA FLS were incubated in 1% oxygen for 24 hours compared to 
21% oxygen (Figure  3.2a). The specificity of HIF-1 DNA-binding was confirmed by 
competition experiments. Briefly, addition of 20pmol/well wild-type competitor HRE-
oligonucleotide to hypoxic nuclear extracts decreased the signal back to normoxic levels, 
whereas the addition of mutated HRE-oligonucleotides had no effect on HIF-1 DNA-binding 
activity. 
I also investigated the induction of HIF-2 DNA-binding activity by hypoxia in RA 
FLS using a primary antibody to HIF-2α in place of the HIF-1α antibody (as there is no 
commercially available ELISA for HIF-2α). A 4.4-fold increase in HIF-2 activity was seen 
when cells were incubated in 1% oxygen for 24 hours, which could be abrogated by the 
addition of 20pmol/well wild-type competitor HRE-oligonucleotide (Figure  3.2b). 
Figure  3.2 HIF DNA-binding is induced by hypoxia in RA FLS  
Human RA FLS were cultured in 21% or 1% oxygen for 24 hours. Nuclear extracts were assayed for 
(a) HIF-1 or (b) HIF-2 binding to wells pre-coated with human HRE-oligonucleotides. A competitive 
study was performed by adding mutated (Mut) or wild-type (Wt) HRE-oligonucleotides to wells prior 
to adding the hypoxic nuclear extract. DNA-binding activity is expressed as OD 450nm and represents 
means ± SEM of ≥ 3 independent experiments performed in duplicate and was analysed using 1-Way 
ANOVA. **p<0.01, ***p<0.001, ns: not significant. 
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exposed to hypoxia compared to cells maintained in normoxic conditions. VEGF protein 
secretion increased from a mean normoxic level of 362pg/mL to 1005pg/mL, which 
represents a mean fold increase of 2.8 (Figure  3.3). 
Figure  3.3 Hypoxia induces VEGF secretion by RA FLS 
Human RA FLS were cultured in 21% oxygen or 1% oxygen for 24 hours and secreted VEGF was 
measured by ELISA. Lines indicate mean of 7 independent experiments with sample assayed in 
triplicate. Data were analysed using paired Student’s t-test ** p<0.01. 
 
 
 
 
 
  
 
 
 
 
 
 
 
To characterise the regulation of HIF-1α by hypoxia in more detail, I incubated RA 
FLS in 1% oxygen for 30 minutes or 1, 2, 8, and 24 hours and determined the concentration 
of HIF-1α protein at each time-point (Figure  3.4a, b). HIF-1α protein accumulation was 
observed to be rapid, with a detectable response following just 30 minutes of exposure to 
hypoxia. Levels of HIF-1α increased over the first 1-2 hours of exposure but stabilised at a 
much lower level following prolonged hypoxia. 
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Figure  3.4 Induction of HIF-1α protein by hypoxia and DMOG 
Human RA FLS were cultured in 21% and 1% oxygen or DMSO and DMOG (1mM) for 30 minutes to 
24 hours and the cell lysates were assayed by (a,c) ELISA or (b) WB where α-tubulin was used as a 
loading control. The graphs show the level of HIF-1α protein in the cell lysates and bars represent 
means ± SEM of samples assayed in triplicate. Data are representative of 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I also characterised the regulation of HIF-2α by hypoxia in more detail. To do so I 
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Figure  3.5 HIF-2 activation by hypoxia in RA FLS 
Human RA FLS were cultured in 21% or 1% oxygen for 1 to 24 hours. Nuclear extracts were assayed 
for HIF-2 binding to wells pre-coated with human HRE-oligonucleotides. DNA-binding activity is 
expressed as OD 450nm and represents means ± SEM of sample assayed in duplicate. The data are 
representative of 3 similar experiments. 
 
 
 
  
 
 
 
 
VEGF secreted into the supernatants prior to the harvest of the cell lysates was 
measured by ELISA (Figure  3.6). A steady increase in VEGF secretion was observed starting 
from 8 hours lasting until 24 hours of exposure to hypoxia after which it levelled off between 
24 hours and 48 hours of hypoxic exposure. The time-course of VEGF secretion was slightly 
delayed compared to HIF-1α protein accumulation as would be expected as VEGF is a HIF 
target gene. 
Figure  3.6 Time-course of VEGF protein induction by hypoxia 
Human RA FLS were cultured in 21% oxygen or 1% oxygen for 2 to 24 hours and secreted VEGF was 
measured by ELISA. Protein levels are expressed as the mean ± SEM of sample assayed in triplicate. 
Data are representative of 3 similar experiments. 
 
 
 
 
0 12 24 36 48
0
1000
2000
3000
4000
21% O2
1% O2
Time of exposure to 1% O2 (hours)
VE
G
F 
pr
ot
ei
n 
pg
/m
L
0 4 8 12 16 20 24
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
21% O2
1% O2
Time of exposure to 1% O2 (hours)
H
IF
-2
 D
N
A
 a
ct
iv
it
io
n 
(O
D
 4
50
)
CHAPTER 3                                                                                Regulation of HIFs by hypoxia 
 87
To investigate the half-life (t½) of HIF-1α in normoxia, I performed a re-oxygenation 
experiment in which RA FLS were incubated in 1% oxygen for 24 hours. After return of 
hypoxic RA FLS cultures to normoxia, HIF-1α levels were seen to decrease rapidly and were 
similar to the basal (i.e. undetectable) levels after 10 minutes (Figure  3.7). In 3 independent 
experiments, the t½ of HIF-1α was seen to range from 5 to 10 minutes. This very rapid 
degradation process corresponds to the PHDs being reactivated by increasing oxygen levels, 
whereby these enzymes initiate the hydroxylation of HIF-1α protein which subsequently 
becomes targeted for proteosomal degradation. These data highlight the importance of 
working quickly and to perform experiments on ice from the moment the cell culture leaves 
the hypoxic environment.  
Figure  3.7 Re-oxygenation and HIF-1α protein degradation 
RA FLS were incubated in 1% oxygen for 24 hours before being returned to 21% oxygen. The cell 
lysates were then harvested at different time-points following re-oxygenation (0-60 minutes) and used 
for the detection of HIF-1α protein by ELISA. Protein levels represent means ± SD of samples assayed 
in triplicate. Data are representative of 3 similar experiments. 
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Maximal HIF-1α response occurred at 1% oxygen following both 2 hours and 24 hours of 
exposure. A half-maximal HIF-1α protein accumulation was seen at approximately 3% 
oxygen after 2 hours of exposure (Figure  3.8a), whereas this was closer to 4% with prolonged 
hypoxia (Figure  3.8b). As shown here, there was approximately twice as much HIF-1α 
protein in the cell lysates after 2 hours of exposure to 1% oxygen, as compared to that of 24 
hours (Figure  3.8a, b). 
Figure  3.8 HIF-1α protein in RA FLS increases with decreasing oxygen tension 
Human RA FLS were cultured in a range of oxygen tensions (1%-21% oxygen). Total protein was 
harvested after 2 hours (a) or 24 hours (b) and HIF-1α protein in the lysates was measured by ELISA. 
HIF-1α protein levels are expressed as means ± SEM of sample assayed in triplicate. Each graph is 
representative of 3 similar experiments. 
 
 
 
 
 
 
 
 
 
 
To determine whether the changes in HIF-1α protein accumulation in the cell lysates, 
were reflected in VEGF secretion, I assayed the corresponding cell supernatants for VEGF 
protein by ELISA. As expected, VEGF protein secretion was seen to correlate with the 
observed HIF-1α accumulation in RA FLS (Figure 3.9a). Exposure of cells to oxygen 
concentrations ranging from 21% to 5% oxygen was associated with a progressive increase in 
VEGF protein secretion as the oxygen tension declined and was maximal following exposure 
to 1% oxygen. I observed the same pattern of VEGF secretion in supernatants from CCD19Lu 
fibroblasts (Figure 3.9b).  
These results show that fibroblasts are capable of responding in vitro to oxygen 
tensions corresponding to 1% to 7%, with a maximal response at 1% oxygen. If hypoxia can 
be defined as an increase in HIF-1α protein availability through increased protein 
accumulation, and VEGF secretion, in vitro hypoxia in this study was seen to correspond to 
oxygen tensions lower than 7%. In subsequent experiments, incubation in 1% oxygen was 
used to induce a state of hypoxia in cell cultures. 
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Figure  3.9 VEGF secretion by fibroblasts increase with decreasing oxygen tensions 
Human RA FLS or CCD19Lu fibroblasts were cultured in a range of oxygen tensions (1%-21% 
oxygen) for 24 hours. ELISA was performed to measure the level of secreted VEGF by (a) RA FLS or 
(b) CCD19Lu fibroblasts. VEGF protein levels are expressed as means ± SEM of samples assayed in 
triplicate. Each graph is representative of 3 independent experiments. 
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3.2.2 Characterisation of HIFα mRNA regulation by hypoxia in fibroblasts 
As mentioned earlier, HIFα is regulated post-translationally by hypoxia, and very few 
publications mention an effect of hypoxia at the mRNA level. To investigate the effect of 
hypoxia on HIF-1α and HIF-2α mRNA in my cell systems, I exposed RA FLS and CCD19Lu 
fibroblasts to 21% or 1% oxygen for 2-24 hours. Unexpectedly, hypoxia appeared to 
downregulate both HIF-1α and HIF-2α mRNA expression after 24 hours in both RA FLS and 
CCD19Lu fibroblasts (Figure 3a, b). HIF-1α mRNA levels declined steadily over time in 
both cell types, whereas 24 hours of hypoxia was required for downregulation of HIF-2α.  
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Figure  3.10 Time-course of HIFα mRNA induction in fibroblasts exposed to hypoxia 
Fibroblasts were cultured in 21% or 1% oxygen for 2, 6 or 24 hours and total RNA was extracted. HIF-
1α or HIF-2α-specific primers were used in the Q-PCR analysis of cDNA from (a) human RA FLS and 
(b) CCD19Lu fibroblasts. Levels of HIFα mRNA are expressed relative to normoxic controls at the 
same time-points. Normoxic controls were set as 1.0 (dotted line). Data are expressed as the mean ± 
SEM of samples assayed in triplicate and the data represent 3 independent experiments.  
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To further investigate this finding, I incubated RA FLS from different patients or 
CCD19Lu fibroblasts at 21% or 1% oxygen for 24 hours and assayed the levels of HIFα 
mRNA by Q-PCR. The graphs illustrate the results as hypoxia-induced fold changes in HIF-
1α and HIF-2α mRNA compared to 21% oxygen. HIF-1α mRNA levels were significantly 
downregulated in RA FLS by hypoxia relative to normoxic controls (Figure  3.11a). In 10 
independent experiments, HIF-1α mRNA was downregulated 1.1 to 2.7-fold (9 to 63%) 
compared to normoxic controls, with a mean fold decrease of 1.8 (56%), whereas in two 
experiments no change or even a slight increase was observed. Interestingly, downregulation 
of HIF-1α mRNA by hypoxia is not a mechanism specific to RA FLS, as I also observed this 
effect in CCD19Lu fibroblasts, where HIF-1α was reduced on average 2.6-fold (65%) (Figure 
 3.11a). HIF-2α mRNA levels were also downregulated by 24 hours of hypoxia relative to 
normoxic controls in both cell types (Figure  3.11b). In 12 independent experiments, HIF-2α 
mRNA was downregulated 1.1 to 4.7-fold (5 to 79%) relative to normoxic controls, with a 
mean fold decrease of 1.9 (47%). HIF-2α mRNA also decreased in two experiments with 
CCD19Lu fibroblasts in response to hypoxia by an average of 1.7-fold (42%). These data 
collectively suggest that HIFα is regulated at the transcriptional level by hypoxia in addition 
to the post-translational regulation reported previously. During hypoxia therefore, a negative 
feedback mechanism may operate at the mRNA level simultaneously with hypoxia-induced 
HIFα protein stabilisation. 
 
 
CHAPTER 3                                                                                Regulation of HIFs by hypoxia 
 91
Figure  3.11 HIF-1α and HIF-2α mRNA is downregulated by hypoxia in fibroblasts 
RA FLS and CCD19Lu fibroblasts were cultured in 21% or 1% oxygen for 24 hours. Total RNA was 
extracted for cDNA synthesis and HIF-1α (a) and HIF-2α (b) mRNA levels were analysed by Q-PCR. 
Fold changes in HIFα mRNA levels relative to 21% oxygen, which was set to 1.0 (dotted line), are 
shown as the mean ± SEM of ≥ 10 independent experiments performed in triplicate. Results were 
analysed using paired Student’s t-test to compare ΔCt values (normoxia versus hypoxia): *** p<0.001. 
CCD19Lu data were not analysed due to low n numbers.  
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Near confluent fibroblasts were next incubated in either 1%, 3%, 5%, 7% or 21% 
oxygen for 24 hours to test if HIFα expression correlated with different oxygen tensions. 
HIF-1α mRNA levels were lower when cells were exposed to 1-5% oxygen in both RA FLS 
(Figure 3.12a) and CCD19Lu (Figure 3.12b), compared to the level at 21% oxygen, which 
confirms my previous data. When RA FLS cultures were incubated at 7-10%, HIF-1α levels 
increased compared to the levels in normoxic controls, whereas HIF-2α approached normoxic 
levels in 7-10% (Figure 3.12a). In CCD19Lu fibroblasts the HIF-1α level increased above the 
normoxic level when oxygen was increased from 5% to 7%, whereas HIF-2α mRNA level 
was below normoxic levels with 1-3% oxygen but then increased above normoxic levels with 
5-7% oxygen (Figure 3.12b). These data collectively support my previous observation that 
hypoxia has a negative effect on both HIF-1α and HIF-2α mRNA levels, and here this is 
demonstrated as a graded response where the negative impact of hypoxia decreases with 
increasing oxygen tension.  
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Figure  3.12 HIFα mRNA levels vary with different oxygen tensions  
Human RA FLS (a) and CCD19Lu fibroblasts (b) were cultured in a range of oxygen tensions (1%-
21% oxygen) for 24 hours. Total RNA was isolated and cDNA generated for measuring mRNA levels 
of HIF-1α and HIF-2α by Q-PCR. Levels of HIFα mRNA are expressed as mean fold change relative 
to normoxic controls which was set to 1.0 (dotted line). Error bars represent means ± SEM of 3 
independent experiments with sample assayed in triplicate. 
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3.2.3 Hypoxia induces the expression of a natural antisense to HIF (aHIF) in RA 
FLS and in total dissociated RA synovial membrane cells 
Very few publications describe regulation of HIFα mRNA by hypoxia. Interestingly, 
eight publications released between 1999 and 2008 describe a  naturally occurring antisense 
to HIF-1α, aHIF (antisense HIF-1α). The aHIF transcript is complementary to the 3’ 
untranslated region (UTR) of HIF-1α and is not complementary to any part of the HIF-2α 
transcript and can therefore only explain hypoxia-induced downregulation of HIF-1α. aHIF 
was initially discovered in 1999 in nonpapillary CC-RCC by Thrash-Bingham (Thrash-
Bingham and Tartof 1999). aHIF appears to be ubiquitously expressed and has been found in 
human muscle, liver, kidney, thymus, brain, lung, leukocyte, breast and bone marrow and in 
three types of tumours; mammary carcinoma, chronic myeloid leukaemia and in 
neuroblastoma (Rossignol et al. 2002). Interestingly, it has been shown that aHIF is expressed 
in response to hypoxia in several cell types (Thrash-Bingham and Tartof 1999; Rossignol et 
al. 2002). 
Based on this existing literature on aHIF, I set out to test if such a natural antisense to 
the HIF-1α locus is expressed by RA FLS and importantly if its transcript is upregulated by 
hypoxia. The presence of a hypoxia-regulated natural antisense transcript to HIF-1α could 
constitute the mechanism responsible for the observed downregulation of HIF-1α mRNA 
when RA FLS cultures are incubated under hypoxia. To test if aHIF is expressed in RA FLS 
in response to hypoxia, I subjected RA FLS to 1% or 21% oxygen for 24 hours. Following 
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RNA isolation and cDNA synthesis I performed conventional PCR and Q-PCR to determine 
if aHIF is expressed in RA FLS and if hypoxia could induce the level of aHIF transcript. As 
seen below (Figure  3.13), Q-PCR using aHIF-specific primers revealed that the aHIF 
transcript is present at low levels in RA FLS under normoxic conditions, and interestingly, 
exposure to hypoxia greatly increased the amount of aHIF present in the cells.  
Figure  3.13 The aHIF transcript is induced by hypoxia  
Human RA FLS were cultured in 21% or 1% oxygen for 24 hours. Total RNA was isolated and cDNA 
generated for measuring aHIF transcript levels by Q-PCR. The level of aHIF RNA is expressed as fold 
change relative to 21% oxygen which was set as 1.0. Data are expressed as mean ± SEM of 4 
independent experiments performed in triplicate, and were analysed using paired Student’s t-test to 
compare ΔCt values (normoxia versus hypoxia): **p<0.01. 
 
 
 
 
 
  
 
 
Cultures of total synovial membrane cells represent a more accurate picture of the 
pathological state in the RA joint than cell cultures selected for RA FLS do and I therefore 
used this mixed cell population to verify my findings from RA FLS whenever possible. I 
dissociated the synovial membrane cells from joint biopsies taken from RA patients just hours 
prior to their use in experiments. To establish whether hypoxia would induce a similar 
regulatory response in the levels of aHIF, HIF-1α, HIF-2α mRNA in these cell cultures, I 
placed culture dishes with newly dissociated synovial membrane cells in 1% or 21% oxygen 
for 24 hours. I also investigated the effect of hypoxia on HIF-3α and VEGF mRNA. As can 
be seen below (Figure 3.14), aHIF was upregulated on average 6-fold by hypoxia compared 
to normoxia whereas HIF-1α and HIF-2α mRNA were downregulated by hypoxia as 
previously described for RA FLS cultures. Interestingly, in contrast to the HIF-1α and HIF-
2α subunits, the HIF-3α mRNA level was induced on average 14-fold by hypoxia, 
emphasising that all three HIFα subunits are differentially regulated by hypoxia. Total VEGF 
mRNA was upregulated 6-fold on average by hypoxia in the mixed RA cell population. 
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Figure  3.14 Hypoxia induces changes in HIFα, aHIF and VEGF in total dissociated synovial 
membrane cell cultures 
Human RA synovial biopsies were digested and dissociated and cell cultures were incubated in 21% or 
1% oxygen for 24 hours. HIF-1α, HIF-2α, HIF-3α, VEGFtotal or aHIF-specific primers were used for 
Q-PCR analysis. The levels of the various transcripts are expressed relative to normoxic controls at the 
same time-point set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 4 independent 
experiments performed in triplicate, and were analysed using paired Student’s t-test to compare ΔCt 
values (normoxia versus hypoxia): * p<0.05, **p<0.01. 
 
 
 
 
 
 
 
3.2.4 The natural antisense aHIF may negatively regulate HIFα during hypoxia 
The hypoxia-inducibility of aHIF in RA FLS and total dissociated RA synovial 
membrane cells implies that the naturally occurring antisense may play a regulatory role in 
the hypoxic response leading to the observed downregulation of HIF-1α mRNA. If aHIF 
plays a direct role in the hypoxia-induced decline of HIF-1α mRNA, then its level should be 
induced by hypoxia in a temporal fashion which correlates with the disappearance of the HIF-
1α transcript. To analyse the temporal expression of aHIF and HIF-1α in relation to one 
another, I incubated RA FLS in 1% or 21% oxygen for 2-24 hours and extracted total RNA. 
Following cDNA synthesis, I performed Q-PCR to determine the time of expression of aHIF 
and HIF-1α (Figure 3.15). I also investigated the expression with time in hypoxia of the other 
two HIF subunits, HIF-2α and HIF-3α (Figure 3.15a). 
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Figure  3.15 Time-course of HIFα and aHIF mRNA induction in RA FLS exposed to hypoxia 
Human RA FLS were cultured in 21% or 1% oxygen for 2, 4, 6 or 24 hours and total RNA was 
extracted for cDNA synthesis. (a) HIF-1α, HIF-2α, HIF-3α or (b) aHIF-specific primers were used for 
Q-PCR analysis. The levels of the various transcripts are expressed relative to normoxic controls at the 
same time-points. Data are expressed as the mean ± SEM of ≥ 3 independent experiments with sample 
assayed in triplicate. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIF-1α was downregulated 1.25-fold (20%) after a short period of 2 hours of 
exposure to hypoxia, the transcript level then steadily declined until there was approximately 
50% left after 24 hours of hypoxia relative to the normoxic levels (Figure 3.15a). 
Interestingly, aHIF was upregulated by hypoxia in a temporal fashion, which inversely 
correlated with the simultaneous decline in HIF-1α mRNA levels between 2-6 hours of 
exposure (Figure 3.15b). Following 2 hours of hypoxia the aHIF levels in RA FLS was 
upregulated 3-fold, and after 6 hours the aHIF transcript had increased by 20-fold compared 
to normoxic controls. Between 6 and 24 hours of hypoxic exposure the aHIF transcript level 
declined but remained high with a 9-fold induction following 24 hours of exposure. This 
inverse relationship between aHIF and HIF-1α at the RNA level suggests that aHIF may 
indeed negatively affect the abundance of the HIF-1α mRNA. Furthermore, it is of interest to 
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note that the initial increase in aHIF and the decline in HIF-1α mRNA occur at a time (2-4 
hours) when HIF-1α protein begins to decrease from the initial high levels (see Figure  3.4). 
Thus aHIF induced downregulation of HIF-1α mRNA may facilitate the reduced expression 
of HIF-1α protein during prolonged hypoxia. Interestingly, the downregulation of HIF-2α 
mRNA appears to require prolonged hypoxia as the transcript level is not significantly 
reduced until the cells have been exposed to 24 hours of hypoxia resulting in a 2.1-fold (53%) 
downregulation (Figure 3.15a and 3.10). This supports the hypothesis that two separate 
mechanisms operate in the downregulation of the HIF-1α and HIF-2α-subunits during 
hypoxia. In contrast, the HIF-3α subunit was greatly upregulated in RA FLS following 24 
hours of hypoxia, pointing to three different mechanisms behind hypoxic regulation of the 
HIFα subunits at the transcriptional level in RA FLS. 
3.2.5 Hypoxia decreases HIF-1α but not HIF-2α mRNA stability in RA FLS 
Two mechanisms operating under hypoxia could be responsible for the observed 
downregulation of HIFα mRNA: 1) hypoxia reduced initiation of transcription of HIFα 
genes, 2) hypoxia-mediated decrease in the stability of the HIFα transcripts. To investigate 
whether hypoxia induces a reduction in HIF-1α and HIF-2α mRNA levels through decreased 
mRNA stability, I measured the half-life (t½) of HIFα mRNA species in hypoxia-treated RA 
FLS by Q-PCR. This was achieved by incubating the cells in 1% oxygen for 6 hours prior to 
the addition of actinomycin D, a transcriptional inhibitor, and harvesting of RNA at various 
time-points following actinomycin D addition. Hypoxia was shown to dramatically destabilise 
HIF-1α mRNA with a t½ = 160 minutes whereas the level of HIF-2α mRNA and aHIF 
remained relatively stable throughout the assay (Figure 3.16). These findings are in agreement 
with similar work done by Uchida et al. measuring t½ of HIF-1α and HIF-2α in A549 human 
lung adenocarcinoma cells using CoCl2 instead of hypoxia (Uchida et al. 2004).  
I also determined the hypoxia-induced changes in HIF-1α, HIF-2α and aHIF after the 
initial 6 hours of hypoxic stimulation relative to its normoxic equivalent just prior to the 
addition of actinomycin D (t = 0). As expected HIF-1α mRNA was downregulated about 2-
fold (50%) after 6 hours of hypoxia, aHIF was upregulated 7-fold and HIF-2α remained the 
same as its downregulation requires prolonged hypoxia (Figure 3.16b, c, d). These results 
indicate that the decrease in HIF-1α observed during hypoxia is related mainly to a decrease 
in its mRNA stability, rather than a decrease in the transcriptional rate of the gene. As aHIF 
remains stable throughout the assay, it is possible that aHIF is responsible for the observed 
hypoxia-mediated destabilising of HIF-1α. In contrast, since HIF-2α mRNA levels remained 
stable throughout the assay, I suggest that the observed decrease of HIF-2α during prolonged 
hypoxia is unrelated to aHIF, and is due to a decreased transcription rate of its gene rather 
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than due to a decrease in HIF-2α mRNA stability.  
Figure  3.16 HIF-1α and HIF-2α mRNA exhibit different RNA decay patterns in hypoxia 
Human RA FLS were cultured in 21% or 1% oxygen for 6 hours followed by the addition of 
actinomycin D. The cell cultures were reincubated in hypoxia for 0, 30, 90, 180 and 240 minutes before 
RNA harvest and cDNA synthesis. Q-PCR was performed to determine the relative transcript levels at 
each time-point following actinomycin D addition and the decay curves for HIF-1α, HIF-2α and aHIF 
are shown (a). The fold change in the level of aHIF (b), HIF-1α (c) and HIF-2α (d) transcripts 
following 6 hours of hypoxia and at the time of actinomycin D addition are shown. Data are expressed 
as the mean ± SEM of 3 independent experiments with sample assayed in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
3.2.6 The natural antisense aHIF may be regulated by HIFs 
To investigate whether the aHIF induction in RA FLS is regulated by HIFs, I 
stimulated the cells with 1mM DMOG for 24 hours, a non-specific inhibitor of PHDs and 
thus activator of HIFs. DMOG strongly induced the expression of aHIF by 46-fold compared 
to the DMSO control (Figure  3.17) and DMOG could mimic the negative effect of hypoxia on 
HIF-1α which was downregulated 2.2-fold (55%) after 24 hours. Thus, it seems likely that 
HIFs induced by DMOG, are responsible for aHIF induction and the decline in HIF-1α 
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mRNA. Interestingly, DMOG induced HIF activation had no effect on HIF-2α mRNA in RA 
FLS indicating that the hypoxia-mediated reduction in HIF-2α is independent of HIFs. 
Figure  3.17 DMOG induces aHIF and reduces HIF-1α but not HIF-2α mRNA in RA FLS 
Human RA FLS were stimulated with DMOG (1mM) or with DMSO for 24 hours. Total RNA was 
isolated and cDNA generated and aHIF (a), HIF-1α (b) or HIF-2α (c) specific primers were used for 
Q-PCR analysis. The fold change of the three transcripts following DMOG stimulation is expressed as 
fold change relative to a DMSO control which was set as 1.0. Data are expressed as the mean ± SEM 
of ≥ 5 independent experiments performed in triplicate, and were analysed using paired Student’s t-test 
to compare ΔCt values (DMSO versus DMOG): **p<0.01, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
I also exposed HSFs to a range of DMOG concentrations to investigate the effect on 
the level of HIF-1α and HIF-2α mRNA in a different cell type to RA FLS. As shown in 
Figure 3.18, 0.1-1mM DMOG mimicked the effect of hypoxia by decreasing the HIF-1α 
mRNA level (Figure 3.18a) HIF-2α on the other hand seemed to be increased several fold by 
DMOG in this cell type (Figure 3.18b). 
Figure  3.18 DMOG reduces HIF-1α but not HIF-2α mRNA in HSFs 
HSFs were stimulated with 1mM DMOG or with DMSO for 24 hours. Total RNA was isolated for 
cDNA synthesis and HIF-1α (a) or HIF-2α (b) specific primers were used for Q-PCR analysis. The 
fold change of the transcripts following DMOG stimulation is expressed as fold change relative to a 
DMSO control which was set as 1.0 (dotted line). Data are expressed as the mean ± SEM of samples 
assayed in triplicate. The graphs represent 3 similar experiments. 
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To determine the specific contribution of HIF-1α and HIF-2α protein to the induction 
of aHIF I used siRNA oligonucleotides to transiently knock-down HIF-1α or HIF-2α mRNA. 
I incubated RA FLS with 10nM of either HIF-1α (siHIF-1α) or HIF-2α siRNA (siHIF-2α) 
oligonucleotides for 4 hours, and then stimulated the cells with the vehicle control DMSO or 
1mM DMOG for 24 hours to mimic hypoxia. I used an siRNA oligonucleotide 
complementary to luciferase mRNA, which is not expressed in mammalian cells, as a 
negative control. Figure 3.19 depicts fold change relative to DMOG stimulated cells 
transfected with siLuc, and as can be seen siRNA oligonucleotide against HIF-1α had no 
effect on HIF-2α mRNA in DMOG stimulated cells. Interestingly, the siRNA oligonucleotide 
for HIF-2α also had an effect on HIF-1α level in addition to reducing HIF-2α levels, 
indicating that trans-regulation between the two HIFα genes is taking place. 
Figure  3.19 Transient knock-down of HIF-1α and HIF-2α in RA FLS using siRNA 
RA FLS were transiently transfected for 4 hours with siRNA oligonucleotides complementary to HIF-
1α (siHIF-1α) or to HIF-2α siRNA (siHIF-2α). Cells were stimulated with DMSO or 1mM DMOG for 
24 hours post-transfection. Total RNA was isolated and cDNA generated and the mRNA level of HIF-
1α (a) and HIF-2α (b) was determined using Q-PCR analysis. Changes in HIF-1α and HIF-2α are 
expressed as fold change relative to the DMOG treated siLuc control set as 1.0 (dotted line) and are 
means ± SEM of 3 independent experiments with sample assayed in triplicate. 
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I also measured the protein level of HIF-1α following transfection of RA FLS with 
siRNA oligonucleotide against HIF-1α. DMOG and hypoxia-induced protein was almost 
undetectable in total protein extracts following transient knock-down of HIF-1α  (Figure 
 3.20). 
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Figure  3.20 Transient knock-down of HIF-1α protein following transfection of RA FLS with 
siRNA against HIF-1α mRNA 
RA FLS were transiently transfected for 4 hours with siRNA oligonucleotides complementary to HIF-
1α (siHIF-1α). Following transfection, cell cultures were grown in 21% or 1% oxygen or stimulated 
with DMSO or 1mM DMOG for 24 hours. HIF-1α protein levels are expressed as means ± SD of 
sample assayed in triplicate. 
 
 
 
 
 
 
 
 
Having established that the siRNA oligonucleotides efficiently knock-down HIF-1α, 
HIF-2α mRNA and HIF-1α protein I next investigated the effect of knocking down either 
isoform on aHIF expression in RA FLS. My starting hypothesis was that the HIF-1α mRNA 
level would be subject to either auto-negative feedback by HIF-1 via aHIF, or to trans-
regulation between HIF-1α and HIF-2α where aHIF is upregulated by HIF-2α hereby leading 
to HIF-1α degradation. As can be seen in Figure 3.21, the siHIF-1α could induce a knock-
down in the DMOG induced increase in aHIF of about 60%, whereas siHIF-2α had no effect. 
The control oligonucleotide siLuc also had no effect on aHIF expression (data not shown). 
Figure  3.21 DMOG-induced aHIF levels are dependent on HIF-1α 
RA FLS were transiently transfected for 4 hours with siRNA oligonucleotides complementary to HIF-
1α (siHIF-1α) or to HIF-2α siRNA (siHIF-2α). The siRNA oligonucleotide siLuc complementary to 
the luciferase gene was used as a negative control. The cell cultures were stimulated with DMSO or 
1mM DMOG for 24 hours post-transfection. Total RNA was isolated and cDNA generated and the 
RNA level of aHIF was determined using Q-PCR analysis. Changes in aHIF levels following 
transfection and DMOG stimulation is expressed as fold change relative to the DMOG treated siLuc 
control set as 1.0 (dotted line). Data are expressed as the mean ± SEM of 3 independent experiments 
with sample assayed in triplicate. 
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3.3 DISCUSSION 
It is commonly recognised that tissues exposed to low oxygen tension will respond by 
raising the activity of the transcription factors HIF-1 and HIF-2. HIFs, in turn, regulate 
several large groups of genes involved in different aspects of oxygen homeostasis, including 
those involved in angiogenesis. Accumulating evidence indicates that in addition to hypoxia, 
several non-hypoxic stimuli such as inflammatory mediators and growth factors can enhance 
HIF-1α accumulation and subsequent VEGF expression. This aspect is interesting in regards 
to the pathological angiogenesis observed in RA, as the altered composition of the RA 
microenvironment includes both local regions of hypoxia and elevated levels of inflammatory 
cytokines.  
In the present report an experimental working concentration of 1% oxygen was 
chosen, based on observations that when RA FLS were subjected to oxygen tensions ranging 
from 1% to 21% oxygen (8 to 150mmHg), downregulation of HIFα mRNA, stabilisation of 
HIF-1α protein and inceased VEGF secretion were maximal at this oxygen setting. In a 
different study, the hypoxic response was reported to be maximal at 0.5% where HIF-1α 
protein levels and HIF-1 activity in HeLa S3 cells were measured and seen to vary inversely 
with a range of 0.5% to 21% oxygen (Jiang et al. 1996). Similarly, Wiesener et al. saw a 
much stronger accumulation of both HIF-1α and HIF-2α protein at 0% oxygen (anoxia) 
compared to 1% oxygen (Wiesener et al. 1998), indicating that cells can respond to even 
further reductions in oxygen levels than those tested in my study. The pathological oxygen 
tensions affecting the FLS in the RA synovium are likely to differ between local regions and 
be affected by many factors simultaneously. As mentioned previously, invasive RA synovium 
has been measured to have a range of oxygen tensions of 2.4%-4.4% O2 (18-33mmHg) 
(Sivakumar et al. 2008). The response of RA FLS to hypoxia in the present study was 
initiated when I lowered the oxygen tension from 7% to 5% (50 to 38mmHg). 
It has been extensively published that hypoxia mediates an effect on HIF activity 
through increased protein stability. In agreement with this, as part of the research described in 
this Chapter, hypoxia was seen to upregulate HIFα protein stability, subsequent HIF-1 and 
HIF-2 DNA-binding activity and VEGF production in RA FLS. Importantly, however, the 
present study has shown that hypoxia, in the form of 1% oxygen, had a strong negative effect 
on the basal steady-state level of both HIF-1α and HIF-2α mRNA in RA FLS and CCD19Lu 
fibroblasts. This effect of hypoxia on HIF-1α mRNA was also seen in combination with 
cytokines, in that hypoxia was seen to partially abrogate or completely counteract the effect of 
cytokine induced increases in HIF-1α mRNA (see Chapter 4). Hypoxic downregulation of 
HIF-1α mRNA was noted before in RA FLS in a small preliminary study, but the magnitude 
of the effect was not reported (El-Gabalawy et al. 2004). Uchida et al. also observed a 
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downregulation (>2-fold or 50%) of HIF-1α by hypoxia in A594 human lung 
adenocarcinoma cells, but in contrast to the data presented here, they observed an increase in 
HIF-2α mRNA when cells were incubated for 12 hours in 0.5% oxygen (Uchida et al. 2004). 
In a separate study, a two-fold reduction in HIF-1α was observed in human lymphocytes 
exposed to 0.1% oxygen for 6.5 hours by Thrash-Bingham et al., but the effect of hypoxia on 
HIF-2α mRNA was not investigated (Thrash-Bingham and Tartof 1999). It appears therefore 
that the present study is the first to describe a downregulation of HIF-2α mRNA by prolonged 
hypoxia. 
The natural antisense to HIF-1α, aHIF, could account for the observed 
downregulation of HIF-1α mRNA by its hybridisation to the 3’UTR, hereby destabilising 
HIF-1α transcripts by exposing instability motifs in the sequence. However this hypothesis 
would not explain hypoxia-induced downregulation of HIF-2α. Very little is known about 
aHIF and its mechanism of action. Rapid amplification of complementary DNA ends (RACE) 
PCR and ribonuclease protection assays have been used in an attempt to obtain the full-length 
sequence of aHIF, which seems to be approximately 1.8 kb where ≈ 1027bp is 
complementary to 3’UTR of HIF-1α and the 5’end represents sequence information unique to 
aHIF (Figure 3.22). A GenBank expressed sequence tag (GenBank accession: BF997067) 
human clone similar to the 5’part of aHIF but with an extra 143 bases further 5’ suggests that 
aHIF may include additional sequence information to the 1.8kb already discovered (Rossignol 
et al. 2002). aHIF appears to exist as an RNA transcript only as the known sequence contains 
no predicted open reading frame indicating that it is probably not translated into protein 
(Thrash-Bingham and Tartof 1999). Importantly, the aHIF sequence is conserved throughout 
evolution and has been shown to be expressed broadly in rodents too (mouse and rat Genbank 
accession numbers:  AY279359 and AY279360) (Rossignol et al. 2004).  
Several aspects of my data support the theory of HIF-1α destabilisation by aHIF: 
Firstly, I observed an inverse relationship in the temporal expression of aHIF and HIF-1α 
mRNA in RA FLS in hypoxic time-course studies such that as aHIF levels increased with 
time in hypoxia, HIF-1α mRNA levels concomitantly declined. In support of my findings, 
Uchida et al. observed an increase in aHIF after 4 hours of exposing A594 cells to 0.5% 
oxygen or the HIF activator CoCl2 (which inhibits PHDs) that remained sustained until 12 
hours of exposure with a maximal induction of the aHIF transcript occurring before any 
reduction in HIF-1α mRNA levels became evident (Uchida et al. 2004). 
Secondly, when I examined the mRNA stability of HIF-1α and HIF-2α, I observed 
that whereas HIF-1α was markedly unstable throughout the period elapsed following addition 
of actinomycin D, HIF-2α levels remained the same throughout the period assayed as did the 
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levels of aHIF (Figure 3.16.a). Similar results were obtained in RNA degradation studies 
performed by Uchida et al. in A549 cells stimulated with the HIF activator CoCl2 (Uchida et 
al. 2004). Given that aHIF is only complementary to the 3’UTR of HIF-1α and not to any 
part of HIF-2α, it seems a plausible explanation that the observed destabilisation of HIF-
1α during my experiment was a consequence of the hybridisation of aHIF to the HIF-
1α 3’UTR. As HIF-2α mRNA remained stable in the presence of aHIF, I concluded that its 
decline during prolonged hypoxia was unrelated to aHIF and due to a reduced transcription 
initiation of the gene rather than a destabilising process. That the two HIFα subunits are 
downregulated by different mechanisms under hypoxia is further supported by the 
observation that HIF-1α starts declining in cells following 2 hours of exposure, whereas 
prolonged hypoxia is necessary for the downregulation of HIF-2α. In support of my findings, 
sequence analysis of the HIF-1α 3’UTR has revealed a 700 bases area downstream of the 
translation termination codon which contains eight pentameric AUUUA instability core 
sequence motifs (positions 2570, 2658, 2733, 2783, 2787, 3140, 3158, 3205; GenBank 
accession number:U22431) which co-localises with three concensus nonameric instability 
elements (UUAUUUAUU; positions 2781, 2785, 3138; GenBank accession number: 
U22431) that have been identified as the minimal elements capable of conferring rapid 
degradation to a heterologous gene. Secondary structure prediction for this area and for the 
whole HIF-1α mRNA demonstrates that these motifs are inside a hairpin structure (Rossignol 
et al. 2002). A similar analysis of the HIF-2α 3’UTR shows that it is short with no AU-rich 
elements (Rossignol et al. 2002). It is therefore possible that aHIF transcript induced by 
hypoxia hybridise with HIF-1α 3’UTR in RA FLS leading to a disruption of the secondary 
hairpin structure and exposure of these instability motifs to RNA binding proteins responsible 
for mRNA degradation.  
The main question which needs answering is whether this decline in HIFα is 
transferred to the protein level and if the hypoxia-mediated effects of aHIF are important to 
RA and other diseases via its effect on the HIF system. I observed that HIF-1α protein 
declines with prolonged hypoxia (Figure 3.4a) and comparable results were obtained with the 
HIFα activator DMOG (Figure  3.4c). It is therefore possible that the initial peak in HIF-
1α protein in acute hypoxia (2-4 hours) occurs before aHIF levels have increased sufficiently 
to have an effect on HIF-1α mRNA. The following decline during prolonged hypoxia (4-24 
hours) reflects the action of accumulated aHIF, a subsequent HIF-1α mRNA destabilisation 
and thus a smaller HIF-1α mRNA pool available for translation and protein stabilisation. In 
support of this hypothesis, Uchida et al. observed a similar decline in HIF-1α protein in A549 
cells following prolonged hypoxia (4-12 hours) and a concomitant upregulation of aHIF. 
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When employing a dominant-negative HIF-2α mutant, also acting as a dominant-negative for 
HIF-1α, they were able to prevent both the decrease in HIF-1α protein and the increase in 
aHIF (Uchida et al. 2004). 
Figure  3.22 Genomic location of aHIF and HIF-1α on chromosome 14 
The aHIF RNA transcript is located in the 3´-UTR region of HIF-1α, and is transcribed from the 
antisense strand. It is approximately 1.8kb of which 1kb overlaps with HIF-1α (red box).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Another option which could explain the decline in both HIF-1α and HIF-2α could be 
that PHDs are reactivated with prolonged hypoxia. This is supported by research reporting  
that PHDs are themselves upregulated by hypoxia (with PHD-2 being regulated in a HIF-
dependent manner) leading to downregulation of HIFα protein levels in prolonged hypoxia 
(24 hours) through increased hydroxylation and thus decreased protein stability (Vengellur et 
al. 2003; Marxsen et al. 2004). As the level of the PHDs increase with exposure to hypoxia, 
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the equilibrium between the available oxygen, PHDs, and HIF stabilisation is shifted in 
favour of HIF hydroxylation. However, the increase in available PHDs would only 
compensate for smaller reductions in available oxygen. In my study, HIF-1α is already 
reduced from its peak upregulation after 4 hours. Thus aHIF is likely to play a role in the 
hypoxia-mediated downregulation of HIF-1α observed in my experiments at earlier time-
points before PHDs become reactivated.  
Most interestingly, it seems that HIFs are involved in upregulating aHIF, creating a 
negative feedback loop controlling the size of the HIF-1α mRNA pool available for 
translation. That aHIF is upregulated by HIFs in hypoxia is consistent with the following 
findings: Firstly, computer analyses of the upstream promoter of aHIF (GenBank accession: 
AL137129) has revealed the presence of 8 height core HRE sequences (Rossignol et al. 2002; 
Uchida et al. 2004). Secondly, aHIF is constitutively overexpressed in carcinomas where 
VHL is mutated and can not be further induced in this cell type by hypoxia (Thrash-Bingham 
and Tartof 1999). Thirdly, a dominant-negative truncated mutant HIF-2α protein which still 
binds to and thus sequesters HIF-1β from both HIF-2α and HIF-1α subunits, was seen to 
abolish aHIF induction and the HIF-1α mRNA decrease by hypoxia in A549 cells (Uchida et 
al. 2004).  
The first indication that HIFs regulate aHIF in my study came from the DMOG 
studies which showed that this synthetic HIF activator could mimic the effect of hypoxia on 
upregulating aHIF and downregulating HIF-1α mRNA and protein. This observation supports 
the hypothesis that HIF protein is involved in an auto-negative feedback regulatory cycle. 
Furthermore, the siRNA work using oligonucleotides against HIF-1α and HIF-2α clearly 
showed that HIF-1α is involved in upregulating aHIF following activation of HIFα by 
DMOG as induction of aHIF by DMOG was markedly surpressed by transient HIF-1α knock-
down. A similar reduction in HIF-2 transcription factor did not seem to interfere with aHIF 
expression. In contrast, Uchida et al. found that both HIF-1α and HIF-2α protein in the 
nuclear extracts from A594 cells could bind to a putative HRE found in the aHIF gene in a 
competitive DNA-binding assay (Uchida et al. 2004). Their findings therefore support both 
the theory of auto-negative regulation of HIF-1α in addition to trans-regulation between the 
HIF-1α and HIF-2α genes. Interestingly, in contrast to what I observed for HIF-1α mRNA, 
DMOG could not mimic hypoxia-induced downregulation of HIF-2α mRNA. Thus while 
both HIFα mRNA species are negatively regulated by hypoxia, the mechanisms underlying 
their regulation differ. Whereas HIF-1α downregulation by hypoxia appears to be mediated 
by HIFs, perhaps via aHIF, the negative effect of hypoxia on HIF-2α seems to occur through 
a HIF-independent pathway. 
Based on my data and that of others, it seems reasonable to hypothesise that a 
CHAPTER 3                                                                                Regulation of HIFs by hypoxia 
 106
sequence of events take place in RA FLS whereby HIF-1α protein is stabilised due to a 
decline in PHD activity, HIF-1 transcription factor is allowed to form, aHIF is upregulated as 
a result which in turn destabilises HIF-1α mRNA leading to a reduction in HIF-1 protein. 
Thus during acute hypoxia HIF-1α is regulated post-translationally via protein stability but 
during prolonged hypoxia an auto-negative feedback loop is set in train in which the HIF-1α 
protein level is regulated negatively at the post-transcriptional level through decreased mRNA 
stability leading to a reduction in the size of the pool of mRNA available for translation. This 
would ensure a controlled response to hypoxic stress (or inflammatory cytokines) and 
facilitate the return of cells to a pre-hypoxic state once the stimulus has subsided. The aHIF 
antisense transcript may therefore represent a long-term transcriptional regulator of HIF-1α 
protein in response to prolonged or chronic hypoxia, whereas HIF-1α post-translational 
modification and stabilisation may be applied for shorter term adaption to hypoxia (Figure 
 3.23). 
Figure  3.23 Differential regulation of HIF-1α during acute and prolonged hypoxia 
During acute hypoxia HIF-1α is regulated post-translationally through increased protein stability and 
protein accumulation due to the shut down of PHDs in hypoxia (1.). During prolonged exposure to 
hypoxia, the cells operate a negative feedback system in which the HIF-1 transcription factor 
negatively regulates its own HIF-1α subunit at the post-transcriptional level by upregulating its natural 
antisense, aHIF. This leads to a reduction in the size of the pool of HIF-1α mRNA available for 
translation and thus a decline in the formation of the HIF-1 transcription factor ensuring a controlled 
response during prolonged hypoxia (2.). HIF-2α mRNA and protein is also negatively regulated under 
hypoxic conditions, however the mechanism behind this finding has yet to be elucidated. 
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4 CHARACTERISATION OF HIFα REGULATION BY 
INFLAMMATORY CYTOKINES IN RA FLS  
4.1 INTRODUCTION 
In parallel to oxygen-dependent regulation of HIFs, levels of these transcription 
factors are also controlled by receptor-mediated signals under normoxic conditions. 
Inflammatory cytokines present in the RA synovium, such as TNFα and IL-1β, act via these 
receptor-mediated pathways and have been reported to induce changes in HIF-1α levels 
and/or transcriptional activation in a number of cell types (Hellwig-Burgel et al. 1999; Albina 
et al. 2001; Jung et al. 2003a; Zhou et al. 2003c). It has been reported that inflammatory 
cytokines and hypoxia can act together on the HIF system augmenting hypoxia-mediated 
upregulation of HIF activity and VEGF secretion in cultures of RA fibroblasts (Berse et al. 
1999). RA FLS in the expanding synovial lining are likely to be exposed to various levels of 
hypoxia and inflammatory cytokines simultaneously. HIFs and RA FLS may therefore 
represent the key convergence point that integrates the cellular response of the RA synovium 
to low oxygen tension and inflammatory cytokines, and thereby driving synovial 
inflammation and angiogenesis.  
The use of antibodies to cytokines as pharmacological antagonists has revealed the 
profound effects of anti-TNFα treatment in reducing inflammation and joint destruction in 
RA. Despite the clear efficacy of anti-TNFα therapy, the actual mechanisms by which TNF-
blocking agents are able to obtain these effects are still incompletely understood. In clinical 
trials using the TNFα inhibitor infliximab, reduced synovial angiogenesis and vascularity 
appears to be an effect associated with the neutralisation of TNFα (Maini et al. 1999; 
Paleolog 2002). This could possibly be explained by the findings from another study, in 
which a decline in serum and joint VEGF levels was observed following treatment compared 
to elevated pre-treatment levels (Paleolog and Miotla 1998). As HIFs regulate a plethora of 
downstream angiogenic factors including VEGF in response to hypoxia and inflammatory 
cytokines, the efficacy of anti-TNFα therapy could, at least in part, be due to a reduction in 
the activation of HIF leading to a decreased synovial vascularity in RA patients.  
The objective of the present work was to characterise the regulation of HIFs by 
inflammatory cytokines in human RA FLS. I investigated the regulation of HIFα in RA FLS 
by cytokines at three different levels, namely (1) at the mRNA level by Q-PCR, (2) at the 
protein level by ELISA and WB and (3) at the activity level by monitoring HIF activity using 
a DNA-binding assay. To examine the potential contribution of cytokines and RA FLS to the 
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angiogenic component of RA I assessed the expression of VEGF by Q-PCR and ELISA. I 
investigated the inflammatory cytokines TNFα, IL-1β and TGFβ in this study, as these are all 
present in the RA synovium. In the following Chapter, I will present the data from in vitro 
studies demonstrating the influence of the inflammatory cytokines TNFα, IL-1β and TGFβ on 
the HIF system as single stimuli and in combination with hypoxia. 
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4.2 RESULTS 
4.2.1 TNFα regulates HIF-1α mRNA, protein accumulation and HIF-1 DNA-
binding in fibroblasts 
As previously shown in this report, the observed accumulation of HIF-1α protein in 
RA FLS under hypoxia was due to HIF-1α protein stabilisation and not due to increased 
levels of HIF-1α mRNA. To investigate if the inflammatory cytokine TNFα regulates the 
steady-state levels of HIFα, I incubated RA FLS for 24 hours in serum-free medium with 
10ng/mL TNFα and measured the effect on HIF-1α and HIF-2α mRNA levels by Q-PCR. 
Exposure of RA FLS to TNFα for 24 hours significantly induced HIF-1α mRNA levels 
relative to untreated controls (Figure  4.1a). Overall, I observed fold changes ranging from 3.8 
to 14.7 following TNFα treatment of RA FLS compared to untreated controls, with a mean 
fold increase of 7.4. I next investigated whether TNFα treatment would have the same effect 
on transcriptional activation of HIF-2α mRNA. Interestingly, there was no significant effect 
of stimulating RA FLS with 10ng/mL TNFα for 24 hours on HIF-2α mRNA levels (Figure 
 4.1b).  
Figure  4.1 TNFα induces HIF-1α but not HIF-2α mRNA under normoxic conditions 
Human RA FLS were cultured in the presence of TNFα (10ng/ml) in 21% oxygen for 24 hours. Total 
RNA was extracted, cDNA generated and Q-PCR was performed to determine changes in mRNA 
levels for (a) HIF-1α and (b) HIF-2α relative to an untreated control which is set to 1. Data are 
expressed as the mean ± SEM of ≥ 6 independent experiments with sample assayed in triplicate, and 
were analysed using paired Student’s t-test to compare ΔCt values (control versus TNFα): *** 
p<0.001, ns: not significant. 
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TNFα alone. To investigate this, I incubated RA FLS with 10ng/mL TNFα in 1% oxygen for 
24 hours. Interestingly, 1% oxygen could counter-regulate the increase in HIF-1α mRNA 
induced by TNFα alone (Figure  4.2). Indeed, in several experiments I observed a complete 
abolishment of cytokine induced HIF-1α mRNA when cells were co-stimulated with hypoxia 
and TNFα. This phenomenon was also observed when RA FLS were stimulated with IL-1β 
and TGFβ in 1% oxygen (shown in Figure 4.9b and Figure 4.15a). 
Figure  4.2 Hypoxia counter-regulates TNFα-mediated upregulation of HIF-1α mRNA 
Human RA FLS were cultured in the presence of TNFα (10ng/mL) in 21% or 1% oxygen for 24 hours 
followed by total RNA extraction and cDNA synthesis. Q-PCR analysis was performed to determine 
changes in mRNA levels for HIF-1α relative to an untreated control which is set to 1 (dotted line). 
Data are expressed as the mean ± SEM of ≥ 5 independent experiments performed in triplicate, and 
were analysed using paired Student’s t-test to compare ΔCt values (TNFα versus 1% O2 + TNFα): 
**p<0.01. 
 
 
 
 
 
 
 
 
 
 
To investigate the effect of TNFα treatment on HIF-1α protein concentrations, I 
treated RA FLS with 10ng/mL TNFα for 24 hours and measured HIF-1α protein by ELISA 
and visualised the protein by WB. HIF-1α protein levels were markedly induced by TNFα. In 
all experiments, TNFα was a stronger inducer of HIF-1α protein accumulation than 1% 
oxygen, as shown here by a representative experiment (Figure 4.3). I next investigated 
whether TNFα had an effect on hypoxic HIF-1α protein accumulation by treating RA FLS 
with 10ng/mL TNFα at 21% or 1% oxygen for 24 hours. Interestingly, a combination of the 
two stimuli did not induce HIF-1α protein accumulation further compared to that of TNFα 
stimulation alone, suggesting that the observed downregulation of HIF-1α mRNA by 1% 
oxygen may be transferred to the protein level or just simply that the HIF-1α protein is 
maximally induced by TNFα. 
To investigate whether the increased HIF-1α protein levels induced by TNFα, also 
leads to an increased HIF-1 DNA-binding activity in RA FLS, I employed a DNA-binding 
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with 10ng/mL TNFα for 24 hours increased 10-fold compared to nuclear extracts from 
unstimulated RA FLS (Figure 4.4). In comparison, hypoxic stimulation of cells for the same 
duration increased HIF-1 activation 15.6-fold. This was rather surprising as TNFα stimulation 
had been a much stronger inducer of HIF-1α protein levels than hypoxia (Figure 4.3). I next 
treated RA FLS with 10ng/mL TNFα at 21% or 1% oxygen for 24 hours to determine if 
TNFα had a differential effect on HIF-1 DNA-binding in hypoxia versus normoxia. 
Interestingly, combining hypoxic stimulation with TNFα treatment for 24 hours led to an 
even greater HIF-1 binding activity, than was observed for either stimulus alone (Figure 4.4). 
Again, changes in HIF-1α protein levels was not proportionate to the change in DNA-binding 
activity, as I did not see an additive effect on protein levels in cells stimulated with both 
TNFα and hypoxia (Figure 4.3a). I have not yet investigated the induction of HIF-2 DNA-
binding activity by TNFα and hypoxia in RA FLS. 
Figure  4.3 TNFα and hypoxia stabilise HIF-1α protein levels in RA FLS 
Human RA FLS were cultured with TNFα (10ng/ml) in 21% or 1% oxygen for 24 hours and total 
protein was extracted. (a) HIF-1α protein levels were measured by ELISA and are means ± SD of 
samples assayed in triplicate. The graph is representative of 4 experiments. (b) Total HIF-1α protein 
was visualised by WB and α-tubulin was used as a loading control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
I confirmed the specificity of TNFα and hypoxia induced HIF-1 DNA-binding by 
competition experiments. Addition of 20pmol/well wild-type competitor HRE-
oligonucleotide to nuclear extracts from TNFα stimulated RA FLS reduced the signal back to 
that seen in the unstimulated control, whereas the addition of mutated HRE-oligonucleotides 
had no effect on the observed TNFα-induced HIF-1 DNA-binding activity. 
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Figure  4.4 TNFα and hypoxia induce HIF-1 DNA-binding in RA FLS 
RA FLS were cultured with TNFα (10ng/ml) in 21% or 1% oxygen for 24 hours. Nuclear extracts were 
assayed for HIF-1 binding to wells pre-coated with human HRE-oligonucleotides. DNA-binding 
activity is expressed as OD 450nm and represents means ± SEM of duplicate wells. A competitive 
study was performed by adding mutated (Mut) or wild-type (Wt) HRE-oligonucleotides to wells prior 
to adding nuclear extracts from treated cells. The graphs represent 3 similar experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
For comparison, I investigated HIF-1 DNA-binding activity in HSFs treated with 
10ng/mL TNFα for 24 hours under normoxia. Indeed, in this single experiment, HIF-1 
binding activity was induced 3.8-fold following TNFα treatment alone compared to basal 
levels in untreated HSFs (Figure  4.5). In comparison, hypoxia induced HIF-1 DNA-binding 
69.5-fold which was a markedly bigger induction than that observed for hypoxia in any of the 
experiments with RA FLS. The specificity of TNFα induced HIF-1 DNA-binding was 
confirmed by competition experiments. Addition of 20pmol/well wild-type competitor HRE-
oligonucleotide to nuclear extracts from TNFα treated RA FLS reduced the signal back to 
control levels, whereas the addition of mutated HRE-oligonucleotides had no effect on HIF-1 
DNA-binding activity. 
I subsequently treated HSFs with 10ng/mL TNFα at 1% oxygen for 24 hours to 
determine if TNFα had a differential effect on HIF-1 DNA-binding in hypoxia versus 
normoxia. Interestingly, TNFα could increase hypoxia-induced HIF-1 activity from 69.5-fold 
to 89-fold relative to untreated control levels (Figure  4.5). Therefore, in this particular 
experiment, when TNFα and hypoxia treatment were combined, a synergistic effect on HIF-1 
DNA-binding in HSFs was observed. 
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Figure  4.5 TNFα and hypoxia induces HIF-1 DNA-binding in HSFs 
HSFs were cultured with TNFα (10ng/ml) in 21% or 1% oxygen for 24 hours. Nuclear extracts were 
assayed for HIF-1 binding to wells pre-coated with human HRE-oligonucleotides. DNA-binding 
activity is expressed as OD 450nm and error bars represent means ± SEM of 3 independent 
experiments with sample assayed in triplicate. A competitive study was performed by adding mutated 
(Mut) or wild-type (Wt) HRE-oligonucleotides to wells prior to adding the nuclear extracts from 
treated cells. 
  
 
 
 
 
 
 
 
 
 
 
 
To examine whether TNFα-induced HIF-1 DNA-binding activity led to an increase 
in the transcription rate of VEGF165, I stimulated RA FLS with 10ng/mL TNFα and hypoxia, 
alone or in combination for 24 hours.  
Stimulation with TNFα caused a significant upregulation of VEGF165 mRNA levels 
in RA FLS. Overall, changes ranging from 5 to 11-fold were observed following TNFα 
treatment of RA FLS compared to untreated controls, with a mean fold increase of 7.6. On 
average, 1% oxygen alone induced VEGF165 transcripts 5.5-fold in the same experiment. I 
likewise investigated whether TNFα had an effect on hypoxia-induced transcription of 
VEGF165 in RA FLS. Indeed, when cells were co-stimulated with hypoxia and TNFα for 24 
hours, RA FLS produced more VEGF165 transcript, than was seen from either stimulus alone 
(Figure 4.6a). The two stimuli combined on average induced VEGF165 mRNA levels 15.7-fold 
thus demonstrating an additive effect on VEGF165 mRNA levels. In one experiment a 
synergistic effect of the two stimuli was observed, but these variable observations are 
probably due to the RA FLS used originating from different patients.  
I also measured secreted VEGF by ELISA and as shown by this representative 
experiment, stimulation with TNFα induced VEGF protein secretion by the RA FLS under 
both normoxic and hypoxic conditions (Figure  4.6b). On average, I saw a similar induction of 
VEGF secretion by RA FLS stimulated with either hypoxia or TNFα compared to basal 
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VEGF secretion. As expected from the VEGF165 mRNA studies, I observed an additive effect 
on VEGF secretion by RA FLS when cells were stimulated with both TNFα and hypoxia 
where the RA FLS secreted more than 3 times the amount of the basal VEGF levels secreted 
by unstimulated cells. 
These observations confirm the notion that inflammatory cytokines act via HIF-
dependent and -independent pathways. Even if hypoxia can downregulate TNFα induced 
HIFα mRNA, an additive effect of the two stimuli on VEGF production is still seen, possibly 
representing TNFα regulation of VEGF through HIF-1-independent pathways. Indeed, 
inflammatory cytokines are known to regulate VEGF transcriptionally through both HIF-
dependent and -independent pathways. An increase in VEGF mRNA can therefore not be 
interpreted solely as a function of the observed HIF-1 DNA-binding activity. 
Figure  4.6 TNFα induces VEGF165 mRNA and total VEGF secretion under normoxic and 
hypoxic conditions  
Human RA FLS were cultured in the presence of 10ng/ml TNFα in 21% or 1% oxygen for 24 hours 
and total RNA was extracted for cDNA synthesis. (a) Q-PCR was performed to determine changes in 
VEGF165 mRNA relative to untreated controls which were set to 1 (dotted line). Data are expressed as 
the mean ± SEM of ≥ 4 independent experiments performed in triplicate (b) Total VEGF protein levels 
in supernatants were measured by ELISA and are means ± SEM of ≥ 8 independent experiments 
performed in triplicate. Data were analysed using 1-Way ANOVA versus control: **p<0.01, 
***p<0.001.  
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4.2.2 IL-1β regulates HIF-1α mRNA, protein accumulation and HIF-1 DNA-
binding in fibroblasts 
IL-1β is an example of another pro-inflammatory cytokine present in the rheumatoid 
joint. To compare the effects of IL-1β on RA FLS with that observed for TNFα, I 
investigated the effect of the cytokine on the steady-state mRNA levels of HIF-1α and HIF-
2α by Q-PCR. Stimulation of RA FLS with 1ng/mL IL-1β for 6 hours lead to a significant 
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upregulation of HIF-1α mRNA levels (Figure  4.7a). Overall, changes in HIF-1α mRNA 
ranging from 2.2 to 6.3-fold following IL-1β treatment of RA FLS were observed compared 
to untreated controls, with a mean fold increase of 4.1. I also investigated the effect of 
stimulating RA FLS with 1ng/mL IL-1β for 6 hours on HIF-2α mRNA. As had been the case 
with TNFα, IL-1β had no effect on HIF-2α mRNA levels (Figure  4.7b). In addition I tested 
whether incubating the cells for 24 hours with up to 100ng/mL IL-1β would have an effect on 
HIF-2α, but increasing the time of stimulation or the concentration of IL-1β did not change 
HIF-2α mRNA levels (data not shown).  
Figure  4.7 IL-1β induces HIF-1α but not HIF-2α mRNA in RA FLS 
RA FLS were cultured in the presence of IL-1β (1ng/ml) in 21% oxygen for 6 hours. Total RNA was 
extracted, cDNA generated and Q-PCR was performed to determine changes in mRNA levels for (a) 
HIF-1α and (b) HIF-2α relative to untreated controls which were set to 1. Data are expressed as the 
mean ± SEM of ≥ 5 independent experiments performed in triplicate, and were analysed using paired 
Student’s t-test to compare ΔCt values (control versus IL-1β): *p<0.05, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
For comparison, I stimulated human CCD19Lu fibroblasts for 6 hours with 1ng/mL 
IL-1β which resulted in a similar induction of HIF-1α mRNA as that seen in RA FLS with 
fold changes ranging from 2.9 to 4 and a mean fold change of 3.6 (Figure 4.8) 
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Figure  4.8 IL-1β induces HIF-1α but not HIF-2α mRNA in CCD19Lu fibroblasts 
CCD19Lu fibroblasts were cultured in the presence of IL-1β (1ng/ml) in 21% oxygen for 6 hours. 
Total RNA was extracted, cDNA generated and Q-PCR was performed to determine changes in mRNA 
levels for (a) HIF-1α and (b) HIF-2α relative to untreated controls which were set to 1. Data are 
expressed as the mean ± SEM of ≥ 4 independent experiments performed in triplicate, and were 
analysed using paired Student’s t-test to compare ΔCt values (control versus IL-1β): ***p<0.001, ns: 
not significant. 
 
 
 
 
 
 
 
 
  
 
 
To test the effect of IL-1β on HIF-1α mRNA under hypoxic conditions, I incubated 
RA FLS in hypoxia with 1ng/mL IL-1β for 6 hours. Curiously, hypoxia did not abrogate IL-
1β-mediated increases in HIF-1α mRNA when cells were stimulated for 6 hours (Figure 
 4.9a). Similarly to my data for TNFα (Figure  4.2), prolonged hypoxia was seen to counteract 
the inducing effect on HIF-1α mRNA of IL-1β in co-stimulated cells (Figure  4.9b). 
Figure  4.9 IL-1β induces HIF-1α mRNA in RA FLS 
RA FLS were cultured in the presence of IL-1β (1ng/ml) in 21% oxygen for 6 or 24 hours. Total RNA 
was extracted, cDNA was generated and Q-PCR was performed to determine changes in mRNA levels 
for HIF-1α following 6 hours (a) or 24 hours (b) relative to untreated controls which were set to 1 
(dotted line). Data are expressed as the mean ± SEM of 4 independent experiments with samples 
assayed in triplicate, and were analysed using 1-Way ANOVA to compare ΔCt values (control versus 
IL-1β and 1% O2+IL-1β) (n=4): * p<0.05, ** p<0.01. 
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To investigate the effect of IL-1β treatment on HIF-1α protein concentrations, I 
treated RA FLS with 1ng/mL IL-1β for 6 hours at 21% oxygen. The HIF-1α protein level was 
slightly induced by IL-1β as shown here by a representative experiment (Figure 4.10). On 
average, HIF-1α protein was induced 1.4-fold by IL-1β stimulation relative to basal levels in 
unstimulated cells (Figure  4.10a). In comparison, 1% oxygen induced HIF-1α protein 
concentrations 2.3-fold in the same experiments. To investigate whether IL-1β has an effect 
on hypoxic HIF-1α protein accumulation, I treated RA FLS with 1ng/mL IL-1β and 1% 
oxygen for 6 hours. Interestingly, a combination of the two stimuli had a synergistic effect on 
the concentration of HIF-1α protein (Figure  4.10a, b). On average, HIF-1α protein levels 
increased 5.1-fold in co-stimulated cells compared to unstimulated controls. 
Figure  4.10 IL-1β and 1% oxygen stabilise HIF-1α protein levels in RA FLS 
Human RA FLS were cultured in the presence of IL-1β (1ng/ml) in 21% or 1% oxygen for 6 hours and 
total protein was extracted. (a) HIF-1α protein was measured by ELISA and is presented as mean ± SD 
of 3 independent experiments with samples assayed in triplicate. (b) HIF-1α protein was visualised by 
WB and α-tubulin was used as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I also investigated the effect of prolonged IL-1β stimulation on HIF-1α protein 
accumulation. RA FLS were incubated with 1ng/mL IL-1β in normoxia or hypoxia for 24 
hours. Interestingly, prolonged hypoxia with simultaneous IL-1β stimulation induced similar 
HIF-1α protein concentration as that observed for IL-1β stimulation alone (Figure 4.11). 
Thus, the synergistic effect of IL-1β and hypoxia seen after 6 hours on HIF-1α was no longer 
evident (Figure 4.10). This pattern was very similar to the HIF-1α protein induction observed 
when RA FLS were stimulated with TNFα (Figure 4.3).  
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Figure  4.11 Prolonged IL-1β stimulation stabilises HIF-1α protein in RA FLS  
Human RA FLS were cultured in the presence of IL-1β (1ng/ml) in 21% or 1% oxygen for 24 hours 
and total protein was extracted. HIF-1α protein was measured by ELISA and the bars represent means 
± SD of 3 independent experiments with samples assayed in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
HIF-1 DNA-binding activity was induced 16.5-fold in nuclear extracts from RA FLS 
incubated with 1ng/mL IL-1β for 6 hours compared to control extracts (Figure 4.12a). In 
comparison, hypoxia induced HIF-1 DNA-binding 12.2-fold, which was a greater induction 
than the 9.2-fold induction observed earlier with prolonged hypoxia (Figure 3.2a). This is in 
agreement with the observation that levels of HIF-1α protein are higher between 2-6 hours of 
hypoxia compared to 24 hours (Figure 3.4a, b). I also investigated the effect of 1ng/mL IL-1β 
for 6 hours on the HIF-2 binding activity in RA FLS. HIF-2 displayed a 2.2-fold and 1.6-fold 
increase in binding activity from basal control levels when I incubated RA FLS in 1% oxygen 
and with IL-1β respectively (Figure 4.12b).  
I next treated RA FLS with 1ng/mL IL-1β at 1% oxygen for 6 hours to determine if 
IL-1β had a differential effect on HIF-1 DNA-binding under hypoxia versus normoxia. 
Interestingly, the combination of the two stimuli induced a 30-fold increase in HIF-1 binding 
to its target sequence HRE compared to control levels (Figure 4.12a). Unlike what I observed 
with TNFα, it appeared that IL-1β could increase HIF-1 DNA-binding activity even further 
under hypoxia compared to IL-1β treatment alone, as co-stimulation of cells had an additive 
effect on HIF-1 DNA-binding. 
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Figure  4.12 IL-1β and hypoxia induce HIF-1 and HIF-2 DNA-binding in RA FLS 
RA FLS were cultured with IL-1β (1ng/mL) in 21% or 1% oxygen for 6 hours. Nuclear extracts were 
assayed for HIF-1(a) or HIF-2 (b) binding to wells pre-coated with human HRE-oligonucleotides. Data 
are expressed as OD 450nm and represent means ± SD of 3 independent experiments with samples 
assayed in duplicate. A competitive study was performed by adding mutated (Mut) or wild-type (Wt) 
HRE-oligonucleotides to wells prior to adding the nuclear extracts from IL-1β treated cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test whether the observed IL-1β-induced HIF-1 and HIF-2 DNA-binding activity 
lead to an increase in the transcription rate of VEGF165 and to subsequent secretion of VEGF, 
I stimulated RA FLS with 1ng/mL IL-1β for 6 hours. Indeed, IL-1β induced VEGF165 mRNA 
1.9-fold (Figure  4.13a) measured by Q-PCR, whereas prolonged stimulation of RA FLS with 
1ng/mL IL-1β for 24 hours induced  VEGF165 4.6-fold (Figure  4.13b).  
Figure  4.13 IL-1β induces VEGF165 mRNA levels in RA FLS 
Human RA FLS were cultured in the presence of IL-1β (1ng/ml) in normoxia for (a) 6 hours or (b) 24 
hours and total RNA was extracted for cDNA synthesis. Q-PCR was performed to determine changes 
in mRNA levels for VEGF165 relative to untreated controls which were set as 1. Data are expressed as 
the mean ± SEM of samples assayed in triplicate and were analysed using paired Student’s t-test to 
compare ΔCt values (control versus IL-1β): *p<0.05, (n=4). 
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I also investigated if IL-β induced VEGF165 levels in CCD19Lu fibroblasts. In three 
experiments, I detected a mean fold upregulation in VEGF165 mRNA of 3.1 (data not shown). 
IL-1β 1ng/mL for 6 hours was also seen to have an additive effect on hypoxia-induced 
transcription of VEGF165 which was the case in both RA FLS and CCD19Lu fibroblasts (data 
not shown).  
I next measured secreted VEGF protein by ELISA following stimulation of RA FLS 
with IL-1β for 6 and 24 hours in 21% or 1% oxygen. Hypoxia induced VEGF secretion after 
6 hours in agreement with the time-course results shown previously (Figure  3.6). However, 
IL-1β did not stimulate VEGF secretion by RA FLS under normoxic or hypoxic conditions 
after 6 hours compared to basal levels (Figure  4.14a). In contrast, prolonged stimulation of 
RA FLS with 1ng/mL IL-1β for 24 hours in normoxia led to a 2.8-fold increase in VEGF 
secretion by RA FLS compared to untreated cells (Figure  4.14b), and hypoxia alone induced 
VEGF secretion 4-fold. When RA FLS were stimulated with 1ng/mL IL-1β for 24 hours in 
the presence of hypoxia, a clear synergistic effect on VEGF secretion was evident as a 
combination of the two stimuli induced VEGF secretion 11.8-fold. IL-1β therefore, is a potent 
inducer of VEGF secretion by RA FLS when the cells are stimulated under normoxia or 
hypoxia for a prolonged period of time. 
Figure  4.14 Prolonged IL-1β stimulation induces VEGF secretion by RA FLS under 
normoxic and hypoxic conditions 
Human RA FLS were incubated with 1ng/mL IL-1β for (a) 6 hours or (b) 24 hours under 1% or 21% 
oxygen and secreted VEGF protein was measured by ELISA. Data are expressed as the mean ± SEM 
of independent experiments with samples assayed in triplicate, and were analysed using 1-Way 
ANOVA (n=7): *** p<0.001, ns: not significant. 
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4.2.3 TGFβ regulates HIF-1α mRNA, protein accumulation and HIF-1 DNA-
binding in fibroblasts 
Recent studies have indicated that the growth factor TGFβ is capable of inducing 
accumulation of the HIF-1α subunit, and induce HIF-1 binding activity in cells such as 
fibrosarcoma HT-1080 cells and VSMCs (Gorlach et al. 2001; Shih and Claffey 2001). To 
determine if this is also the case in fibroblasts, I stimulated RA FLS and HSFs with 10ng/mL 
TGFβ for 6 or 24 hours and the effect of the growth factor was measured at the HIF-1α 
mRNA and protein level in addition to its effect on HIF-1 and HIF-2 DNA-binding activity. 
Exposure of RA FLS to TGFβ for 24 hours induced the HIF-1α mRNA level 4.8-fold 
compared to untreated cells (Figure 4.15a). In contrast, TGFβ seemed to have a negative 
impact on the steady-state HIF-2α mRNA level. Stimulation of RA FLS for 24 hours with 
10ng/mL TGFβ in normoxia induced a mean fold downregulation in HIF-2α mRNA of 3.2-
fold (69%) compared to untreated cells (Figure 4.15b). TGFβ stimulation for 24 hours had a 
similar effect on the HIF-2α mRNA levels in HSFs, where a 3.3-fold (67%) downregulation 
was observed (data not shown). This negative effect of TGFβ on HIF-2α mRNA was seen 
only with prolonged stimulation, and was not observed in either cell type after 6 hours of 
stimulation with the same concentration of TGFβ (data not shown).  
To test the effect of TGFβ on HIF-1α mRNA in hypoxia, I stimulated RA FLS with 
10ng/mL TGFβ in hypoxia for 24 hours. Interestingly, and in agreement with my previous 
observations in this Chapter, hypoxia abrogated cytokine-mediated upregulation of HIF-1α 
mRNA. When I cultured RA FLS for 24 hours with TGFβ in hypoxia the HIF-1α mRNA 
level was reduced to control levels or below (Figure 4.15a). This effect on HIF-1α mRNA 
was also evident in both RA FLS and HSFs after 6 hours treatment (data not shown). 
Treatment with either TGFβ or hypoxia had a negative impact on HIF-2α mRNA levels in 
RA FLS, but when cells were subjected to both stimuli this negative effect appeared stronger 
than that observed for either stimulus alone (Figure 4.15b). 
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Figure  4.15 TGFβ induces HIF-1α but suppresses HIF-2α mRNA in RA FLS 
Human RA FLS were cultured in the presence of TGFβ (10ng/ml) in 21% or 1% oxygen for 24 hours. 
Total RNA was extracted, cDNA synthesised and Q-PCR was performed to determine changes in 
mRNA levels for (a) HIF1α or (b) HIF-2α relative to untreated controls which were set to 1 (dotted 
line). Data are expressed as the mean ± SEM of ≥ 3 independent experiments and were analysed using 
1-Way ANOVA to compare ΔCt values (1%O2, TGFβ and 1% O2+TGFβ versus control) (n=4): * 
p<0.05, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, TGFβ was capable of inducing HIF-1α mRNA in normoxia in both RA 
FLS and HSFs. The presence of hypoxia was seen to partially or completely abrogate this 
effect of TGFβ on HIF-1α mRNA. In contrast, TGFβ stimulation of RA FLS for 24 hours 
appeared to have a negative impact on HIF-2α mRNA levels under both normoxic and 
hypoxic conditions. 
To investigate the effect of TGFβ treatment on HIF-1α protein concentrations, I 
treated RA FLS with 10ng/mL TGFβ for 24 hours alone or in combination with 1% oxygen. 
The HIF-1α protein level in RA FLS was seen to be markedly induced by TGFβ under 
normoxic conditions (Figure 4.16a, b). In two experiments with cells from different patients, 
TGFβ increased HIF-1α protein concentrations to 95 and 125pg/mL respectively from 
undetectable control levels. In both cases, this induction in HIF-1α by TGFβ protein was 
lower than that induced by hypoxia in the same experiments. The simultaneous stimulation of 
RA FLS with TGFβ and hypoxia resulted in an additive effect as HIF-1α protein 
concentrations were further increased to 355 and 833pg/mL. A similar additive or synergistic 
effect on HIF-1α protein levels had not been observed when RA FLS were stimulated with 
either 1ng/mL IL-1β or 10ng/mL TNFα for 24 hours under hypoxic conditions. In those 
experiments the level of HIF-1α protein was similar following stimulation with the cytokine 
alone and following co-stimulation with cytokine and hypoxia (Figure 4.3 and Figure 4.11). 
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This indicates that the negative effect of hypoxia on HIF-1α mRNA was transferred to the 
protein level in the TNFα and IL-1β co-stimulation experiments, as opposed to representing 
the HIF-1α protein being maximally induced by these cytokines, as TGFβ seems to be 
capable of inducing HIF-1α protein to an even further extend than did TNFα and IL-1β. The 
negative effect induced by hypoxia at the HIF-1α mRNA level was not evident at the HIF-1α 
protein level in the experiments with TGFβ shown here, perhaps because the additive effect 
of hypoxia and TGFβ on HIF-1α protein was so strong, that a smaller negative effect would 
remain undetectable. 
Figure  4.16 TGFβ and hypoxia stabilise HIF-1α protein levels in RA FLS 
Human RA FLS were cultured in the presence of TGFβ (10ng/ml), 21% or 1% oxygen for 24 hours 
and total protein was extracted. (a) HIF-1α protein was measured by ELISA and error bars represent 
means ± SEM of samples assayed in triplicate. The graph is representative of 3 similar experiments. (b) 
HIF-1α protein was visualised by WB and α-tubulin was used as a loading control.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I next performed a time-course where I stimulated RA FLS with TGFβ or 1% oxygen 
and harvested cells at different time-points to be able to compare the effect of TGFβ with that 
of hypoxia on HIF-1α protein during acute and prolonged exposure. Interestingly, I found 
that both stimuli induced an initial peak in HIF-1α protein levels with acute hypoxia, but that 
prolonged exposure of cells to either stimulant lead to a sustained elevation of HIF-1α protein 
at much lower levels to that observed during acute hypoxia (Figure  4.17). It is possible that 
aHIF could be involved in regulating HIF-1α protein levels during prolonged exposure to 
TGFβ in addition to hypoxia. This would require that TGFβ is also capable of inducing aHIF, 
which seems likely as aHIF induction is HIF-1-dependent as I showed previously and 
TGFβ induces HIF-1α protein strongly. In a subsequent Section of the present Chapter, I shall 
therefore investigate the effect of inflammatory cytokines on the expression of aHIF. The 
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slightly delayed induction of HIF-1α protein following TGFβ stimulation compared to that 
seen with 1% oxygen (6 versus 2 hours) probably reflects that TGFβ induces HIF-1α at the 
mRNA level whereas hypoxia induces stabilisation of existing protein HIF-1α subunits, a 
much more rapid process. 
Figure  4.17 Time-course of TGFβ and hypoxia-induced HIF-1α protein in RA FLS 
Human RA FLS were cultured in the presence of TGFβ (10ng/ml), 21% oxygen or 1% oxygen for 15 
minutes to 24 hours and total protein was extracted. HIF-1α protein was measured by ELISA and error 
bars represent means ± SEM of samples assayed in triplicate. The graph is representative of 3 similar 
experiments. 
 
 
 
 
 
 
 
 
To determine whether TGFβ-induced HIF-1α protein in fibroblasts forms functional 
transcriptional complexes capable of binding to the target sequence HRE, I employed the 
DNA-binding assay for HIF-1 using nuclear extracts from RA FLS and HSFs incubated under 
21% or 1% oxygen for 24 hours. Surprisingly, despite a substantial increase in HIF-1α 
protein after TGFβ treatment in normoxia, HIF-1 DNA-binding activity in the nuclear 
extracts was not different compared to the basal activity in unstimulated cells (Figure  4.18a, 
b). Hypoxia on the other hand, increased HIF-1 DNA-binding activity 2.6-fold in RA FLS 
(Figure  4.18a) and 5.5-fold in HSFs compared to untreated cells in the same experiments 
(Figure  4.18b). I next treated RA FLS or HSFs with 10ng/mL TGFβ in hypoxia for 24 hours 
to determine if the cytokine had a differential effect on HIF-1 activity in hypoxia. Indeed, 
HIF-1 DNA-binding activity was increased beyond the signal observed for hypoxic 
stimulation of cells alone (Figure 4.18a, b). In both types of fibroblasts, it appeared that TGFβ 
could potentiate the effect of hypoxia on HIF-1 DNA-binding activity, without having an 
effect on its own. HIF-1 activity in nuclear extracts from RA FLS stimulated with TGFβ in 
hypoxia was increased 5.8-fold relative to control cells, whereas hypoxia-induced a 2.6-fold 
increase in HIF-1 activity (Figure  4.18a). In comparison, nuclear extracts from HSFs 
subjected to both stimuli for 24 hours showed an even greater induction of HIF-1 DNA-
binding activity at 7.2-fold compared to nuclear extracts from controls and those stimulated 
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with TGFβ in normoxia (Figure  4.18b). In these cells, hypoxic conditions alone stimulated 
HIF-1 DNA-binding 5.5-fold. 
Figure  4.18 TGFβ induces HIF-1 activity in fibroblasts under hypoxic conditions only 
Human RA FLS and HSFs were cultured with TGFβ (10ng/mL) in 21% oxygen or 1% oxygen for 24 
hours. Nuclear extracts from (a) human RA FLS and (b) HSFs were assayed for HIF-1 binding to wells 
pre-coated with human HRE-oligonucleotides. Data are expressed as OD 450nm and represent means ± 
SEM of samples assayed in duplicate. The graphs each represent 3 similar experiments. 
  
 
 
 
 
 
 
 
 
 
 
 
 
I also looked at the effect of TGFβ stimulation on HIF-2 DNA-binding activity, as 
single stimuli and under hypoxic conditions. As seen in Figure 4.19 TGFβ had little or no 
effect on HIF-2 DNA-binding as a single stimulus. Surprisingly, TGFβ also had no effect in 
combination with 1% oxygen, which was in contrast to what I had observed for HIF-1. 
Figure  4.19 TGFβ stimulation does not induce HIF-2 activity in RA FLS 
Human RA FLS were cultured with TGFβ (10ng/mL) in 21% or 1% oxygen for 24 hours. Nuclear 
extracts from (a) human RA FLS were assayed for HIF-2 binding to wells pre-coated with human 
HRE-oligonucleotides. Data are expressed as OD 450nm and represent means ± SEM of 3 independent 
experiments with samples assayed in duplicate. 
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Together, these results show that despite the ability of TGFβ to induce accumulation 
of HIF-1α protein, stimulation with this cytokine was not sufficient to increase HIF-1 DNA-
binding. Despite this, TGFβ appeared to be able to work in concert with hypoxia to induce 
HIF-1 binding in a synergistic way in both cell types investigated. In contrast, HIF-2 DNA-
binding activity was unaffected by TGFβ stimulation regardless of the oxygen tension. 
TGFβ has previously been described as a pro-angiogenic molecule, owing in part to its ability 
to induce VEGF secretion by a variety of cell types (Berse et al. 1999; Shih and Claffey 2001; 
McMahon et al. 2006). To determine if TGFβ could induce VEGF expression in RA FLS, I 
measured the effect of the growth factor on VEGF production at the transcriptional level by 
Q-PCR, and at the protein level by ELISA after incubating RA FLS for 6 or 24 hours in 1% 
oxygen with or without 10ng/mL TGFβ. Despite the inability of TGFβ to induce HIF-1 DNA-
binding activity under normoxic conditions, the cytokine alone had a strong positive effect on 
the steady-state levels of VEGF165 mRNA suggesting the activation of HIF-independent 
pathways. In two experiments using RA FLS, TGFβ stimulation for 6 and 24 hours induced 
VEGF165 mRNA 7.3-fold and 4.2-fold respectively (Figure 4.20a, b). When I subjected RA 
FLS to a combined treatment of TGFβ and hypoxia for 6 or 24 hours, I observed a strong 
synergistic induction of VEGF165 mRNA of 18 and 48-fold (Figure 4.20a, b). The synergistic 
effect of TGFβ and hypoxia on HIF-1 activity which I had previously observed in RA FLS 
(Figure  4.18a) seemed to translate into a synergistic effect on the transcription of VEGF165. 
Figure  4.20 TGFβ and hypoxia induce VEGF165 mRNA levels in FLS  
Human RA FLS were incubated with 10ng/mL TGFβ for 6 or 24 hours in 1% or 21% oxygen. Total 
RNA was extracted for cDNA synthesis after 6 (a) or 24 hours (b) and Q-PCR was performed to 
determine changes in mRNA levels for VEGF165 relative to untreated which were set to 1.0 (dotted 
line). Data are mean ± SEM of independent experiments with samples performed in triplicate, and were 
analysed using 1-Way ANOVA to compare ΔCt values versus control (n=4): ** p<0.01, *** p<0.001. 
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I also measured the amount of secreted VEGF in these experiments. Neither TGFβ, 
nor 1% oxygen had a significant effect on VEGF protein secretion after 6 hours, whereas the 
combined stimulation of RA FLS induced VEGF production 3.2-fold compared to basal 
VEGF secretion (Figure  4.21a). After 24 hours however, the mean fold increase in VEGF 
secretion was induced 3.2-fold by TGFβ, 2.6-fold by hypoxia and the combined treatment 
resulted in a much higher production of VEGF seen as a 9.9-fold increase compared to 
untreated cells (Figure  4.21b). In five out of seven experiments, a synergistic effect on VEGF 
secretion was observed when combining hypoxia and TGFβ treatment, whereas an additive 
effect was observed in the remaining two experiments. 
Figure  4.21 TGFβ and hypoxia increase VEGF secretion by RA FLS 
Human RA FLS were incubated with 10ng/mL TGFβ for 6 or 24 hours in 1% or 21% oxygen. Secreted 
VEGF was measured by ELISA following 6 hours (a) and 24 hours (b). Data are expressed as the mean 
± SEM of independent experiments with samples performed in triplicate, and were analysed using 1-
Way ANOVA (n=7): * p<0.05, *** p<0.001.  
 
 
 
 
 
 
 
 
 
 
 
These data imply that TGFβ and hypoxia triggered pathways can converge to induce 
HIF-1 binding activity, transcription of VEGF and subsequent protein secretion by RA FLS in 
a synergistic manner. Importantly, the data implies that TGFβ is capable of inducing VEGF 
expression in normoxia solely via HIF-1-independent pathways, as no HIF-1 binding activity 
was observed in response to TGFβ alone. Under hypoxic conditions however, TGFβ may 
induce VEGF expression via both HIF-1-dependent and -independent pathways, as TGFβ 
appeared to potentiate HIF-1 DNA-binding activity when cells were cultured in 1% oxygen. 
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4.2.4 The inflammatory cytokines TNFα and IL-1β induce aHIF RNA in RA 
FLS 
The data from the siRNA experiments in Section  3.2.6 strongly suggests that aHIF 
upregulation by DMOG is HIF-1-dependent. Based on the observation that TNFα, ILβ and 
TGFβ were all seen to induce HIF-1α mRNA and protein, I decided to investigate whether 
the cytokines could induce aHIF in RA FLS or CCD19Lu fibroblasts alone or in combination 
with hypoxia. Interestingly, when I stimulated RA FLS with 10ng/mL TNFα for 24 hours I 
observed an 11-fold increase in aHIF transcript levels whereas 1% oxygen as a single 
stimulus induced a 5-fold change in aHIF in this particular experiment (Figure  4.22). 
Furthermore, when I co-stimulated RA FLS with TNFα in hypoxia, the cells induced aHIF in 
a synergistic manner. Co-stimulation of cell cultures with 10ng/mL TNFα and hypoxia for 24 
hours led to a 30-fold increase in aHIF expression (Figure  4.22). 
Figure  4.22 TNFα induces aHIF expression in RA FLS 
RA FLS were incubated with 10ng/mL TNFα in 21% or 1% oxygen for 24 hours. Q-PCR was 
performed to determine changes in aHIF RNA in response to cytokine stimulation and hypoxia relative 
to an untreated control which was set to 1.0 (dotted line). The RNA levels are means ± SEM of sample 
assayed in triplicate. The graph represents 3 similar experiments. 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
I likewise tested the effect of IL-1β on aHIF in CCD19Lu fibroblasts for 6 hours and 
as seen below, aHIF transcript was induced 2.5-fold and had an additive effect in combination 
with hypoxia where an 8-fold increase was observed (Figure  4.23). It is not surprising that 
aHIF is induced in fibroblasts stimulated with cytokines as aHIF appears to be regulated by 
HIF-1 and cytokines specifically induce HIF-1α mRNA and protein but not HIF-2α. The 
effect of TGFβ on aHIF expression has not yet been investigated but constitutes work which 
is in progress. 
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Figure  4.23 IL-1β induces aHIF expression in CCD19Lu fibroblasts 
CCD19Lu fibroblasts were incubated with 1ng/mL IL-1β for 6 hours. Q-PCR was performed to 
determine changes in aHIF RNA in response to cytokine stimulation relative to an untreated control 
which was set to 1.0 (dotted line). The RNA levels are means ± SEM of sample assayed in triplicate. 
The graph represents 3 similar experiments. 
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4.3 DISCUSSION 
Low oxygen tensions and inflammatory cytokines are conditions common to the 
inflamed synovium. Besides hypoxia-mediated HIF-1α protein stabilisation and HIF-1α 
mRNA destabilisation, inflammatory cytokines offer another mode of HIF-1α regulation as 
cytokines can upregulate HIF-1α mRNA levels. All three cytokines tested in this study had 
the ability to upregulate HIF-1α mRNA levels several fold. Interestingly, HIF-2α mRNA 
levels were either unaffected by cytokine treatment or even significantly reduced in both RA 
FLS and CCD19Lu fibroblasts. All cytokines could increase HIF-1α protein accumulation 
and VEGF secretion by RA FLS in normoxia and in this regard TGFβ was the most potent of 
the cytokines tested. HIF-1 DNA-binding activity was increased by both IL-1β and 
TNFα, but surprisingly TGFβ did not seem to induce HIF-1 activity in RA FLS or CCD19Lu 
under normoxic conditions. In contrast to this finding, a synergistic effect on HIF-1 DNA-
binding was induced by TGFβ in hypoxia in the same experiments. In agreement with this, a 
synergistic effect of TGFβ and hypoxia on HIF-1α protein accumulation and VEGF secretion 
in RA FLS was also seen. These observations could potentially be explained by TGFβ 
activating signalling pathways which converge upon and reinforce a signalling pathway 
mediated by hypoxia that is not active in normoxia. Synergy by TGFβ and hypoxia on VEGF 
secretion has been reported before in HT-1080 fibrosarcoma cells and has been shown to 
involve the activation and binding of AP-1 and HIF-1 to the VEGF promoter as well as HIF-
1-independent pathways (Shih and Claffey 2001). The last observation is in agreement with 
findings in the present report where TGFβ induced VEGF secretion under normoxia without 
increasing HIF-1 activity in RA FLS, indicating that TGFβ is capable of inducing VEGF 
expression in RA FLS in a manner which is independent of the HIF-1 pathway.  
I also investigated the effect of IL-1β and TGFβ on the activation of HIF-2 binding in 
RA FLS, and I found that TGFβ had no effect on HIF-2 activity under normoxic or hypoxic 
conditions, whereas IL-1β as a single stimulus could induce HIF-2 activity. This raises the 
question of whether cytokines can induce HIF protein stability in addition to increasing HIF-
1α mRNA. If IL-1β does not induce HIF-2α mRNA levels, yet has a positive effect on HIF-2 
DNA-binding, it seems likely that this cytokine can induce HIF-2α protein stability. The 
effect of cytokine treatment on HIF-1α and HIF-2α protein stability needs to be tested by 
measuring protein half-lives following cytokine treatment in the presence of cycloheximide to 
block ongoing protein synthesis. 
Interestingly, the work carried out with inflammatory cytokines in the study showed a 
induction of aHIF when fibroblasts were stimulated with TNFα or IL-1β similar to that which 
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was observed with hypoxia. Furthermore, a synergistic and an additive effect on aHIF were 
observed when fibroblasts were co-stimulated with either TNFα or IL-1β in the presence of 
hypoxia (Figure  4.22 and Figure  4.23) which could explain the stronger repression of HIF-1α 
mRNA in the co-stimulated cells compared to that observed in cells treated with hypoxia 
alone (Figure 4.2). Moreover, I observed that HIF-1α protein declines with prolonged TGFβ 
treatment (8-24 hours) (Figure  4.17) in a similar fashion to the decline in HIF-1α protein in 
cells exposed to prolonged hypoxia. The findings that inflammatory cytokines can upregulate 
aHIF too, suggests that a similar mechanism of HIF-1 induced aHIF upregulation and a 
subsequent HIF-1α mRNA destabilisation could account for the decline in HIF-1α protein 
that I observed with prolonged exposure to TGFβ (Figure  4.17). As the cytokines only 
induced HIF-1α and not HIF-2α in the present study it seems likely that HIF-1α is 
responsible for both hypoxia and cytokine-mediated upregulation of aHIF.  
In summary, I have shown in the present study that RA FLS respond to both 
inflammatory cytokines and hypoxia by increasing HIFα protein, HIF DNA-binding activity 
and VEGF secretion. These observations raise interesting questions such as how these distinct 
pathways interact and where they converge. In addition, the data in this Chapter suggest 
inflammatory cytokines can also regulate HIF-1α through the ability to induce aHIF 
expression. A better understanding of the mechanisms involved in hypoxia and cytokine-
mediated regulation of HIFs could lead to the development of tools to control the downstream 
effects which are characterised by the secretion of more inflammatory cytokines and 
angiogenic growth factors. In the subsequent Chapters I will describe in more detail the 
response of synovial fibroblasts to hypoxia in the context of RA. 
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5 IDENTIFICATION OF NOVEL HYPOXIA-REGULATED 
ANGIOGENIC GENES IN HUMAN SYNOVIAL 
FIBROBLASTS 
5.1 INTRODUCTION 
RA is a diverse and heterogenous disease with high variability in responsiveness to 
treatment modalities. A powerful way to gain an insight into the molecular complexity of 
cells and tissues in RA is represented by DNA microarray technology, which facilitates 
identification of sets of genes and molecular pathways which are differentially or equally 
expressed among patients. Several genomics research studies have attempted to decipher the 
molecular complexity of RA in order to build a transcription profile of the disease. This work 
has contributed to the knowledge of pathogenesis, and to identification of biomarkers of the 
disease and subtyping of patients and prognostication. The gene profiling studies conducted 
so far in RA have made use of various RA tissues including synovial biopsies (van der Pouw 
Kraan et al. 2003a; van der Pouw Kraan et al. 2003b; Devauchelle et al. 2004; Tsubaki et al. 
2005; Lindberg et al. 2006a; Lindberg et al. 2006b; Timmer et al. 2007; van der Pouw Kraan 
et al. 2008), whole blood (Maas et al. 2005; van der Pouw Kraan et al. 2007; van der Pouw 
Kraan et al. 2008), peripheral blood mononuclear cells (Bovin et al. 2004; Olsen et al. 2004; 
Batliwalla et al. 2005; Lequerre et al. 2006; Koczan et al. 2008), B-cells (Szodoray et al. 
2006) and FLS (Watanabe et al. 2002; Gallagher et al. 2003; Kasperkovitz et al. 2005; 
Taberner et al. 2005). The comparisons which were made in synovial biopsies include intra- 
and inter-individual patient (Lindberg et al. 2006b), RA versus OA (Devauchelle et al. 2004), 
early versus long-standing RA (Tsubaki et al. 2005), before versus after infliximab treatment 
(Lindberg et al. 2006a), responders versus non-responders to infliximab treatment (van der 
Pouw Kraan et al. 2008), within the RA synovium (Timmer et al. 2007) and within RA and 
versus OA (van der Pouw Kraan et al. 2003a; van der Pouw Kraan et al. 2003b). The gene 
array comparisons performed using RA FLS include RA FLS versus healthy controls 
(Watanabe et al. 2002), resting RA FLS versus TNFα or IL-1β stimulated cells (Gallagher et 
al. 2003; Taberner et al. 2005) and within RA (Kasperkovitz et al. 2005). These studies 
identified gene profiles which appeared to be common denominators in autoimmune disease, 
such as activation of the interferon-response genes, genes involved in inflammation, 
signalling, apoptosis, ubiquitin/proteosome function and cell cycle (reviewed in (van Baarsen 
et al. 2009)).  
Thus, none of the existing microarray RA studies have specifically addressed the 
hypoxic gene profile of RA FLS which is a crucially important research area given the 
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hypoxic state of the RA synovium (see Chapter 3). In the present study, I have compared 
normoxic RA FLS versus hypoxic RA FLS (subjected to 1% oxygen). I have further 
narrowed down my search to identify angiogenic genes in RA FLS which change their 
expression in response to hypoxia. Unlike the microarray studies which rely on cDNA 
fragments for gene profiling, I used Human Angiogenesis RT2 profilerTM PCR arrays, which 
rely on the presence of a set of lyophilized primers in each well on a 96-well plate and the 
subsequent addition of cDNA from the sample of interest. The primers are designed to 
amplify the cDNA from known angiogenic genes. Thus, this is a small scale study with five 
patients, two time-points and the screening of 84 genes in total. Nevertheless, I have 
identified angiogenic factors which change in all five patients in response to hypoxia, and I 
have addressed the heterogeneity in the angiogenic profiles between the RA FLS from 
individual patients. I have also tried to determine whether HIF is involved in the hypoxia-
induced changes on the PCR arrays by using the HIF activator DMOG. Based on these results 
I have selected two of the angiogenic genes which changed expression in response to hypoxia 
and DMOG and determined which of the HIF isoforms, HIF-1α or HIF-2α, are implicated in 
their transcription. 
The discovery of novel hypoxia-induced angiogenic genes in RA FLS can lead to 
development of novel anti-angiogenic interventions to halt the pathological synovial 
angiogenesis observed in patients. It is also possible that an angiogenic profile of RA patients 
can help identify responders and non-responders to existing and future treatment modalities. 
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5.2 RESULTS 
5.2.1 The Human Angiogenesis RT2 ProfilerTM  PCR Array 
The Human Angiogenesis RT2 ProfilerTM PCR Arrays are produced in a 96-well format 
where each well contains a lyophilized primer set designed to amplify a gene that has 
previously been reported to be angiogenic in other settings. A list of the 84 angiogenic genes 
which were screened on the array is shown below (Table  5.1), followed by the 5 
housekeeping genes used for normalisation to correct for differences in the amount of RNA 
added to and the efficiencies of the RT-reactions. The housekeeping genes on the 96-well 
plate of which the specific mRNA did not vary with the experimental conditions were chosen 
to normalise samples. The fold change in gene expression in response to hypoxia was 
determined using the 2 -∆∆ Ct mathematical model. Genes were considered to be up- or 
downregulated by hypoxia if there was a fold change ≥ 2.0 or ≤ -2.0 compared to normoxic 
controls. Q-PCR was performed with primers designed in-house to confirm fold changes 
found using PCR array expression analysis.  
Table  5.1 Genes contained on the Human Angiogenesis RT2 ProfilerTM  PCR Array 
The PCR array contains lyophilised primer sets for the genes indicated below including several 
housekeeping genes for normalisation purposes. The 96-well plates are run on an ABI 7900 HT 
sequence detector and the CT values obtained using Sequence Detection Software version 1.9.1 for 
MAC from Applied Biosystems. The reference sequence (RefSeq) for the National Center for 
Biotechnology Information (NCBI) database is shown along with the symbol and gene name. A brief 
description of the corresponding protein and its function is also given. 
 
RefSeq Symbol Gene Name Description Function 
NM_005163 AKT1 PKB/PRKBA 
V-akt murine thymoma viral 
oncogene homolog 1 
Transcription 
factor 
NM_001146 ANGPT1 AGP1/AGPT Angiopoietin 1 Growth factor 
NM_001147 ANGPT2 AGPT2/ANG2 Angiopoietin 2 Growth factor 
NM_014495 ANGPTL3 ANGPT5 Angiopoietin-like 3 
Adhesion 
molecule 
NM_016109 ANGPTL4 ANGPTL2/ARP4 Angiopoietin-like 4 Adipocytokine 
NM_001150 ANPEP CD13/LAP1 
Alanyl (membrane) 
aminopeptidase 
(aminopeptidase N, 
aminopeptidase M, 
microsomal aminopeptidase, 
CD13, p150) 
Protease 
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Continued…. 
NM_001702 BAI1 BAI1 
Brain-specific angiogenesis 
inhibitor 1 
Adhesion 
molecule 
NM_002986 CCL11 SCYA11 
Chemokine (C-C motif) 
ligand 11 
Chemokine 
NM_002982 CCL2 
GDCF-2/GDCF-2 
HC11 
Chemokine (C-C motif) 
ligand 2 
Chemokine 
NM_001795 CDH5 7B4 
Cadherin 5, type 2, VE-
cadherin (vascular 
epithelium) 
Adhesion 
molecule 
NM_030582 COL18A1 KNO 
Collagen, type XVIII, alpha 
1 
Adhesion 
molecule 
NM_001795 CDH5 7B4 
Cadherin 5, type 2, VE-
cadherin (vascular 
epithelium) 
Adhesion 
molecule 
NM_030582 COL18A1 KNO 
Collagen, type XVIII, alpha 
1 
Adhesion 
molecule 
NM_000091 COL4A3 TUMSTATIN 
Collagen, type IV, alpha 3 
(Goodpasture antigen) 
Adhesion 
molecule 
NM_001511 CXCL1 GRO1/GROa 
Chemokine (C-X-C motif) 
ligand 1 (melanoma growth 
stimulating activity, alpha) 
Chemokine 
NM_001565 CXCL10 C7/IFI10 
Chemokine (C-X-C motif) 
ligand 10 
Chemokine 
NM_002090 CXCL3 CINC-2b/GRO3 
Chemokine (C-X-C motif) 
ligand 3 
Chemokine 
NM_002994 CXCL5 ENA-78/SCYB5 
Chemokine (C-X-C motif) 
ligand 5 
Chemokine 
NM_002993 CXCL6 CKA-3/GCP-2 
Chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) 
Chemokine 
NM_002416 CXCL9 CMK/Humig 
Chemokine (C-X-C motif) 
ligand 9 
Chemokine 
NM_001953 ECGF1 MNGIE/PDECGF 
Endothelial cell growth 
factor 1 (platelet-derived) 
Growth factor 
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Continued…. 
NM_001400 EDG1 
CHEDG1/ 
D1S3362 
Endothelial differentiation, 
sphingolipid G-protein-
coupled receptor, 1 
Adhesion 
molecule 
NM_182685 EFNA1 B61/ECKLG Ephrin-A1 Growth factor 
NM_004952 EFNA3 EFL2/EPLG3 Ephrin-A3 Growth factor 
NM_004093 EFNB2 EPLG5/HTKL Ephrin-B2 Growth factor 
NM_001963 EGF URG 
Epidermal growth factor 
(beta-urogastrone) 
Growth factor 
NM_000118 ENG CD105/END 
Endoglin (Osler-Rendu-
Weber syndrome 1) 
Adhesion 
molecule 
NM_004444 EPHB4 HTK/MYK1 EPH receptor B4 
Growth factor 
receptor 
NM_001432 EREG ER Epiregulin Growth factor 
NM_000800 FGF1 AFGF/ECGF 
Fibroblast growth factor 1 
(acidic) 
Growth factor 
NM_002006 FGF2 BFGF/FGFB 
Fibroblast growth factor 2 
(basic) 
Growth factor 
NM_000142 FGFR3 ACH/CEK2 
Fibroblast growth factor 
receptor 3 (achondroplasia, 
thanatophoric dwarfism) 
Growth factor 
receptor 
NM_004469 FIGF VEGF-D/VEGFD 
C-fos induced growth factor 
(vascular endothelial growth 
factor D) 
Growth factor 
NM_002019 FLT1 FLT/VEGFR1 
Fms-related tyrosine kinase 
1 (vascular endothelial 
growth factor/vascular 
permeability factor receptor) 
Growth factor 
receptor 
NM_021973 HAND2 DHAND2/Hed 
Heart and neural crest 
derivatives expressed 2 
Transcription 
factor 
NM_000601 HGF F-TCF/HGFB 
Hepatocyte growth factor 
(hepapoietin A; scatter 
factor) 
Growth factor 
NM_001530 HIF1A 
HIF-1alpha/HIF1-
ALPHA 
Hypoxia-inducible factor 1, 
alpha subunit (basic helix-
loop-helix transcription 
factor) 
Transcription 
factor 
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Continued…. 
NM_006665 HPSE HPA/HPR1 Heparanase Protease 
NM_002165 ID1 ID 
Inhibitor of DNA-binding 1, 
dominant negative helix-
loop-helix protein 
Transcription 
factor 
NM_002167 ID3 HEIR-1 
Inhibitor of DNA-binding 3, 
dominant negative helix-
loop-helix protein 
Transcription 
factor 
NM_024013 IFNA1 IFL/IFN Interferon, alpha 1 Cytokine 
NM_002176 IFNB1 IFB/IFF Interferon, beta 1, fibroblast Cytokine 
NM_000619 IFNG IFG/IFI Interferon, gamma Cytokine 
NM_000618 IGF1 IGFI 
Insulin-like growth factor 1 
(somatomedin C) 
Growth factor 
NM_000576 IL1B IL-1/IL1-BETA Interleukin 1, beta Cytokine 
NM_000600 IL6 BSF2/HGF 
Interleukin 6 (interferon, 
beta 2) 
Cytokine 
NM_000584 IL8 3-10C/AMCF-I Interleukin 8 Cytokine 
NM_002210 ITGAV CD51/MSK8 
Integrin, alpha V 
(vitronectin receptor, alpha 
polypeptide, antigen CD51) 
Adhesion 
molecule 
NM_000212 ITGB3 CD61/GP3A 
Integrin, beta 3 (platelet 
glycoprotein IIIa, antigen 
CD61) 
Adhesion 
molecule 
NM_000214 JAG1 AGS/AHD 
Jagged 1 (Alagille 
syndrome) 
Growth factor 
NM_002253 KDR FLK1/VEGFR 
Kinase insert domain 
receptor (a type III receptor 
tyrosine kinase) 
Growth factor 
receptor 
NM_005560 LAMA5 KIAA1907 Laminin, alpha 5 
Adhesion 
molecule 
NM_007015 LECT1 BRICD3/CHM-I 
Leukocyte cell derived 
chemotaxin 1 
Chemokine 
NM_000230 LEP OB/OBS 
Leptin (obesity homolog, 
mouse) 
Adipocytokine 
NM_002391 MDK MK/NEGF2 
Midkine (neurite growth-
promoting factor 2) 
Growth factor 
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Continued…. 
NM_004530 MMP2 CLG4/CLG4A 
Matrix metallopeptidase 2 
(gelatinase A, 72kDa 
gelatinase, 72kDa type IV 
collagenase) 
Matrix 
NM_004994 MMP9 CLG4B/GELB 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
Matrix 
NM_004557 NOTCH4 INT3/NOTCH3 
Notch homolog 4 
(Drosophila) 
Transcription 
factor 
NM_003873 NRP1 
DKFZp686A0313
4/DKFZp781F14
14 
Neuropilin 1 
Adhesion 
molecule 
NM_003872 NRP2 NP2/NPN2 Neuropilin 2 
Adhesion 
molecule 
NM_002607 PDGFA PDGF-A/PDGF1 
Platelet-derived growth 
factor alpha polypeptide 
Growth factor 
NM_000442 PECAM1 CD31/PECAM-1 
Platelet/endothelial cell 
adhesion molecule (CD31 
antigen) 
Adhesion 
molecule 
NM_002619 PF4 CXCL4/SCYB4 
Platelet factor 4 (chemokine 
(C-X-C motif) ligand 4) 
Chemokine 
NM_002632 PGF PLGF/PlGF-2 
Placental growth factor, 
vascular endothelial growth 
factor-related protein 
Growth factor 
NM_002658 PLAU ATF/UPA 
Plasminogen activator, 
urokinase 
Matrix 
NM_000301 PLG 
DKFZp779M022
2 
Plasminogen Protease 
NM_020405 PLXDC1 TEM3/TEM7 Plexin domain containing 1 
Transmembrane 
protein 
NM_021935 PROK2 BV8/MIT1 Prokineticin 2 Growth factor 
NM_000962 PTGS1 COX1/COX3 
Prostaglandin-endoperoxide 
synthase 1 (prostaglandin 
G/H synthase and 
cyclooxygenase) 
Transcription 
factor 
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Continued…. 
NM_002615 SERPINF1 EPC-1/PEDF 
Serpin peptidase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived factor), 
member 1 
Growth factor 
NM_021972 SPHK1 SPHK Sphingosine kinase 1 
Transcription 
factor 
NM_015136 STAB1 
CLEVER-
1/FEEL-1 
Stabilin 1 
Adhesion 
molecule 
NM_000459 TEK CD202B/TIE-2 
TEK tyrosine kinase, 
endothelial (venous 
malformations, multiple 
cutaneous and mucosal) 
Growth factor 
receptor 
NM_003236 TGFA TFGA 
Transforming growth factor, 
alpha 
Growth factor 
NM_000660 TGFB1 CED/DPD1 
Transforming growth factor, 
beta 1 (Camurati-
Engelmann disease) 
Growth factor 
NM_003238 TGFB2 TGF-beta2 
Transforming growth factor, 
beta 2 
Growth factor 
NM_004612 TGFBR1 
ACVRLK4/ALK-
5 
Transforming growth factor, 
beta receptor I (activin A 
receptor type II-like kinase, 
53kDa) 
Growth factor 
receptor 
NM_003246 THBS1 THBS/TSP Thrombospondin 1 
Adhesion 
molecule 
NM_003247 THBS2 TSP2 Thrombospondin 2 
Adhesion 
molecule 
NM_003254 TIMP1 CLGI/EPA 
TIMP metallopeptidase 
inhibitor 1 
Matrix 
NM_003255 TIMP2 CSC-21K 
TIMP metallopeptidase 
inhibitor 2 
Matrix 
NM_000362 TIMP3 
HSMRK222/K22
2 
TIMP metallopeptidase 
inhibitor 3 (Sorsby fundus 
dystrophy, 
pseudoinflammatory) 
Matrix 
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Continued…. 
NM_000594 TNF DIF/TNF-alpha 
Tumor necrosis factor (TNF 
superfamily, member 2) 
Cytokine 
NM_006291 TNFAIP2 B94 
Tumor necrosis factor, 
alpha-induced protein 2 
Cytokine 
NM_003376 VEGF VEGFA/VPF 
Vascular endothelial growth 
factor 
Growth factor 
NM_005429 VEGFC Flt4-L/VRP 
Vascular endothelial growth 
factor C 
Growth factor 
X03205 18SrRNA 18SRNA Human 18S ribosomal RNA Housekeeping 
NM_012423 RPL13A RPL13A Ribosomal protein L13a Housekeeping 
NM_002046 GAPDH G3PD/GAPD Glyceraldehyde-3-
phosphate dehydrogenase 
Housekeeping 
NM_001101 ACTB PS1TP5BP1 Actin, beta Housekeeping 
NM_000194 HPRT1 HGPRT/HPRT 
Hypoxanthine 
phosphoribosyltransferase 1 
Housekeeping 
 
 
5.2.2 Identification of hypoxia-regulated angiogenic genes in RA FLS using the 
Human Angiogenesis RT2 ProfilerTM  PCR Array    
FLS isolated from digested RA synovial biopsies were incubated in normoxia or 
hypoxia for 4 or 24 hours and cDNA was made from the total RNA extract and mixed with 
SYBR green before this mixture was added to the PCR array wells containing the primer sets. 
The changes in gene expression in RA FLS in response to hypoxia on the PCR array, is 
shown below (Table  5.2). The fold up- or downregulation represents the average fold change 
in the expression of a given gene in FLS from RA patients number #1-3 (4 hour experiment) 
and patients number #1-5 (24 hour experiment). If a gene changed on average ≥ 2.0-fold 
across FLS from all patients tested, it was included in Table  5.2. 
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Table  5.2 Angiogenic genes which change expression under hypoxia in RA FLS from 5 
patients 
Human Angiogenesis RT2 ProfilerTM PCR Arrays were used to screen the cDNA from RA FLS 
incubated for 4 or 24 hours in 21% (normoxia) or 1% oxygen (hypoxia). The Table shows the 
angiogenic genes which changed in response to hypoxia and the average fold change relative to 
normoxic controls at the same time-points. If a gene changed on average ≥ 2.0-fold across FLS from all 
patients tested, it was included in the Table. The P value represents a paired Student's t-test comparing 
ΔCt values (normoxia versus hypoxia). The symbol (-) represents no change in gene expression. 
 
SYMBOL Gene name Protein Fold up- or 
downregulation 
P  value 
Students t-
test 
Upregulated 4 hours: 
ANGPTL4 ANGPTL2/A
RP4 
Angiopoietin-like protein 
4 
20.5 <0.01 
EFNA3 EFL2/EPLG3 Ephrin-A3 2.5 <0.05 
Lep OB/OBS Leptin (obesity homolog, 
mouse) 
59.2 <0.001 
VEGF VEGFA/VPF Vascular endothelial 
growth factor 
5.6 <0.05 
Downregulated 4 hours 
None - - - - 
Upregulated 24 hours 
ANGPTL4 ANGPTL2/A
RP4 
Angiopoietin-like protein 
4 
11.9 <0.01 
EFNA3 EFL2/EPLG3 Ephrin-A3 2.2 <0.05 
Lep OB/OBS Leptin (obesity homolog, 
mouse) 
108.7 <0.01 
VEGF VEGFA/VPF Vascular endothelial 
growth factor 
8.3 <0.01 
TGFB1 TGFB1 Transforming growth 
factor, beta 1 
2.2 <0.05 
Downregulated 24 hours 
HIF1A HIF-1alpha Hypoxia-inducible factor 
1, alpha subunit (basic 
helix-loop-helix 
transcription factor) 
-2.3 <0.05 
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Out of 84 genes screened, 6 genes changed significantly in FLS from all five patients 
upon exposure to hypoxia (Figure  5.1 and Table  5.2). Following 4 hours of exposure to 
hypoxia, the expression of 4 genes was upregulated, namely ANGPTL-4, EFNA3, Leptin and 
VEGF-A, and none were downregulated. These genes were also upregulated in RA FLS 
exposed to 24 hours of hypoxia. In addition, TGFβ1 expression by RA FLS was induced 2-
fold after 24 hours of hypoxic exposure. In agreement with my work presented in Chapter 3, I 
observed hypoxia-induced downregulation of HIF-1α expression on the PCR array to 
approximately half of its normoxic levels (-2.3-fold) following hypoxic exposure for 24 
hours. HIF-1α was the only gene observed to decrease with hypoxia in FLS from all five RA 
patients. Upregulation of VEGF-A in RA FLS in response to hypoxia has been reported 
previously, however the upregulation of specific VEGF isoforms has not been reported before 
and will be described in more detail in Section 5.2.5. 
Figure  5.1 Angiogenic genes which change expression under hypoxia in RA FLS detected 
using the Human Angiogenesis RT2 ProfilerTM PCR Array 
The data from Table 5.2 are shown here. FLS were exposed to 21% or 1% oxygen for 4 or 24 hours. 
Genes were considered to be up- or downregulated by hypoxia if there was an average fold change ≥ 
2.0 compared to normoxic controls (dotted line). The bars represent the average fold change in a gene 
following (a) 4 hours (n=3) or (b) 24 hours (n=5) of exposure to hypoxia. Data were analysed using 
paired Student's t-test to compare ΔCt values (normoxia versus hypoxia): * p<0.05, **p<0.01, 
***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 5 10 15 20 25 40 45 50 55 60 65
ANGPTL4
EFNA1
Leptin
VEGFA
**
***
*
*
-5 0 5 5 10 15 20 80 12
0
16
0
HIF-1A
TGFB1
VEGFA
Leptin
EFNA3
ANG PTL4 **
**
**
*
*
*
(a)
(b)
CHAPTER 5                Identification of novel hypoxia-regulated angiogenic genes in RA FLS 
 145
The expression of ANGPTL-4 was greatly induced by hypoxia in RA FLS. Following 
4 and 24 hours of hypoxic exposure, ANGTPL-4 expression increased 20.5-fold and 11.9-fold 
respectively (Figure  5.1 and Table  5.2). The expression of ANGPTL-4 in RA FLS and total 
dissociated RA membrane cells in response to hypoxia was further investigated and the 
results are shown in Section 5.2.6. 
The most striking change observed in response to hypoxia however, was that of the 
obesity gene (OB) encoding leptin protein. Following exposure of RA FLS to 4 hours of 
hypoxia, the average expression of leptin had increased almost 60-fold, and after 24 hours 
leptin expression had increased 108-fold. Based on these findings and what is known about 
leptin in the literature I decided to study the role of leptin in RA further. This work will be 
presented separately in Chapter 6. 
5.2.3 Heterogeneity of the hypoxia-induced angiogenic profile in RA FLS across 
patients 
As the sample size in the present study was small, it was difficult to address the 
heterogeneity between FLS derived from different patients. However, as I did not pool my 
samples in the study, it was possible to look at the changes in the gene expression profile in 
individual patients. The angiogenic genes which changed expression in response to 24 hours 
of hypoxia are listed in Table  5.3.  
Table  5.3 Angiogenic genes which change expression under hypoxia in FLS from 
individual RA patients 
Human Angiogenesis RT2 ProfilerTM PCR Arrays were used to screen cDNA from hypoxic FLS from 
five RA patients. The RA FLS were incubated for 24 hours in normoxia or hypoxia and the fold change 
relative to normoxic controls are shown. The symbol (-) represents no change in gene expression in the 
given patient. 
 
 
Fold up- or downregulation Symbol Gene 
name 
 
Protein 
Patient: 
#1          #2          #3         #4        #5 
ANGPT2 AGPT2/AN
G2 
Angiopoietin 2 - - -3 - - 
ANGPTL4 ANGPTL2/
ARP4 
Angiopoietin-like protein 4 30 9.2 9.8 5.2 5.4 
COL4A3 TUMSTATI
N 
Collagen, type IV, alpha 3 
(Goodpasture antigen) 
- - - 2.9 - 
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Continued…. 
CCL11 SCYA11 Chemokine (C-C motif) 
ligand 11 
-14.4 -3.1 -8.5 - - 
CCL2 GDCF-
2/GDCF-2 
HC11 
Chemokine (C-C motif) 
ligand 2 
-8.5 - - - - 
CXCL1 GRO1/GRO
a 
Chemokine (C-X-C motif) 
ligand 1 (melanoma 
growth stimulating 
activity, alpha) 
-5.6  -2.7   
CXCL10 C7/IFI10 Chemokine (C-X-C motif) 
ligand 10 
-18.1 - -26.6 - - 
CXCL3 CINC-
2b/GRO3 
Chemokine (C-X-C motif) 
ligand 3 
-9.1 - - - - 
CXCL5 ENA-
78/SCYB5 
Chemokine (C-X-C motif) 
ligand 5 
-2.8 -2 - - - 
CXCL6 CKA-
3/GCP-2 
Chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) 
-8.2 -2 -2.1 - - 
CXCL9 CMK/Humi
g 
Chemokine (C-X-C motif) 
ligand 9 
- 3 - - - 
EFNA3 EFL2/EPLG
3 
Ephrin-A3 2.9 2.1 2.5 2.3 1.3 
EREG ER Epiregulin - 2.5 - - - 
FGF1 AFGF/ECG
F 
Fibroblast growth factor 1 
(acidic) 
- - - -2.3 - 
FIGF VEGF-
D/VEGFD 
C-fos induced growth 
factor (vascular endothelial 
growth factor D) 
- -3.4 - - - 
FLT1 FLT/VEGF
R1 
Fms-related tyrosine 
kinase 1 (vascular 
endothelial growth 
factor/vascular 
permeability factor 
receptor) 
- - - 5.8 - 
HAND2 DHAND2/H
ed 
Heart and neural crest 
derivatives expressed 2 
-2.4 - - - - 
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Continued…. 
HGF F-
TCF/HGFB 
Hepatocyte growth factor 
(hepapoietin A; scatter 
factor) 
-2.7 - - - - 
HIF1A HIF-1alpha Hypoxia-inducible factor 
1, alpha subunit (basic 
helix-loop-helix 
transcription factor) 
-4.5 -2 -1.2 -1.2 -2.6 
HPSE HPA/HPR1 Heparanase - -2.7 -2 - - 
ID1 ID Inhibitor of DNA-binding 
1, dominant negative 
helix-loop-helix protein 
- - - 2 - 
IFNA1 IFL/IFN Interferon, alpha 1 - - 3 - - 
IFNB1 IFB/IFF Interferon, beta 1, 
fibroblast 
- - 2.4 - - 
IGF1 IGFI Insulin-like growth factor 
1 (somatomedin C) 
- - -2 2.4 - 
IL1B IL-1/IL1-
BETA 
Interleukin 1, beta - -2.7 - - - 
IL6 BSF2/HGF Interleukin 6 (interferon, 
beta 2) 
- - - 2.9 - 
IL8 3-
10C/AMCF-
I 
Interleukin 8 -4.5 2.1 - - - 
ITGB3 CD61/GP3
A 
 
Integrin, beta 3 (platelet 
glycoprotein IIIa, antigen 
CD61) 
-2.3 - - - - 
JAG1 AGS/AHD Jagged 1 (Alagille 
syndrome) 
-2.5 -  - - 
LAMA5 KIAA1907 Laminin, alpha 5 - - 2.7 - - 
LECT1 BRICD3/C
HM-I 
Leukocyte cell derived  
chemotaxin 1 
- - 4.1 - - 
Lep OB/OBS Leptin (obesity homolog, 
mouse) 
235.6 113.6 140.7 43.7 9.7 
NOTCH4 INT3/NOT
CH3 
Notch homolog 4 
(Drosophila) 
- - - 2.6 - 
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Continued…. 
NRP2 NP2/NPN2 Neuropilin 2 -2.1 - - - - 
PECAM1 CD31/PEC
AM-1 
Platelet/endothelial cell 
adhesion molecule (CD31 
antigen) 
- 16.3 4.7 - - 
PGF PLGF/PlGF
-2 
 
Placental growth factor, 
vascular endothelial 
growth factor-related 
protein 
-2.6 3.1 - - -2.1 
PLAU ATF/UPA Plasminogen activator, 
urokinase 
-3.3 - - 2.2 - 
PLG DKFZp779
M0222 
Plasminogen -2.1 - - - - 
PLXDC1 TEM3/TEM
7 
Plexin domain containing 
1 
-2.9 - - - - 
PTGS1 COX1/COX
3 
Prostaglandin-
endoperoxide synthase 1 
(prostaglandin G/H 
synthase and 
cyclooxygenase) 
- - - 2.6 - 
STAB1 CLEVER-
1/FEEL-1 
Stabilin 1 - - 2.5 5.7 - 
TEK CD202B/TI
E-2 
TEK tyrosine kinase, 
endothelial (venous 
malformations, multiple 
cutaneous and mucosal) 
- - - 2 2 
TGFB1 TGFB1 Transforming growth 
factor, beta 1 
1.3 3.1 3.1 1.8 1.6 
TGFB2 TGF-beta 2 Transforming growth 
factor, beta 2 
-2.2 - -2.9 - - 
THBS2 TSP2 Thrombospondin 2 4.6 - - - - 
TNFAIP2 B94 Tumor necrosis factor, 
alpha-induced protein 2 
- - -3.8 - - 
VEGF VEGFA/VP
F 
Vascular endothelial 
growth factor 
4.1 18.4 11.3 5.5 2.1 
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Out of the 84 angiogenic genes tested, 47 genes changed expression in response to 
hypoxia in one or more patients. Several of the genes screened were upregulated in one 
patient and downregulated in another including IGF1, ATF/UPA, PLGF/PlGF-2 and TGFβ2. 
It appears therefore that in addition to the common changes taking place in the RA FLS 
in response to hypoxia (Table  5.2), the FLS from the different RA patients screened in this 
study also harbour distinct and unique angiogenic profiles induced under hypoxic conditions 
(Table  5.3). 
5.2.4 Multiple genes change in response to DMOG in RA FLS from a single 
patient on the Human Angiogenesis RT2 ProfilerTM  PCR Array 
Having discovered which of the 84 angiogenic genes on the PCR array were regulated 
by hypoxia (Table  5.3), my next goal was to determine which of these genes where regulated 
via the HIF pathway. To address this matter, I applied the FLS cDNA from a single RA 
patient (Patient #6) which had been incubated with DMSO or 1mM of the HIF-activator 
DMOG for 24 hours to the PCR arrays and determined which of the hypoxia-induced changes 
were replicated by activating HIFs with DMOG. As is shown in Table  5.4, DMOG induced 
changes in the expression of 22 angiogenic genes relative to DMSO treated controls: 
 
Table  5.4 Angiogenic genes which changed expression in DMOG-exposed FLS from a 
single patient on the Human Angiogenesis RT2 ProfilerTM PCR Array 
Human Angiogenesis RT2 ProfilerTM PCR Arrays were used to screen cDNA from DMOG stimulated 
FLS from 1 RA patient. The RA FLS were incubated for 24 hours in DMSO or 1mM DMOG and the 
fold change relative to the DMSO control is shown. The genes which were also seen to be up- or 
downregulated in one or more patients by hypoxia are shown in italics. 
 
Symbol Gene name Protein Fold up- or 
downregulation 
Patient #6 
Up-regulated 24 hours: 
ANGPTL4 ANGPTL2/ARP4 Angiopoietin-like protein 4 65.9 
EFNA3 EFL2/EPLG3 Ephrin-A3 8.6 
Lep OB/OBS Leptin (obesity homolog, mouse) 34.5 
VEGF VEGF/VEGF-A Vascular endothelial growth factor A 41.1 
FLT1 FLT/VEGFR1 
 
Fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability factor 
receptor) 
8.7 
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Continued…. 
CXCL3 CINC-2b/GRO3 Chemokine (C-X-C motif) ligand 3 4.1 
EDG1 CHEDG1/D1S33
62 
 
Endothelial differentiation, 
sphingolipid G-protein-coupled 
receptor, 1 
2.7 
EFNB2 EPLG5/HTKL Ephrin-B2 12.9 
PGF PLGF/PlGF-2 
 
Placental growth factor, vascular 
endothelial growth factor-related 
protein 
25.8 
TIMP3 HSMRK222/K22
2 
 
TIMP metallopeptidase inhibitor 3 
(Sorsby fundus dystrophy, 
pseudoinflammatory) 
3.5 
Down-regulated 24 hours: 
HIF1A HIF-1alpha/HIF1-
ALPHA 
Hypoxia-inducible factor 1, alpha 
subunit (basic helix-loop-helix 
transcription factor) 
-2.6 
CCL2 GDCF-2/GDCF-2 
HC11 
Chemokine (C-C motif) ligand 2 -3.9 
FGF1 AFGF/ECGF Fibroblast growth factor 1 (acidic) -6.9 
HAND2 DHAND2/Hed Heart and neural crest derivatives 
expressed 2 
-3.3 
NRP2 NP2/NPN2 Neuropilin 2 -3 
BAI1 FLJ41988 Brain-specific angiogenesis inhibitor 1 -2.1 
CDH5 7B4/CD144 Cadherin 5, type 2, VE-cadherin 
(vascular epithelium) 
-3.7 
ID1 ID Inhibitor of DNA-binding 1, dominant 
negative helix-loop-helix protein 
-7.9 
ID3 HEIR-1 Inhibitor of DNA-binding 3, dominant 
negative helix-loop-helix protein 
-3.3 
IGFI IGFI Insulin-like growth factor 1 
(somatomedin C) 
-3.9 
PLAU ATF/UPA Plasminogen activator, urokinase -3.8 
TIMP1 CLGI/EPA TIMP metallopeptidase inhibitor 1 -2.1 
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As the PCR arrays with DMOG stimulated RA FLS were done for 1 patient only, the 
results must be interpreted with precaution. Nevertheless, DMOG induced 10 of the genes 
which had changed in response to hypoxia in one or more patients (Table  5.5), indicating that 
these genes are HIF-driven in hypoxia. Only the genes which changed in the same direction in 
response to hypoxia and DMOG were considered. 
Table  5.5 Genes which are up- or downregulated by both hypoxia and DMOG 
DMOG stimulation of RA FLS from a single patient lead to the activation of 10 genes on the PCR 
array which were also seen to change in response to hypoxia. The arrows indicate the direction of 
change. Only genes which changed in the same direction with both treatments were included.  
 
Genes which change expression in 
response to both hypoxia and DMOG 
ANGPTL4 HIF-1α 
EFNA3 CCL2 
Leptin FGF1 
VEGFA HAND2 
FLT1 NRP2 
 
DMOG could mimic the hypoxia-induced expression of ANGPTL-4, EFNA3, Leptin 
VEGFA and FLT1 mRNA suggesting these are all regulated by HIFs under hypoxia. The 
genes were upregulated to a much higher degree by DMOG compared to that seen with 
hypoxia, with the exception of leptin (34.5- versus 108.3-fold in hypoxia). Leptin expression 
may therefore be induced by both HIF-dependent as well as HIF-independent pathways in 
hypoxia. As I observed previously (Chapter 3), DMOG was able to downregulate the level of 
HIF-1α to a similar degree to hypoxia, supporting my theory that this observation represents 
an auto-negative feedback mechanism where activated HIF-1 is involved in downregulating 
HIF-1α, possibly via aHIF. Interestingly, with the exception of CCL-2 the hypoxia-induced 
downregulation of the chemokine ligands CXCL-3, -5, -6, -10 and -11, all seemed to occur 
via HIF-independent pathways as DMOG had no effect on their expression. DMOG was also 
able to downregulate the mRNA level of FGF-1, HAND-2 and NRP-2. DMOG-induced 
changes in HIF-1α, ANGPTL-4, leptin and VEGF-A by DMOG was verified in several 
patients (Figure 3.1, 3.17, 3.18, 5.7b, 5.10. 5.12, 6.3, 6.7) which supports the current findings 
on the PCR array. 
In addition to the genes regulated by both hypoxia and DMOG, a whole list of genes 
was upregulated by DMOG on the PCR array, the expression of which had not changed in 
response to hypoxia (Table  5.4). A good example of one such gene is EFNB2, which did not 
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change with hypoxia in FLS from any of the five patients, but was induced 12.9-fold by 
DMOG albeit in a separate patient. This indicates that these genes may be regulated by some 
repressor function such that hypoxia activated levels of HIFs are insufficient to induce their 
expression. DMOG however, is a much stronger inducer of HIFs than hypoxia (see Chapter 
3) and it could be that this high level of available HIF-1 and HIF-2 can override any such 
negative control and induce a forced expression of repressed HIF target genes. Similarly, 
many genes were downregulated by DMOG which had not changed in response to hypoxia. 
Again this could be due to the high and unphysiological levels of HIFs induced by DMOG 
relative to that induced by hypoxia which forces changes in the expression level of genes 
unaffected by HIFs under physiological conditions. Thus, 37 genes were uniquely altered by 
hypoxia, 12 by DMOG and 10 genes were changed with both types of treatments. 
 
5.2.5 Expression of VEGF isoforms in RA FLS and total dissociated RA 
membrane cells 
Total VEGF mRNA was upregulated on average 5.6-fold and 8.3-fold in RA FLS 
from 5 patients on the PCR arrays following 4 and 24 hours of hypoxic stimulation 
respectively (Table 5.2). The occurrence of VEGF has been repeatedly observed in human 
synovial fluids and synovial tissue of patients with RA (Fava et al. 1994; Koch et al. 1994; 
Giatromanolaki et al. 2003). Very few studies have focused on the expression of the 
individual VEGF splice variants however, and so far no one has employed Q-PCR to 
determine whether hypoxia has a differential effect on the expression of three major VEGF 
splice variants, VEGF121, -165 and -189, in RA FLS. In the present study I analysed the hypoxia-
induced expression pattern of VEGF splice variants in RA FLS by Q-PCR. For comparison, I 
also investigated VEGF isoform expression in human CCD19Lu fibroblasts. The primers 
used were designed to span the splice junctions allowing for the amplification of each splice 
variant individually (Figure  5.2). 
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Figure  5.2 Primer sets used to amplify VEGF isoforms 
The forward primer which is located in the common exon 3 was used for PCR in combination with 
isoform-specific reverse primers as indicated. The reverse primer Ex6/7R was designed to span exon 6 
and 7, an exon junction specific for splice variant VEGF189. The reverse primer Ex5/7R was designed 
to span exon 5 and 7, an exon junction specific for VEGF165, Ex7/9R was used to amplify VEGF165b 
and finally the reverse primer Ex5/8R was designed to span exon 5 and 8, an exon junction specific for 
VEGF121.  
 
 
 
 
 
 
 
 
 
 
 
 
 
I incubated RA FLS and CCD19Lu fibroblasts in either 1% or 21% oxygen for 24 
hours, harvested total RNA and generated cDNA. The ΔCt values obtained from the Q-PCR 
run were used in the statistical analyses, to show that 24 hours of incubation under 1% oxygen 
significantly upregulated the mRNA for all isoforms tested in both RA FLS and CCD19Lu 
fibroblasts (Figure  5.3a and b).  
Figure  5.3 Expression of VEGF isoforms in RA FLS and CCD19Lu fibroblasts  
Human RA FLS (a) or CCD19Lu fibroblasts (b) were incubated in either 21% or 1% oxygen for 24 
hours. VEGF121, VEGF165 and VEGF189-specific primers were used for Q-PCR analysis. The levels of 
the various transcripts are expressed relative to normoxic controls at the same time-point set as 1.0 
(dotted line). Data are expressed as mean ± SEM of 3 independent experiments with sample assayed in 
triplicate, and were analysed using 1-Way ANOVA to compare ΔCt values (normoxia versus hypoxia): 
** p<0.01, ***p<0.001. 
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As VEGF isoforms have different heparin-binding capacities, in addition to tissue- 
and cell-specific expression, it is likely that their roles in RA pathophysiology differ. The next 
step was therefore to determine if the three VEGF splice variants were differentially 
upregulated by hypoxia in RA FLS and CCD19Lu fibroblasts. Using a 1-Way ANOVA 
statistical test to analyse the data, I concluded that there was no significant difference in the 
upregulation by hypoxia of the three VEGF splice forms investigated in either cell type. 
To establish whether hypoxia would induce a similar regulatory response in the levels 
of VEGF121, -165 and -189, in total dissociated RA membrane cells, I placed culture dishes with 
newly dissociated cells from RA biopsies in either 1% or 21% oxygen for 24 hours. As can be 
seen below in Figure  5.4, the three isoforms were upregulated to a similar extent by hypoxia 
to approximately 6-fold above normoxic levels which was similar to the results obtained in 
FLS. I also investigated whether the inhibitory VEGF isoform VEGF165b was expressed in the 
synovial membrane cells. In contrast to the other VEGF isoforms, this inhibitory variant did 
not appear to change in response to hypoxia, although there were small amounts of the 
VEGF165b variant expressed in the mixed cell population. As expected, since the VEGFtotal 
primer set was designed to amplify all VEGF isoforms, a similar increase of 6-fold to that of 
the individual isoforms was observed for total VEGF in the cell cultures in response to 
hypoxia.  
Figure  5.4 Expression of VEGF isoforms in total dissociated RA membrane cell cultures 
Human RA synovial biopsies were digested and dissociated and cell cultures were incubated in 21% 
oxygen or 1% oxygen for 24 hours. VEGF121, VEGF165, VEGF165b, VEGF189 and VEGFtotal-specific 
primers were used for Q-PCR analysis. The levels of the various transcripts are expressed relative to 
normoxic controls at the same time-point set as 1.0 (dotted line). Data are expressed as the mean ± 
SEM of ≥ 3 independent experiments with sample assayed in triplicate, and were analysed using paired 
Student's t-test to compare ΔCt values (normoxia versus hypoxia): *p<0.05, **p<0.01, ns: not 
significant. 
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5.2.6 Expression of ANGPTL-4 in RA FLS and total dissociated RA synovial 
membrane cell cultures 
ANGPTL-4, also known as fasting-induced adipose factor (FIAF), peroxisome 
proliferator-activated receptor (PPAR)-gamma angiopoietin-related protein (PGAR) and 
hepatic fibrinogen/angiopoietin-related protein (HFARP), was greatly upregulated in RA FLS 
by hypoxia and DMOG on the Q-PCR array. To confirm and further investigate these 
findings, I incubated FLS from three different RA patients for 4 or 24 hours in normoxia or 
hypoxia. Using this cDNA and PCR primers specifically designed for ANGPTL-4 I 
performed RT-PCR on the cDNA and ran the products on a 2% agarose gel. As expected 
from the Q-PCR arrays, 4 and 24 hours of hypoxia could greatly induce ANGPTL-4 in FLS 
from all three RA patients (Figure  5.5a, b). The RA FLS from all three patients expressed 
ANGPTL-4 under normoxic conditions, but patient #2 seemed to have a particularly high 
basal expression of ANGPTL-4. 
Figure  5.5 Basal and hypoxia-induced expression of ANGPTL-4 in RA FLS 
RA FLS were cultured in either 21% (N) or 1% oxygen (H) for 4 and 24 hours and total RNA was 
extracted for cDNA synthesis. RT-PCR analysis was carried out with ANGPTL-4-specific primers to 
detect changes in the expression of the ANGPTL-4 gene following exposure to (a) 4 hours and (b) 24 
hours of hypoxia in three RA patients (#1, #2 and #3). The amplification of the housekeeping gene 
ARP was performed to control for the amount of cDNA in PCR reactions and equal loading on the 2% 
agarose gels. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To analyse the temporal expression of ANGPTL-4 with hypoxia, I incubated RA FLS 
in either 1% or 21% oxygen for 0-24 hours and extracted total RNA at each time-point. 
Following cDNA synthesis, I performed Q-PCR to determine the fold change of ANGPTL-4 
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with time in hypoxia. The expression of ANGPTL-4 increased rapidly within the first 6 hours 
of hypoxic exposure to about 9-fold above normoxic levels (Figure  5.6a). After this initial 
increase, the levels rose slightly and remained stable throughout the 24 hours assayed. I also 
investigated the expression of ANGPTL-4 in RA FLS incubated with 1mM DMOG for 0-24 
hours. This time-course of ANGPTL-4 induction looked similar to that seen when cells were 
incubated in hypoxia (Figure 5.6b), but DMOG induced approximately 10-fold more 
ANGPTL-4 mRNA at each time-point emphasising that a stronger activation of HIF 
transcription factors leads to an equally higher increase in the transcription of its target gene, 
ANGPTL-4. That DMOG is a stronger activator of HIFs than hypoxia was shown in Chapter 
3 (Figure 3.1). 
Figure  5.6 Time-course of ANGPTL-4 induction by hypoxia and DMOG in RA FLS 
Human RA FLS were cultured in either 21% and 1% oxygen or (a) DMSO and 1mM DMOG (b) for 0, 
1, 2, 4, 6 or 24 hours and total RNA was extracted for cDNA synthesis. ANGPTL-4-specific primers 
were used for Q-PCR analysis. The level of the transcripts is expressed relative to time-matched 
normoxic controls set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 3 independent 
experiments with sample assayed in triplicate and were analysed using 1-Way ANOVA to compare 
ΔCt values (normoxia versus hypoxia or DMSO versus DMOG): * p<0.05, ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
To determine the critical range of oxygen tension which would induce ANGPTL-4 
accumulation, I subjected near confluent RA FLS cultures to a range of oxygen percentages 
(1%, 3%, 5%, 7% or 21%) for 6 hours. Exposure of RA FLS to oxygen levels ranging from 
21% to 1% for 6 hours was associated with a progressive increase in ANGPTL-4 mRNA as 
the oxygen level declined. Statistically significant results were obtained when cells were 
incubated at 1% and 3% oxygen for 6 hours (Figure  5.7). The maximal ANGPTL-4 response 
occurred at 1% oxygen with a half-maximal expression of ANGPTL-4 mRNA seen between 
1% and 3% oxygen. The fold changes occurring at 1-5% oxygen would probably have been 
even greater than observed here if a similar experiment was conducted for 24 hours. It is 
however interesting that ANGPTL-4 is upregulated by 3% oxygen in addition to 1% as this 
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(Sivakumar et al. 2008).  
Figure  5.7 ANGPTL-4 expression in RA FLS is influenced by the level of oxygen 
Human RA FLS were cultured in a range of oxygen tensions (1% to 21% oxygen) for 6 hours. Total 
RNA was isolated and cDNA generated for measuring the mRNA level of ANGPTL-4 by Q-PCR. 
Levels of ANGPTL-4 mRNA are expressed as mean fold change relative to normoxic controls which 
was set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 3 independent experiments 
performed with sample assayed in triplicate and were analysed using 1-Way ANOVA to compare ΔCt 
values (normoxia versus hypoxia): ***p<0.001, ns: not significant. 
 
  
 
 
 
 
 
 
 
 
 
As cultures of total synovial membrane cells represent a more accurate picture of the 
pathological state in the RA joint than cell cultures selected for RA FLS do, I used this mixed 
cell population to verify my findings from the RA FLS. To establish whether hypoxia could 
induce a similar regulatory response in the levels of ANGPTL-4 mRNA in these cell cultures, 
I placed culture dishes with newly dissociated synovial membrane cells from joint biopsies in 
either 1% or 21% oxygen for 24 hours. Indeed, ANGPTL-4 was upregulated approximately 
10-fold by hypoxia in the cell cultures which was similar to the fold induction in mRNA 
observed for the well-known angiogenic factor VEGF (Figure  5.8). 
Figure  5.8 ANGPTL-4 induction in total dissociated RA synovial membrane cells 
Human RA synovial biopsies were digested and dissociated and cell cultures were incubated in either 
21% or 1% oxygen for 24 hours. ANGPTL-4 and VEGFtotal-specific primers were used for Q-PCR 
analysis. The levels of the transcripts are expressed relative to normoxic controls set as 1.0 (dotted 
line). Data are expressed as mean ± SEM of ≥ 3 independent experiments with sample assayed in 
triplicate, and were analysed using paired Student's t-test to compare ΔCt values (normoxia versus 
hypoxia): ** p<0.01, ***p<0.001. 
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5.2.7 Hypoxia-driven expression of ANGPTL-4 in RA FLS is HIF-dependent 
The results from the PCR array analysis using DMOG strongly suggest that ANGPTL-
4 is regulated by HIFs. To confirm the result obtained on the PCR array with one patient, I 
amplified ANGPTL-4 from cDNA from hypoxic or DMOG stimulated RA FLS from several 
patients. As was previously observed on the PCR arrays, DMOG could strongly induce 
ANGPTL-4, the level of which increased > 60-fold compared to control cultures incubated 
with DMSO (Figure  5.9). This was a much better induction than the 7-fold increase observed 
when cells were incubated in 1% oxygen for 24 hours due to the strong induction of HIFs by 
DMOG. Based on these findings and reports from the literature it seems plausible to assume 
that ANGPTL-4 is regulated by HIFs in RA FLS exposed to hypoxia. 
Figure  5.9 ANGPTL-4 induction by DMOG and hypoxia in RA FLS 
Human RA FLS were cultured in either 21% or 1% oxygen or in the presence of DMSO or 1mM 
DMOG for 24 hours. ANGPTL-4-specific primers were used for Q-PCR analysis. The level of the 
transcript is expressed relative to normoxic controls or DMSO set as 1.0 (dotted line). Data are 
expressed as the mean ± SEM of ≥ 5 independent experiments with sample assayed in triplicate, and 
were analysed using paired Student's t-test to compare ΔCt values (normoxia versus hypoxia and 
DMSO versus DMOG): * p<0.05. 
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regulated by both HIF-1 and HIF-2 under hypoxia, and that when either of the HIFα isoforms 
is removed the other isoform can take over hypoxia-induced transcription of ANGPTL-4. 
This is further supported by the additive effect of transfecting the cells with both siRNA 
oligonucleotides. The remaining ANGPTL-4 in the double transfected cells could be induced 
by HIF-independent pathways in hypoxia. Hypoxic regulation of ANGPTL-4 thus looks very 
similar to that of the well-known angiogenic factor VEGF (Figure 5.10b), which is regulated 
at multiple levels by both HIF-dependent and independent pathways and was included for 
comparison. 
Figure  5.10 HIF-1 and HIF-2 are involved in ANGPTL-4 induction by hypoxia in FLS 
RA FLS were transiently transfected for 4 hours with siRNA oligonucleotides complementary to HIF-
1α (siHIF-1α) or to HIF-2α siRNA (siHIF-2α). The siRNA oligonucleotide siLuc complementary to 
the luciferase gene was used as a negative control. The cell cultures were in 21% (N) or 1% oxygen (H) 
for 24 hours post-transfection. Total RNA was isolated and cDNA generated and the mRNA level of 
ANGPTL-4 and VEGFtotal was determined using Q-PCR analysis. Changes in (a) ANGPTL-4 and (b) 
VEGFtotal levels are expressed as fold change relative to the hypoxia-treated siLuc control set as 1.0 
(dotted line). Data are expressed as the mean ± SEM of ≥ 5 independent experiments with sample 
assayed in triplicate and were analysed using 1-Way ANOVA to compare ΔCt values (siHIF-
1αΗ and/or siHIF-2αΗ versus siLucH): *p<0.05, ** p<0.01, *** p<0.001 ns: not significant. 
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compared to HIF-2α mRNA to deplete with the siRNA oligonucleotides generating a greater 
knock-down effect. Once again, the effect of knocking down HIF isoforms had very similar 
effects on ANGPTL-4 and VEGF (Figure 5.11a, b) indicating that these two angiogenic 
factors are equally regulated by HIF isoforms in response to both hypoxia and DMOG in RA 
FLS. 
Figure  5.11 HIF-1 is the main factor involved in DMOG-induced expression of ANGPTL-4 
in RA FLS 
RA FLS were transiently transfected for 4 hours with siRNA oligonucleotides complementary to HIF-
1α (siHIF-1α) and/or to HIF-2α siRNA (siHIF-2α). The siRNA oligonucleotide siLuc complementary 
to the luciferase gene was used as a negative control. The cell cultures were stimulated with DMSO or 
1mM DMOG for 24 hours post-transfection. Total RNA was isolated and cDNA generated and the 
mRNA level of ANGPTL-4 and VEGFtotal was determined using Q-PCR analysis. Changes in (a) 
ANGPTL-4  and (b) VEGFtotal levels are expressed as fold change relative to the DMOG treated siLuc 
control set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 5 independent experiments 
with sample assayed in triplicate and were analysed using 1-Way ANOVA to compare ΔCt values 
(siHIF-1α DMOG and siHIF-2α DMOG versus siLuc DMOG): * p<0.05, **p<0.01, ns: not 
significant.  
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5.3 DISCUSSION 
In the present study, I used a PCR array-based approach to discover novel hypoxia-
regulated angiogenic genes in RA and to investigate inter-individual similarities and 
differences in the angiogenic gene profiles of FLS from five RA patients. Of the 84 genes 
screened on the PCR array, the expression of 47 genes changed in response to 24 hours of 
hypoxia (Table 5.3). Of these 47 genes, only 6 changed significantly in FLS from all five 
patients following 24 hours of hypoxia, namely ANGPTL-4, EFNA3, leptin, VEGF-A, 
TGFβ1 and HIF-1α (Table 5.2). ANGPTL-4, EFNA3, leptin and VEGF-A changed 
significantly after just 4 hours of hypoxia. Overall, the expression of the two adipokines 
ANGPTL-4 and leptin showed the most dramatic changes in RA FLS in response to 1% 
oxygen and DMOG. Based on the PCR array data and on what is already known about these 
two factors I decided to further investigate their expression and regulation in RA FLS. The 
work on ANGPTL-4 was described in the present Chapter whereas the work on leptin will be 
described in Chapter 6. As VEGF is a well-described hypoxia and HIF-regulated target gene 
it was processed in parallel to leptin and ANGPTL-4 as a positive control to confirm that my 
treatments, PCR array experiments, siRNA experiments and data processing were valid. 
When looking more closely at the gene expression in FLS from individual patients, I 
found that 21 genes were upregulated and 22 genes were downregulated, in addition to 4 
genes, IGF1, IL-8, PGF and PLAU, which showed changes in both directions in response to 
hypoxia. These 4 genes will therefore not be considered in the assessments that follow, 
leaving 43 genes. To determine which of these 43 genes were HIF-driven, I used the HIF 
activator DMOG in place of hypoxia to stimulate the FLS. Thus of the 21 genes which were 
upregulated by hypoxia in one or more patients (Table 5.3), only 5 genes (24%) were also 
upregulated by DMOG (Table 5.4 and 5.5). Similarly, of the 22 genes which were 
downregulated by hypoxia, 5 genes (23%) were also downregulated by DMOG. These results 
strongly suggest that the 10 genes in question are regulated by HIFs. In addition to the 10 
genes, 12 other genes changed in response to DMOG but not hypoxia and 37 genes changed 
in response to hypoxia but not DMOG. The finding that there is only a partial overlap 
between expression patterns between the two treatments can be explained by previous work 
showing that several other signalling pathways in addition to HIFs may operate in hypoxia, 
including p42/44 MAPK (Mottet et al. 2003), p38 MAPK (Emerling et al. 2005), JNK (Scott 
et al. 1998), PI3K/AKT (Bardos and Ashcroft 2005) and the NFκB pathway (Jeong et al. 
2005). One or more of these pathways could therefore selectively drive HIF-independent 
transcription in hypoxia. Furthermore, it could be that certain potential HIF target genes are 
subject to transcriptional repression, and that hypoxia produces insufficient amounts of HIF 
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factors to overcome this repression. DMOG however, is a much stronger HIF activator than 
hypoxia (see Chapter 3, Figure 3.1), and might drive a forced expression of these genes. 
Finally, the discrepancies between the gene expression profiles of DMOG and hypoxia-
treated RA FLS could be due to activation of non-HIF substrates by DMOG as has been 
reported before for both DMOG and CoCl2, another chemical activator of hypoxia (Vengellur 
et al. 2003; Elvidge et al. 2006). In a large hypoxia expression profiling study using mouse 
embryonic fibroblasts, Vengellur and colleagues similarly found a large number of genes 
uniquely expressed following hypoxia and CoCl2 with a modest overlap between treatments 
calling into question the actual HIF specificity of these ubiquitously used chemical HIF 
activators (Vengellur et al. 2003). 
All genes which are screened on the RT2 ProfilerTM PCR Arrays in this study have 
previously been reported to be involved in angiogenesis in other settings. ANGPTL-4, 
however, is best known for its role in adipose differentiation, energy homeostasis and 
systemic lipid metabolism, mainly due to its ability to suppress the activity of lipoprotein 
lipase, the enzyme responsible for catalysing the hydrolysis of triglycerides (Li 2006; 
Mandard et al. 2006; Shan et al. 2009). The ANGPTL-4 knock-out mouse is viable, but 
demonstrates the essential role of ANGPTL-4 in controlling plasma lipoprotein metabolism 
(Li 2006). ANGPTL-4, first identified in 2000 (Kersten et al. 2000; Yoon et al. 2000), is 
named for its structural similarity to the angiopoietins, however unlike these proteins it does 
not bind to receptor tyrosine kinases Tie-1 and -2. The target receptors through which 
ANGPTL-4 exerts its angiogenic effects on the vascular system remain unknown and it is 
currently classified as an orphan ligand (Lee et al. 2004; Oike et al. 2004). The angiogenic 
effects of ANGPTL-4 include the ability to confer anti-apoptotic activity in HUVECs (Kim et 
al. 2000), induce tubule formation in a HUVEC based matrigel assay (Hermann et al. 2005) 
and in the chicken chorio-allantoic membrane (CAM) assay independently of VEGF (Le Jan 
et al. 2003). Accordingly, ANGPTL-4 has been found to be selectively localised to highly 
vascular tissues such as placenta and fat (Kersten et al. 2000; Yoon et al. 2000). 
Interestingly, ANGPTL-4 has previously been linked with arthritis. In one study 
using articular chondrocytes from RA and OA patients, Murata et al. were able to show a 10-
fold increase in ANGPTL-4 mRNA and protein in response to hypoxia in cells from both 
groups. In vivo expression of the protein was also demonstrated in human articular cartilage 
specimens using IHC. Most interestingly, incubation of the chondrocytes with recombinant 
ANGPTL-4 enhanced expression of the angiogenic factors MMP-1 and -3 in a dose-
dependent manner, whereas MMP-2 and -9 were unaffected in the study (Murata et al. 2009). 
In a gene expression profiling analysis ANGPTL-4 was identified as one of the most highly 
expressed genes early in CIA, a widely used mouse model of RA (Thornton et al. 2002). 
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Moreover, in agreement with my findings, the same laboratory localised ANGPTL-4 
transcripts to stromal fibroblast-like cells adjacent to blood vessels in the mouse arthritic 
tissue using IHC. No signal was detected in the endothelium lining the blood vessels or in 
infiltrating neutrophils (Hermann et al. 2005).  
In the present study, ANGPTL-4 mRNA was upregulated approximately 10-fold in RA 
FLS after exposing the cell cultures to 24 hours of hypoxia. The expression was slightly 
higher in total dissociated synovial membrane cultures, probably because other cells in the 
mixed culture contributed to the pool. The observed fold induction in ANGPTL-4 expression 
was similar to VEGF, a well-known key angiogenic mediator. ANGPTL-4 has previously 
been described to be hypoxia responsive (Belanger et al. 2002; Le Jan et al. 2003; Murata et 
al. 2009) and to be regulated by HIF-1 and CoCl2 in hypoxic cardiomyocytes (Belanger et al. 
2002). However this work did not address the involvement of HIF-2 in hypoxic induction of 
ANGPTL-4.  
Although increased ANGPTL-4 expression in response to hypoxia and HIF has been 
demonstrated previously, to my knowledge, the present study is the first to demonstrate the 
increased expression of ANPTL-4 by human RA FLS and total dissociated synovial 
membrane cultures in response to hypoxia and the involvement of both HIF-1α and HIF-
2α. In addition to establishing the involvement of HIFs in hypoxic ANGPTL-4 regulation 
using DMOG, I used siRNA technology to investigate the role of the individual isoforms 
HIF-1α and HIF-2α in upregulating ANGPTL-4 levels under hypoxia. Interestingly, although 
1% oxygen could strongly upregulate ANGPTL-4, knocking down either HIF isoform lead to 
a modest 20% reduction in ANGPTL-4 levels (Figure  5.10). This suggests that one isoform 
can take over from the missing isoform, which is supported by the observation that knock-
down of both isoforms simultaneously, further reduces ANGPTL-4 levels to 50% relative to 
hypoxic siLuc transfected controls. The siRNA experiments using DMOG as a stimulant in 
place of hypoxia emphasise that in a HIF activated, non-hypoxic environment, HIF-1α seems 
to be more important than HIF-2α in controlling ANGPTL-4 regulation, as knock-down of 
HIF-1α lead to a 70% decrease in ANGPTL-4 levels, whereas a 20% decrease was observed 
when HIF-2α was depleted (Figure 5.11). This mode of HIF regulation was similar to that 
observed for VEGF.  
In addition to hypoxia, PPARα and -γ regulate ANGPTL-4 (Kersten et al. 2000; 
Yoon et al. 2000). In adipose tissue, the binding partner of PPARα and -γ is retinoid X 
receptor (RXR) and it is thought that the PPARα and -γ/RXR induction of ANGPTL-4 is 
involved in its role in lipid metabolism (reviewed in (Kersten 2005)). In hypoxic nonadipose 
tissues, ANGPTL-4 may be mainly regulated by the HIF pathway. For instance, ANGPTL-4 
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has been reported to be regulated by HIF-1 and CoCl2 independently of PPARα which 
remained inactive in hypoxic cardiomyocytes (Belanger et al. 2002). Most interestingly, a 
PPARα agonist was shown to cause the synergistic activation of ANGPTL-4 when the cells 
were transfected with adenovirus expressing stable HIF-1α (Belanger et al. 2002). This might 
suggest that a synergistic regulation of ANGPTL-4 could occur under physiological 
conditions where both systems are activated simultaneously, a scenario which may be 
relevant to hypoxic adipose tissue. As the siRNA knock-down effect of HIF-1α and HIF-2α 
on ANGPTL-4 mRNA in hypoxia was relatively modest, the question is raised whether the 
PPARα and -γ/RXR or yet other pathways are active in hypoxic FLS thus contributing to 
upregulated ANGPTL-4 levels and this remains to be investigated. Regardless of its modes of 
regulation, as ANGPTL-4 is expressed in a similar fashion to other angiogenic molecules it 
may represent an attractive target for potential therapeutic inhibition of angiogenesis in RA. 
RA FLS exposed to 24 hours of hypoxia and DMOG responded by upregulating 
VEGF 8.3- and 41.1-fold respectively in the PCR array screens. The occurrence of VEGF has 
been repeatedly observed in human synovial fluids and synovial tissue of patients with RA 
(Fava et al. 1994; Koch et al. 1994; Giatromanolaki et al. 2003), but few studies have focused 
on the expression of the various VEGF isoforms. As VEGF isoforms have different heparin-
binding capacities, in addition to tissue and cell-specific expression, it is likely that their roles 
in RA pathophysiology differ. To my knowledge, the present work is the first to investigate 
the effect of hypoxia on the expression levels of VEGF121, VEGF165 and VEGF189 in RA FLS 
by Q-PCR. All isoforms were shown to be significantly upregulated by hypoxia in both RA 
FLS, CCD19Lu fibroblasts and total dissociated RA membrane cells, but contrary to 
expectations, all isoforms were upregulated to the same extent. In contrast to my findings, 
Pufe et al. found expression of VEGF121 and VEGF165 but not VEGF189 when analysing whole 
synovial tissues from RA patients by Q-PCR (Pufe et al. 2001). In addition, hypoxia has been 
previously described to have a differential effect on VEGF isoforms in the menisci of rabbits 
exposed to systemic hypoxia (Hofstaetter et al. 2004). The RA FLS in the current study were 
exposed to 1% oxygen for 2, 6 and 24 hours, but there was no selective induction of any of 
the isoforms at any time-point. Furthermore, I also investigated the expression of the isoforms 
in hypoxic total dissociated synovial RA membrane cells and again I did not detect any 
differences in the expression level of the isoforms. Perhaps the presence of an additional 
stimulus in vivo such as inflammatory cytokines can account for the differential induction of 
VEGF isoforms observed elsewhere. I also investigated whether the inhibitory VEGF isoform 
VEGF165b was expressed in the membrane cells originally discovered by Bates et al. (Bates et 
al. 2002). In contrast to the other VEGF isoforms, this inhibitory variant did not appear to 
change in response to hypoxia. 
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Two growth factors, TGFβ1 and EFNA3, were significantly upregulated on average 
2.2-fold in FLS from 5 patients in response to 24 hours hypoxia. EFNA3 was also upregulated 
2.5-fold following hypoxic exposure for 4 hours (Table 5.2). EFNA3 is a component of the 
Eph/ephrin tyrosine kinase system, which participates in vasculature development. This 
receptor/ligand system is associated with various signaling pathways related to cell growth 
and viability, cytoskeletal organisation, cell migration, and apoptosis (reviwed in (Merlos-
Suarez and Batlle 2008)). Accumulated evidence suggests that aberrant regulation of EFNA3 
and its genetic alterations are implicated in the development and progression of various 
cancers. Interestingly, DMOG was also capable of inducing EFNA3 expression in RA FLS by 
8.6-fold following 24 hours of exposure, indicating that this is a HIF-regulated gene. In 
contrast, TGFβ1 expression did not undergo any changes in response to DMOG stimulation. 
As expected, HIF-1α was downregulated on the PCR array confirming my work on HIF 
regulation which I presented in Chapter 3. 
In addition to the six genes which changed expression in response to hypoxia in all five 
RA patients screened, a number of genes changed in one or more of the patients (Table 5.3) 
suggesting that FLS from each RA patient has a unique angiogenic profile in addition to their 
common changes. Despite this heterogeneity, there appear to be certain changes in groups of 
genes across patients which share similar functions. For instance, hypoxia seemed to mediate 
a general suppression of the expression of the chemokine ligands represented on the PCR 
array. The chemokines were originally discovered as mediators of leukocyte trafficking to 
sites of inflammation. All of the chemokine ligands screened here have been reported to have 
chemotatic effects on a broad array of inflammatory cells (reviewed in (Strieter et al. 2005)) 
(Balestrieri et al. 2008). There are four subgroups of chemokines, two of them, the CXCs and 
the CCs, are present on the arrays. The CXC or alpha subgroup is further subdivided in the 
ELR(+) and ELR(-) chemokines, a specific amino acid sequence of glutamic acid-leucine-
arginine (or ELR for short). Intriguingly, the CXC chemokines are either angiogenic or 
angiostatic, depending on whether they contain the ELR motif or not. Members that contain 
the ELR motif bind to CXC chemokine receptor 2 (CXCR-2) and are angiogenic. For 
instance, CXCL-1, -3, and -5 have been shown to activate angiogenesis in rabbit cornea and 
have chemotactic effects on ECs (Balestrieri et al. 2008). In contrast, most of the CXC 
chemokines without ELR motif bind to CXCR-3 and are angiostatic (reviewed in (Strieter et 
al. 2005)). Of the angiogenic CXC chemokine ligands on the PCR array, CXCL-1, -3, -5 and 
-6 were all downregulated in or more patients (Table 5.3). Among the chemokine subfamilies, 
the two CC chemokines represented on the PCR array, CCL-2 and -11 are both known 
inducers of angiogenesis (Salcedo 2009, Balestrieri 2008) and these were both downregulated 
by hypoxia. In fact, CCL-11 was downregulated in FLS from three of the five patients 
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screened by 14.4-, 3.1- and 8.5-fold respectively. In regard to the angiostatic CXC chemokine 
ligands, CXCL-10 was greatly downregulated in FLS from two patients by 18.1- and 26.6-
fold respectively. In contrast to any of the other chemokine ligands screened, the angiostatic 
CXCL-9 chemokine ligand was upregulated 3-fold in just one patient. With the exception of 
CCL-2 which was downregulated in two patients by 8.5- and 3.9-fold by hypoxia and DMOG 
respectively, the hypoxia-induced downregulation of chemokine ligands could not be 
replicated with DMOG (Table 5.4), and thus the reduction in the level of chemokines seems 
to occur independently of HIFs. 
Based on these findings it seems that in addition to promoting angiogenesis and 
inflammation, hypoxia may also promote anti-inflammatory and angiostatic properties in FLS 
by reducing the expression of a large group of angiogenic and inflammatory chemokine 
ligands. The only change in chemokine expression which was potentially pro-angiogenic was 
the dramatic decrease observed in two patients of the angiostatic factor CXCL-10. All the 
other changes observed would in their own right repress angiogenesis and inflammation but it 
is difficult to know if these changes are relevant to pathological synovial angiogenesis and 
inflammation. The hypoxic synovial milieu might not drive a reduction in chemokine ligand 
expression and/or other factors may interfere with their expression by FLS. It would be 
interesting to study the expression of the chemokine ligands in total dissociated RA 
membrane cells, to gain a better understanding of their regulation in RA. Most interestingly, a 
study comparing gene expression profiles in arthroscopic biopsies before and after anti-TNF 
treatment with infliximab, found CXCL-3 and CXCL-1 to be downregulated following 
treatment in good responders. Moreover, CXCL-1 was higher in good responders than in non-
responders before treatment (Lindberg et al. 2006a). The findings that CXCL-1 can be 
induced by TNFα may explain this result (Koch et al. 1995). 
Other common denominators to be extracted from the emerging hypoxic profiles of 
FLS include the changes in the expression of several adhesion molecules. COL4A3, PECAM-
1, STAB-1 and LAMA-5 were all seen to be upregulated in FLS from one or more RA 
patients. Two additional adhesion molecules ITGB-3 and NRP-2 were downregulated in two 
patients. Adhesion molecules influence the activity and infiltration of the synovium and 
synovial cavity by inflammatory cells where they secrete angiogenic and inflammatory 
molecules (Han et al. 2003). 
ECM modification is an important step in angiogenesis as matrix remodelling is 
necessary for laying down new blood vessels. Several matrix modifying genes were screened 
on the PCR arrays including MMP-2, MMP-9, PLG, PLAU, HPSE and TIMP-1-3. Very few 
changes took place in this group of genes in response to hypoxia. However, HPSE was 
downregulated in two patients by 2.7 and 2-fold respectively, PLG was downregulated 2.1-
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fold in one patient, and PLAU was upregulated 2.2-fold in one patient and downregulated 3.3-
fold in another.  
Finally, other studies using selective candidate gene approaches have described several 
hypoxia regulated angiogenic genes in RA FLS including MCP-1 (Galindo et al. 2001), IL-8 
(Galindo et al. 2001; Ahn et al. 2008), VEGF-A (Jackson et al. 1997; Berse et al. 1999), 
MMP-1, MMP-3 and IL-6 (Ahn et al. 2008), SDF-1/CXCL-12 (Hitchon et al. 2002), 
ANGPT-1 and -2 (Scott et al. 2002), COX-2 (Demasi et al. 2004) and ICAM-1 (Han et al. 
2003). Of these genes IL-6, IL-8, ANGPT-1 and -2 and VEGF-A were present on the PCR 
array but only VEGF-A was consistently upregulated in all patients tested. ANGPT-1 showed 
no changes in response to hypoxia, whereas ANGPT-2 was downregulated in RA FLS from 
one patient by 3-fold. IL-6 was upregulated in one RA patient by 2.9-fold and IL-8 was 
upregulated 2-fold in one patient and downregulated 4.5-fold in another. MMP-1 and -3 were 
not present on the PCR array, but MMP-2 and -9 did not change in response to hypoxia 
(Table 5.3).  
In the present study I used the Human Angiogenesis RT2 ProfilerTM PCR Array to 
screen for angiogenic genes which change in RA FLS in response to hypoxia and DMOG 
which lead to several interesting and novel findings. The microarray approach has the 
superior advantage of screening thousands of genes in one round, but it also tends to 
underestimate changes in expression of potentially relevant genes relative to Q-PCR analysis 
(Vengellur et al. 2003; Lindberg et al. 2006a). Furthermore, the Q-PCR array approach 
enables a more refined search for changes within a defined pathological niche, such as 
“hypoxia-regulated angiogenesis in RA FLS” researched in the current study. Although this 
work was done on a small scale, and represents more of an important pilot study, useful 
information on the interindividual differences and similarities between the angiogenic profiles 
of hypoxic FLS has been extracted from the work. Furthermore I was able to show which of 
the genes were regulated by HIFs, and in the case of ANGPTL-4 (and leptin, see Chapter 6), 
also which HIF isoform is responsible for driving its expression under hypoxia.  
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6 LEPTIN EXPRESSION IN THE RHEUMATOID 
SYNOVIUM 
6.1 INTRODUCTION 
The application of the Human Angiogenesis RT2 ProfilerTM PCR Array to screen RA 
FLS subjected to 1% oxygen identified two inflammation-related adipokines, leptin and 
ANGPTL-4, as being highly hypoxia-inducible. The PCR array data and regulation of 
ANGPTL-4 by HIFs were presented in Chapter 5. In the current Chapter I will present novel 
work describing the hypoxic regulation of leptin, and the work involved in deciphering the 
role of leptin in the RA synovium. 
Leptin was originally discovered in 1994 for its role as a hypothalamic regulator of 
food intake and body weight homeostasis (Zhang et al. 1994). It is a 16-kDa non-glycosylated 
peptide hormone, encoded by the obesity gene (OB), and is mainly and constitutively 
produced by adipocytes to signal the repletion of body energy stores to the hypothalamus, and 
as a consequence circulating leptin levels are directly correlated with body mass index (BMI) 
(Considine et al. 1996). Initially, the effects of leptin were thought to be only centrally 
mediated but it is becoming clear that leptin has pleiotropic peripheral effects. Many cell-
types and non-adipose tissues including HSFs (Glasow et al. 2001), peripheral blood 
mononuclear cells (Sanchez-Margalet and Martin-Romero 2001), placenta (Hendler et al. 
2005) and skeletal muscle (Wang et al. 1998) produce leptin, and locally produced leptin has 
peripheral effects but may also contribute to circulating leptin levels. 
Structurally leptin belongs to the type I cytokine super-family and exerts its biologic 
actions through receptors encoded by the diabetes (db) gene. These receptors belong to the 
class I cytokine receptor super-family of receptors to which the IL-6 receptor also belongs 
(Tartaglia et al. 1995). A single transcript from the db gene gives rise to 6 receptor isoforms, 
ObRa-c, which differ mainly in the length of their cytoplasmic domains allowing for their 
classification into short, long and secreted forms (Lee et al. 1996). ObRe has no cytoplasmic 
domain and is secreted and soluble, ObRa, c, d, and f constitute the short forms, and ObRb 
contains the longest domain and is thought to be the only signalling version of the leptin 
receptors. It is through this receptor that leptin exerts its central effects on body weight in the 
hypothalamus by acting as a negative-feedback signal on the hypothalamic neurons to 
decrease food intake and increase energy expenditure. As is the case with other class I 
cytokines and receptors, leptin binding to ObRb leads to the activation of the JAK-STAT 
pathway where JAK-2 activation leads to the phosphorylation of STAT1, STAT3 and STAT5 
(Sanchez-Margalet and Martin-Romero 2001; Otero et al. 2006). Leptin-induced STAT3 
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signalling regulates the expression of suppressor of cytokine signalling (SOCS)-3 which has 
been shown to be a negative regulator of leptin. Interestingly, obese people develop resistance 
to leptin despite high levels of circulating leptin, which is thought to be correlated to the 
overexpression of SOCS-3 (Bjorbaek et al. 1998). Several other signalling cascades are 
activated in response to leptin, including MAPK and PI3K (Martin-Romero and Sanchez-
Margalet 2001; Fruhbeck 2006).  
In addition to its central expression, ObRb appears to be ubiquitously expressed in the 
periphery, which explains the diverse range of physiological functions of leptin (reviewed in 
(Fantuzzi and Faggioni 2000; Otero et al. 2005)). Besides its role in body weight homeostasis, 
leptin has been shown to participate in a wide range of biological functions which are well 
illustrated by the db/db and ob/ob knock-out mice. These mice, which share a similar 
phenotype, are not only obese but also develop a complex syndrome characterised by 
abnormal reproductive function, hormonal imbalances and alterations in hematopoietic and 
immune system (Chua et al. 1996). The role of leptin as immunomodulator in humans is 
strongly supported by the increased incidence of severe infections in subjects with leptin 
deficiency (Ozata et al. 1999) and by the immune system deficiency observed during 
starvation and malnutrition, conditions both characterised by low leptin levels (Fraser et al. 
1999). Interestingly, leptin has a dual role in inflammation and immunity. On the one hand, it 
stimulates monocyte/macrophage cells to release proinflammatory cytokines, TNFα and IL-6 
(Zarkesh-Esfahani et al. 2001), and activates and modifies T lymphocytes towards the pro-
inflammatory Th1 response with the release of IFNγ and IL-2 (Lord et al. 1998), and on the 
other hand, leptin shows anti-inflammatory effects by inducing IL-1 receptor antagonist 
secretion (Gabay et al. 2001). 
These effects of leptin may be highly relevant to the autoimmune and inflammatory 
pathogenesis in RA as several studies describe elevated serum leptin levels in RA patients 
compared to healthy controls (Bokarewa et al. 2003; Gunaydin et al. 2006; Otero et al. 2006; 
Seven et al. 2009). Several studies have implicated leptin in autoimmune inflammatory 
conditions, such as experimental autoimmune encephalomyelitis (Sanna et al. 2003), type I 
diabetes (Matarese et al. 2002), intestinal inflammation (Tuzun et al. 2004) and RA (Lee et 
al. 2007a). The involvement of leptin in RA pathogenesis is strongly supported by the 
observation that leptin deficient mice develop resistance to experimental antigen-induced 
arthritis compared to wild-type mice, developing less synovial tissue proliferation and 
humoral response to the injected antigen with less IL-1β and TNFα present in synovial fluid 
(Hultgren and Tarkowski 2001; Busso et al. 2002). Moreover, some studies show elevated 
leptin levels in RA patients (Bokarewa et al. 2003; Gunaydin et al. 2006; Otero et al. 2006; 
Seven et al. 2009), and fasting in RA patients leads to an improvement of different clinical 
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and biological measures of disease which is associated with a marked decrease in serum 
leptin level and a shift toward a Th2 cytokine production (Fraser et al. 1999).  
Leptin has been reported to have proliferative and anti-apoptotic effects on a variety of 
cell types (Gainsford et al. 1996; Bouloumie et al. 1998; Lord et al. 1998; Simopoulou et al. 
2007; Gao et al. 2009), and to induce angiogenesis in vivo and in vitro (Bouloumie et al. 
1998; Sierra-Honigmann et al. 1998; Cao et al. 2001; Park et al. 2001; Artwohl et al. 2002; 
Goetze et al. 2002; Talavera-Adame et al. 2008). Moreover, leptin has been shown to activate 
inflammatory cells such as T-lymphocytes and macrophages, as these have been reported to 
express ObRb (Lord et al. 1998; Martin-Romero and Sanchez-Margalet 2001). At the cellular 
level, Otero et al. have shown that leptin has a direct and a synergistic pro-inflammatory 
effect with INFγ on articular chondrocytes by activating NOS type II and increasing NO 
production (Otero et al. 2007). This free radical is known to interfere with chondrocyte 
function with loss of cartilage matrix through induction of apoptosis and activation of MMPs 
(Jang and Murrell 1998). All these processes are known to contribute to the pathological 
progression in the RA synovium. Based on the findings in the present study and previous 
publications it therefore seems reasonable to hypothesise that leptin secretion by FLS in the 
hypoxic synovium might contribute to synovial angiogenesis, inflammation and/or 
proliferation of the pannus and hence RA pathogenesis.  
In this Chapter, the regulation of leptin by hypoxia was further investigated as were 
the possible autocrine effects of leptin on RA FLS. The angiogenic potential of FLS secreted 
leptin was also investigated, however this aspect of leptins role in RA constitutes my future 
work and the strategy for this work will be outlined in Chapter 7.  
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6.2 RESULTS 
6.2.1 Expression of leptin in RA FLS and total dissociated synovial membrane 
cell cultures 
The gene encoding the adipokine leptin was the gene that showed the greatest change 
in expression on the Q-PCR arrays in RA FLS in response to hypoxia and DMOG. On 
average, leptin changed 59.2-fold in FLS from five RA patients. In contrast, DMOG induced 
a 108.7-fold increase in leptin mRNA in a single patient (Chapter 5). 
To confirm and further investigate these findings, I designed a set of PCR primers 
specific for leptin which were different to the primers on the PCR array. I incubated FLS from 
three different RA patients for 4 or 24 hours in either normoxia or hypoxia, and subsequently 
isolated total RNA, performed RT-PCR on the RNA and ran the products on a 2% agarose 
gel. As expected, 4 and 24 hours of hypoxia could greatly induce leptin in FLS from the three 
RA patients (Figure  6.1a, b). All three patients expressed some leptin under normoxic 
conditions, but there seemed to be less in the normoxic controls from the 24 hour experiment. 
This could be due to a less efficient RT-PCR reaction as there was also less ARP product after 
24 hours compared to 4 hours. 
Figure  6.1 Basal and hypoxia-induced expression of leptin in RA FLS  
RA FLS were cultured in either 21% (N) or 1% oxygen (H) for 4 or 24 hours and total RNA was 
extracted for cDNA synthesis. RT-PCR analysis was carried out with leptin-specific primers to detect 
changes in the expression of the leptin gene following exposure to (a) 4 hours and (b) 24 hours of 
hypoxia in three RA patients (#1, #2 and #3). The amplification of the HKG ARP was performed to 
control for the amount of cDNA in PCR reactions and equal loading on the 2% agarose gels. 
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To analyse the temporal expression of leptin in hypoxia, I incubated RA FLS in either 
21% or 1% oxygen for 0-24 hours and extracted total RNA at each time-point. Following 
cDNA synthesis, I performed Q-PCR to determine the fold change of leptin with time in 
hypoxia. The expression of leptin increased rapidly within the first 6 hours of hypoxic 
exposure to about 15-fold above normoxic levels (Figure  6.2a). After this initial increase, the 
levels rose dramatically and following 24 hours of exposure, the RA FLS were producing 75-
fold more leptin relative to a time-matched control. Using an ELISA assay, I investigated 
whether the hypoxia-induced increase in leptin mRNA also led to an increased secretion of 
leptin protein by RA FLS into the supernatants. As can be seen in Figure  6.2b, prolonged 
hypoxia led to a significant increase in leptin secretion from undetectable levels to 923pg/mL 
following 48 hours of hypoxia. 
Figure  6.2 Time-course of leptin mRNA and protein induction by hypoxia in RA FLS 
RA FLS were cultured in either 21% or 1% oxygen for 0, 2, 4, 6, 24 or 48 hours and total RNA was 
extracted for cDNA synthesis. Leptin-specific primers were used for Q-PCR analysis. (a) The level of 
the transcript is expressed relative to time-matched normoxic controls. Data are expressed as the mean 
± SEM of ≥ 3 independent experiments with sample assayed in triplicate and were analysed using 1-
Way ANOVA to compare ΔCt values (normoxia versus hypoxia). (b) Supernatants were assayed for 
the presence of leptin protein by ELISA and data are expressed as the mean ± SEM of ≥ 3 independent 
experiments with sample assayed in triplicate and were analysed using 1-Way ANOVA: * p<0.05, 
**p<0.01, ***p<0.001, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
I next investigated the expression of leptin in RA FLS incubated with 1mM DMOG 
(or DMSO vehicle control) for 0-24 hours (Figure  6.3). This time-course of leptin induction 
appeared similar to the hypoxic time-course, with a steady increase in leptin levels throughout 
the 24 hours assayed. Up until 6 hours the degree of leptin induction was similar between the 
two modes of stimulation, but after 24 hours DMOG induced approximately 3.8 times more 
leptin mRNA relative to a time-matched control than hypoxia did at the same time-point 
emphasising that a stronger activation of HIF transcription factors leads to an equally higher 
increase in the transcription of leptin. That DMOG is a stronger inducer of HIF-1α protein 
than hypoxia was reported in Chapter 3 (Figure 3.1). 
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Figure  6.3  Time-course of leptin mRNA induction by DMOG in RA FLS 
RA FLS were cultured in the presence of either DMSO or 1mM DMOG for 0-24 hours and total RNA 
was extracted for cDNA synthesis. Leptin-specific primers were used for Q-PCR analysis. The level of 
the transcript is expressed relative to time-matched DMSO controls. Data are expressed as the mean ± 
SEM of ≥ 3 independent experiments with sample assayed in triplicate and were analysed using 1-Way 
ANOVA to compare ΔCt values (DMSO versus DMOG): ***p<0.001, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
Next, the expression of leptin in total dissociated RA membrane cells was 
determined. To establish whether hypoxia could induce a similar response in leptin 
expression in these cell cultures, I placed culture dishes with freshly dissociated synovial 
membrane cells from joint biopsies in either 1% or 21% oxygen for 24 hours. Indeed, leptin 
was upregulated approximately 132-fold by hypoxia in the synovial cell cultures, which was a 
10-fold greater change versus normoxic controls compared to the changes observed for 
ANGPTL-4 and VEGF in the same experiments (Figure  6.4). The change in leptin mRNA 
was greater than that observed for hypoxic RA FLS which may be due to production of leptin 
by other cells in the mixed population. 
Figure  6.4 Leptin induction in total dissociated RA synovial membrane cells 
Human RA synovial biopsies were digested and dissociated and cell cultures were incubated in either 
21% oxygen or 1% oxygen for 24 hours. Leptin, ANGPTL-4 and VEGFtotal -specific primers were used 
for Q-PCR analysis. The levels of the various transcripts are expressed relative to normoxic controls at 
the same time-point set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 3 independent 
experiments with samples assayed in triplicate, and were analysed using paired Student's t-test to 
compare ΔCt values (normoxia versus hypoxia): ** p<0.01, ***p<0.001. 
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I subsequently investigated the expression of leptin in human RA synovial paraffin 
sections. As can be seen in Figure  6.5a, an antibody against leptin gave rise to staining of 
plasma cells in lymphocytic infiltrates. Moreover, a diffuse staining in the surrounding tissue 
was also seen. Staining of tissues with an isotype control, used at the same concentration and 
with the same staining protocol, did not give a signal (Figure 6.5b).  
Figure  6.5 Leptin expression in human RA synovial paraffin sections 
 (a) A leptin-specific antibody stains plasma cells in lymphocytic infiltrates. (b) An Isotype control 
antibody does not give a signal. The sections were counter-stained with haematoxylin. 
(a) (b)
 
To determine the critical range of oxygen tension which would induce leptin 
accumulation, I subjected near confluent RA FLS cultures to a range of oxygen percentages 
(1%, 3%, 5%, 7% or 21%) for 6 hours. Exposure of RA FLS to oxygen levels ranging from 
21% to 1% was associated with a progressive increase in leptin mRNA as the oxygen level 
declined. Statistically significant results were obtained when cells were incubated at 1% and 
3% oxygen for 6 hours (Figure  6.6). The maximal leptin response occurred at 1% (8mmHg) 
oxygen with a half-maximal expression of leptin mRNA observed between 1% and 3% 
oxygen. The fold changes which occurred at 1-5% (8-38mmHg) oxygen are likely to have 
been even greater if a similar experiment was conducted for 24 hours. Nevertheless, the 
oxygen levels within the RA synovium is within the range which induces leptin expression in 
FLS in the current study (Sivakumar et al. 2008), and it is therefore likely that the hypoxic 
RA synovium can drive leptin production by the resident FLS. 
Figure  6.6 Leptin expression in RA FLS is influenced by changes in oxygen levels 
Human RA FLS were cultured in a range of oxygen tensions (0 to 21%) for 6 hours. Levels of leptin 
mRNA are expressed as mean fold change relative to normoxic controls which were set as 1.0 (dotted 
line). Data are expressed as the mean ± SEM of ≥ 3 independent experiments with sample assayed in 
triplicate and were analysed using 1-Way ANOVA to compare ΔCt values (normoxia versus hypoxia): 
***p<0.001. 
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6.2.2 Hypoxia-driven expression of leptin in RA FLS is HIF-dependent 
Leptin has previously been reported to be regulated by HIFs in other cell types 
(Ambrosini et al. 2002; Grosfeld et al. 2002; Cascio et al. 2008). Along with the results from 
the PCR array analysis in Chapter 5 and the time-course using DMOG (Figure  6.3) it seems 
likely that leptin is regulated by HIFs in RA FLS. To confirm these results using a larger 
patient group, FLS from several patients were incubated with either 1mM DMOG or in 
hypoxia for 24 hours, the RNA was isolated, cDNA synthesised and Q-PCR was performed. 
As was previously observed on the PCR arrays, DMOG could strongly induce leptin, the level 
of which increased > 96-fold compared to control cultures incubated with DMSO (Figure 
 6.7). This was a better induction than the 62-fold increase observed when cells were 
incubated in 1% oxygen, most likely due to the stronger induction of HIFs by DMOG. Based 
on my findings and reports from the literature it seems reasonable to assume that leptin is 
regulated by HIFs in hypoxic RA FLS. 
Figure  6.7 Leptin induction by DMOG and hypoxia in RA FLS 
Human RA FLS were cultured in either 21% or 1% oxygen or in the presence of DMSO or 1mM 
DMOG for 24 hours. Leptin-specific primers were used for Q-PCR analysis. The level of the transcript 
is expressed relative to normoxic controls or DMSO set as 1.0 (dotted line). Data are expressed as the 
mean ± SEM of ≥ 5 independent experiments with sample assayed in triplicate, and were analysed 
using paired Student's t-test to compare ΔCt values (normoxia versus hypoxia and DMSO versus 
DMOG): * p<0.05, ** p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As DMOG activates both HIF-1 and -2, I next investigated whether HIF-1 and/or 
HIF-2 is involved in hypoxia-mediated upregulation of leptin. Using the siRNA 
oligonucleotides described in Chapter 3 to transiently knock-down HIF-1α and HIF-
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Figure  6.8a siHIF-1α induced a modest knock-down of ~13% of the hypoxia-induced leptin 
mRNA. In contrast to the data observed for ANGPTL-4 (Chapter 5, Figure  5.10), HIF-2 
seems to play a bigger role in regulating leptin in hypoxia than HIF-1, as transfection of FLS 
with siHIF-2α resulted in a ~57% knock-down of hypoxia-induced leptin. That both HIF-1 
and -2 participate in leptin regulation which is emphasised by the synergistic effect of a 
double-transfection with both siRNA oligonucleotides resulting in an even greater knock-
down in leptin levels of ~91%. That the effect was synergistic and not just additive, suggests 
that when either of the HIFα isoforms is removed, the other isoform can compensate to a 
certain degree to upregulate transcription of leptin. The little remaining leptin in the double 
transfected cells could be induced by HIF-independent pathways in hypoxia or be due to 
depleted siRNA oligonucleotides. Overall, both HIF isoforms seem to partake in hypoxic 
regulation of leptin, but HIF-2 plays the more important part. GLUT-1 is included as an 
example of a gene that is specifically regulated by HIF-1 (Figure 6.8b), where knocking down 
HIF-2α does not appear to make a difference on hypoxic induction of GLUT-1. 
Figure  6.8 HIF-2 is the main isoform involved in hypoxia-induced leptin expression in FLS 
RA FLS were transfected for 4 hours with siRNA oligonucleotides complementary to HIF-1α (siHIF-
1α) and/or to HIF-2α siRNA (siHIF-2α). The siRNA oligonucleotide siLuc complementary to the 
luciferase gene was used as a negative control. The cell cultures were in 21% (N) or 1% oxygen (H) for 
24 hours post-transfection. Total RNA was isolated and cDNA generated and the mRNA level of leptin 
(a) and GLUT-1 (b) was determined using Q-PCR analysis. Changes in leptin and GLUT-1 levels are 
expressed as fold change relative to hypoxia-treated siLuc control set as 1.0 (dotted line). Data are 
expressed as the mean ± SEM of ≥ 4 independent experiments with sample assayed in triplicate. 
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knock-down in leptin levels. When I transfected the cells with a combination of both siRNA 
oligonucleotides I saw a slightly greater reduction in leptin levels of ~79% compared to that 
observed with siHIF-1α alone. Thus knocking down HIF-1 seems to have a greater impact on 
DMOG-induced leptin levels (~74%) compared to that observed under hypoxia (~13%). This 
difference could be due to the fact that there is more transcriptionally active HIF-1α 
compared to HIF-2α mRNA to deplete in DMOG-induced cells generating a greater knock-
down effect. The difference can also be explained by DMOG inhibiting FIH-1 in addition to 
PHDs and FIH-1 inhibition of HIF-mediated transcription has been shown to be more 
important for HIF-1 than HIF-2 (Bracken et al. 2006;Khan et al. 2008). In contrast, the 
impact of siRNA knock-down of HIF-2α was similar in hypoxia and DMOG-stimulated cells 
(~57% versus ~51% respectively).  
Figure  6.9 Knock-down of HIFα isoforms and leptin induction by DMOG in RA FLS 
RA FLS were transfected for 4 hours with siRNA oligonucleotides complementary to HIF-1α (siHIF-
1α) and/or to HIF-2α siRNA (siHIF-2α). The siRNA oligonucleotide siLuc was used as a negative 
control. The cell cultures were stimulated with either DMSO or 1mM DMOG for 24 hours post-
transfection. Total RNA was isolated and cDNA generated and the mRNA level of leptin was 
determined using Q-PCR analysis and is expressed as fold change relative to the DMOG treated siLuc 
control set as 1.0 (dotted line). Data are expressed as the mean ± SEM of ≥ 4 independent experiments 
with sample assayed in triplicate. 
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(Figure  6.10). My findings that cytokines induce HIF-1α, but not HIF-2α, may be  relevant to 
the lack of leptin induction by cytokines as HIF-2 appears to be far more important in 
inducing leptin under hypoxia than HIF-1 (Figure  6.8). Thus, lack of HIF-2 induction by 
cytokines and HIF-2-dependent leptin regulation could explain why leptin is not upregulated 
by cytokines in the present study. 
Figure  6.10 Inflammatory cytokines do not induce leptin expression in RA FLS 
Human RA FLS were cultured in the presence of 1% and either 10ng/mL of Il-1β, TNFα or TGFβ for 
24 hours. Total RNA was extracted, cDNA generated and Q-PCR performed to determine changes in 
mRNA levels of leptin relative to untreated controls which were set to 1 (dotted line). Data are 
expressed as the mean ± SEM of ≥ 3 independent experiments with sample assayed in triplicate, and 
were analysed using paired Student's t-test to compare ΔCt values (control versus IL-1β, TNFα, TGFβ 
or 1% oxygen): ** p<0.01, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
6.2.3 Leptin receptors are expressed by RA FLS and total dissociated synovial 
membrane cells 
RA FLS have previously been reported to express ObRb (Tong et al. 2008). As RA 
FLS express high levels of leptin in response to hypoxia, it is possible that leptin has an 
autocrine effect on the resident FLS in the synovium in addition to the putative paracrine 
angiogenic effect it has on the synovial ECs. To test whether the RA FLS in the present study 
express ObRb, and to investigate whether its expression level is affected by hypoxia, I 
subjected FLS to either 21% or 1% oxygen and isolated total RNA. I then performed PCR on 
RNA with primers specific for ObRb and the PCR products were loaded onto a 2% agarose 
gel. As can be seen below, the RA FLS express high levels of ObRb mRNA and this level 
seems to be unaffected by hypoxia (Figure  6.11a). This was confirmed by Q-PCR on the same 
cDNA (Figure  6.11b). 
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Figure  6.11 RA FLS express mRNA for the leptin receptor ObRb 
RA FLS were cultured in either 21% or 1% oxygen for 24 hours and total RNA was extracted for 
cDNA synthesis. (a) RT-PCR analysis or (b) Q-PCR was carried out with ObRb-specific primers to 
detect changes in expression of the leptin receptor following exposure to hypoxia. The products of the 
RT-PCR reaction were loaded onto a 2% gel. The Q-PCR data are expressed as the mean ± SEM of ≥ 5 
independent experiments with sample assayed in triplicate, and were analysed using paired Student's t-
test to compare ΔCt values (normoxia versus hypoxia): ns: not significant. 
 
 
  
 
  
 
 
 
 
 
 
Leptin has been reported to regulate the expression of several of its receptors, 
including ObRb. In one study, leptin-induced ObRa and ObRb receptors in liver (Cohen et al. 
2005), which contrasted with a second study where leptin stimulation of HepG2 cells, a 
human hepatocellular carcinoma cell line, lead to inhibition of ObRb expression (Liu et al. 
2004). To determine whether the ObRb mRNA is translated into protein in RA FLS and 
whether leptin can affect the expression of ObRb, I performed WB on total protein lysates 
from FLS stimulated for 0, 15 or 30 minutes with 40ng/mL of recombinant leptin using an 
antibody against the ObRb receptor. Interestingly, the RA FLS expressed plenty of ObRb 
protein, and this level was negatively regulated by leptin, an effect which appeared stronger 
with stimulation time (Figure 6.12). The predicted molecular weight of ObRb is 132.4 kDa, 
but as the native leptin receptor is a homodimer held together with disulfide bonds, it migrates 
on a reducing SDS-PAGE as bands of approximately 60 kDa subunits. Further, variation in 
size is seen here and is possibly due to glycosylation. Moreover, the lowest band may 
represent one of the smaller versions of the ObR. 
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Figure  6.12 RA FLS express ObRb protein 
Human RA FLS were cultured with 40ng/mL leptin for 0, 15 or 30 minutes and total cell extracts were 
prepared. BCA was performed to ensure equal loading of protein samples and STAT3 was used as a 
loading control.                              
 
 
 
 
 
 
 
 
 
 
I next investigated whether ObRb expression could be detected in total dissociated 
synovial membrane cells and whether hypoxia could influence any such expression. Using 
cDNA from the previous experiments, I performed Q-PCR on the cDNA using a primer set 
specific for ObRb. As can be seen below, I could detect expression of ObRb in total 
dissociated synovial membrane cell cultures which was not significantly changed in response 
to hypoxia (Figure  6.13) in agreement with the data obtained for RA FLS (Figure  6.11). 
Figure  6.13 RA synovial membrane cell cultures express the leptin receptor ObRb 
Human RA synovial biopsies were digested and dissociated and cell cultures were incubated in either 
21% or 1% oxygen for 24 hours. ObRb-specific primers were used for Q-PCR analysis. The level of 
the ObRb transcript is expressed relative to normoxic controls at the same time-point. Data are 
expressed as the mean ± SEM of ≥ 3 independent experiments with samples assayed in triplicate, and 
were analysed using paired Student's t-test to compare ΔCt values (normoxia versus hypoxia): ns: not 
significant. 
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receptor, ObRb, I set out to uncover what autocrine effects hypoxia-induced leptin secretion 
may have on RA FLS. Leptin has previously been reported as being capable of inducing 
VEGF secretion by several cell types including cytotrophoblastic cells (Islami et al. 2003) 
and ECs (Park et al. 2001). Therefore, in addition to its direct angiogenic effect on ECs, leptin 
has also been reported to have indirect effects on angiogenesis via VEGF. To investigate 
whether leptin can induce VEGF secretion by RA FLS in a similar fashion to hypoxia, I 
incubated total dissociated synovial membrane cells from RA biopsies in 1% oxygen or with 
100ng/mL leptin for 24 hours and assayed the supernatants for VEGF by ELISA. As is shown 
below (Figure  6.14), hypoxia significantly induced VEGF secretion from the RA cell culture, 
whereas leptin stimulation had no effect on VEGF secretion.  
Figure  6.14 Leptin has no effect on VEGF secretion by RA synovial membrane cell cultures 
Human RA FLS were cultured in either 21% or 1% oxygen or with 100ng/mL leptin for 24 hours and 
total VEGF secreted into the supernatants was measured by ELISA. Data are expressed as the mean of 
≥ 3 independent experiments with sample assayed in triplicate, and were analysed using 1-Way 
ANOVA (control verus leptin and 1% oxygen). *** p<0.001, ns: not significant. 
 
 
 
 
 
 
 
 
 
 
 
Tong et al. have previously described that RA FLS secrete the inflammatory 
cytokines IL-6 and IL-8 in response to leptin. Unfortunately they used unphysiological levels 
of leptin of 48,000ng/mL to stimulate RA FLS in their experiments making these results 
highly questionable. To investigate the effect of physiological levels of leptin on RA FLS 
ELISA was used to measure secretion of IL-6 and IL-8 by RA FLS stimulated with 10-
100ng/mL leptin which is within the range of serum leptin levels found in healthy controls 
and RA patients (Hizmetli et al. 2007; Seven et al. 2009). For comparison, I also included the 
concentration used by Tong et al. of 48,000ng/mL. As is shown below, I could not detect any 
IL-6 or IL-8 at physiological concentrations of leptin, but expression of both cytokines was 
achieved in response to a non-physiological leptin dose of 48,000ng/mL (Figure  6.15). 
 
 
 
Control Leptin 1% O2
0
250
500
750
1000
1250
1500
1750
2000
2250
2500
2750
***
ns
V
E
G
F 
pr
ot
ei
n 
pg
/m
L
CHAPTER 6   Leptin expression in the rheumatoid synovium 
 183
 
Figure  6.15 IL-6 and IL-8 secretion is induced by leptin at unphysiological concentrations 
Human RA FLS were cultured with 0, 10, 100 or 48,000ng/mL leptin for 24 hours and (a) total IL-6 or 
(b) IL-8 secretion into the supernatants was measured by ELISA. Data are expressed as mean of ≥ 3 
independent experiments with sample assayed in triplicate, and were analysed using 1-Way ANOVA 
(control versus 10ng/ml, 100ng/ml, and 48,000ng/mL). *** p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
Leptin has been reported to induce proliferation in a variety of cell types such as 
osteoblasts, endometrial cancer cells, oesophageal adenocarcinoma cells, VSMCs and renal 
glomerular ECs (Wolf et al. 1999; Gordeladze et al. 2002; Li et al. 2005b; Gao et al. 2009). 
Since RA FLS in the synovial lining undergo extensive proliferation with a subsequent 
formation of the invasive pannus, I decided to address whether leptin could induce RA FLS 
proliferation. To investigate the hypothesis I incubated FLS with leptin at 0, 1, 5 or 10ng/mL 
for 4 days and then analysed cell proliferation using an MTT assay. Interestingly, I found that 
FLS proliferated significantly more when stimulated with 10ng/mL leptin compared to 
unstimulated controls (Figure  6.16). Stimulation of cells with either 1 or 5ng/mL did not have 
an effect.  
Figure  6.16 Leptin induces RA FLS proliferation in culture 
Human RA FLS were stimulated with 0, 1, 5 or 10ng/mL leptin for 4 days and cell proliferation was 
measured using an MTT assay. Data are expressed as mean of ≥ 3 independent experiments with 
sample assayed in triplicate, and were analysed using 1-Way ANOVA (control versus 1, 5 and 
10ng/mL). * p<0.05, ns: not significant. 
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6.3 DISCUSSION 
In the present study, I confirmed by Q-PCR the findings from the Human 
Angiogenesis RT2 ProfilerTM PCR Array described in Chapter 5, which showed that leptin 
mRNA is highly and rapidly induced by hypoxia in RA FLS. Furthermore, I demonstrated 
that leptin appears to be induced by a range of oxygen tensions and is strongly upregulated by 
hypoxia in total dissociated membrane cells from RA biopsies, in addition to RA FLS.  
Several studies have shown that ECs express ObRb leptin receptor including the 
present report (see Future work, Chapter 7), such as HUVECs, porcine aortic ECs, 
microvascular and bovine aortic ECs, human adipose and dermal microvascular ECs 
(Bouloumie et al. 1998; Sierra-Honigmann et al. 1998), and it is now generally accepted that 
leptin can act to induce angiogenesis in a direct and indirect fashion. Leptin has been reported 
to induce angiogenesis directly in cornea pocket and CAM assays (Bouloumie et al. 1998; 
Talavera-Adame et al. 2008) and to influence EC migration, proliferation, survival, and 
apoptosis in vitro (Bouloumie et al. 1998; Sierra-Honigmann et al. 1998; Cao et al. 2001; 
Park et al. 2001; Artwohl et al. 2002; Goetze et al. 2002). Moreover, leptin was shown to 
induce neo-vacularisation in corneas from Zucker rats but not from fa/fa Zucker rats lacking 
ObRb receptor (Sierra-Honigmann et al. 1998). Leptin may also act on angiogenesis 
indirectly by potentiating VEGF-mediated angiogenesis as leptin has been reported to 
increase VEGF secretion by ECs (Park et al. 2001) and has shown to act synergistically with 
VEGF and FGF-2 to induce angiogenesis in a cornea pocket assay (Cao et al. 2001). 
Moreover, leptin has been shown to induce the expression of angiogenic factors MMP-9 and 
MMP-13 and IL-1β in chondrocytes which may lead to angiogenesis indirectly (Simopoulou 
et al. 2007). Interestingly, leptin elicited a comparable angiogenic activity to that of VEGF in 
several of the studies mentioned here. 
As is the case for VEGF, leptin has been reported to be regulated by hypoxia in certain 
cell types (Ambrosini et al. 2002; Grosfeld et al. 2002; Wang et al. 2008a). In the present 
study, leptin expression was induced at a range of oxygen tensions relative to normoxic 
controls, a novel finding in the context of RA. Importantly, leptin expression was activated at 
1-5% oxygen (8-38mmHg), which includes the range of oxygen tension measured in the joint 
synovium of RA patients of 2.4-4.4% (18 to 32mmHg) by our laboratory (Sivakumar et al. 
2008). In the present study I was able to show that leptin is regulated by HIFs using DMOG, 
and siRNA technology to transiently knock-down the two isoforms, HIF-1α and HIF-2α 
(Figure  6.8 and Figure  6.9). Other studies have reported that leptin is regulated by HIF-1 in 
various cell types (Ambrosini et al. 2002; Grosfeld et al. 2002; Cascio et al. 2008), but none 
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of these studies have attempted to dissect out the role of the individual HIF isoforms in leptin 
regulation. For instance, Cascio et al. have shown that overexpression of leptin in MCF-7 
breast cancer cells is HIF-1-driven using a luciferase reporter assay (Cascio et al. 2008). 
Ambrosini et al. used leptin promoter deletion constructs and a gel shift assay to confirm the 
role of HIF-1 in leptin expression in HSFs (Ambrosini et al. 2002), and Grosfeld et al. used a 
HIF-1α expression vector and a luciferase reporter assay with the leptin promotor in 
trophoblast-derived BeWo cells (Grosfeld et al. 2002). Curiously, the role of HIF-2 was not 
investigated in any of the studies. The DMOG experiments in my present study confirmed 
that leptin is regulated by HIFs and in agreement with the previous work I conclude that HIF-
1 transcription factor has an influence on leptin regulation by hypoxia. Interestingly however, 
HIF-2 seems to be the more important isoform in regulating leptin expression in RA FLS, as 
knocking down HIF-1α versus HIF-2α lead to a reduction in hypoxia-induced leptin mRNA 
of 13% and 57% respectively. Transfection of FLS with both siRNA oligonucleotides had a 
synergistic effect on the reduction in leptin mRNA of 91% further supporting the role of both 
isoforms in leptin regulation in hypoxia. 
The expression of the ObRb leptin receptor in RA FLS has been reported previously 
(Tong et al. 2008) and was also detected in RA FLS in the present study. Moreover, I 
determined that ObRb expression is unaffected by hypoxia whereas it appeared to be 
downregulated time-dependently in a negative feedback manner by leptin (Figure 6.12). The 
latter observation was previously reported in a human hepatocellular carcinoma cell line (Liu 
et al. 2004). The presence of ObRb in RA FLS suggests that leptin may have autocrine effects 
on RA FLS in the synovium in addition to potential paracrine effects on ECs and 
inflammatory cells. In this regard I investigated whether leptin could stimulate proliferation of 
RA FLS, and found that when cells were cultured in the presence of 10ng/mL leptin for 4 
days, they proliferated significantly more than the control cells (Figure 6.16). In support of 
my findings, leptin has been reported to induce proliferation of a number of cell types 
including HUVECs (Bouloumie et al. 1998), chondrocytes (Simopoulou et al. 2007), T-
lymphocytes (Lord et al. 1998), haematopoietic cells (Gainsford et al. 1996) and human 
endometrial cancer cells (Gao et al. 2009) where mitogen-activated protein kinases p42/44 
MAPK activation was shown to be involved in leptin-induced cell proliferation of HUVECs 
(Bouloumie et al. 1998). Similarly, leptin has been shown to have anti-apoptotic effects on 
several cell types and in human dendritic cells this was shown to be a result of leptin-
mediated upregulation of the anti-apoptotic mediators, Bcl-2, Bcl-xL and NF-κB, via the 
PI3K-AKT pathway (Mattioli et al. 2009). Normal synovium provides a protective layer, a 
few cells thick, over joints and tendons. In RA, this synovial lining becomes thickened 
through excessive proliferation and hyperplasia of the lining cells (RA FLS and MLS). The 
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proliferative and anti-apoptotic effects displayed by leptin could therefore play a role in RA 
pathogenesis where leptin could enhance the formation of the pannus through directly 
affecting RA FLS proliferation and/or apoptosis of the synovial lining. 
In the present study, I did not see any changes in the expression of leptin mRNA in 
RA FLS stimulated with 10ng/mL of the inflammatory cytokines IL-1β, TGFβ and TNFα 
(Figure  6.10). This could be due to leptin transcription being predominantly under the control 
of HIF-2 and as shown in Chapter 4, IL-1β, TGFβ and TNFα selectively induce HIF-1α but 
not HIF-2α mRNA. It is worth mentioning that one publication has demonstrated that TNFα 
can exert a dual effect on leptin synthesis and release by adipose tissue. TNFα treatment for 4 
to 8 hours in one study increased leptin 4-fold, but this effect was lost at 24 hours and leptin 
accumulation in the culture medium decreased after 24 to 48 hours (Zhang et al. 2000). This 
bi-phasic effect on leptin secretion by cytokines was also observed when adipocytes were 
stimulated with IL-1β, where an initial increase in leptin secretion was replaced by a gradual 
decrease, followed by a phase of leptin inhibition which was significant after 8 hours of 
treatment. Moreover, IL-1β had a dose-dependent inhibitory effect on both leptin gene 
expression and secretion (Bruun et al. 2002). Thus in contrast to the acute stimulation with 
pro-inflammatory cytokines, a chronic stimulation with pro-inflammatory cytokines seems to 
cause a suppression of leptin which could explain the lack of effect of cytokines on leptin 
expression by RA FLS in the present study. An earlier time-point might have yielded different 
results to the 24 hour time-point investigated. Nevertheless, the findings that prolonged 
exposure to inflammatory cytokines can lead to inhibition of leptin production would explain 
why some clinical studies do not find any positive correlation between serum leptin levels and 
serum TNFα levels (Gunaydin et al. 2006; Popa et al. 2009) or inflammatory status in long-
term RA patients assessed by CRP and ESR (Bokarewa et al. 2003; Gunaydin et al. 2006; 
Popa et al. 2009). The chronic inflammatory condition with high levels of circulating 
cytokines might simply suppress leptin expression in patients. Interestingly, in contrast to this 
hypothesis, a recent study has shown that there was no clear effect of short or long-term 
treatment of RA patients with the anti-TNFα antibody, infliximab, on serum leptin levels 
while decreasing inflammation and circulating TNFα (Popa et al. 2009). Therefore it seems 
that in patients with RA, chronic inflammation and TNFα levels and suppression of these 
during anti-TNF therapy have limited influence on plasma leptin concentrations. 
In conclusion, my findings provide evidence for a specific local dysregulation of the 
adipokine leptin in the RA synovium. Elevated synovial fluid leptin levels may be a direct 
consequence of local tissue hypoxia in the synovium driving leptin secretion by RA FLS. 
Local intra-articular leptin may contribute to joint pathogenesis and perpetuation of disease 
by activating inflammatory cells, stimulate proliferation and inhibit apoptosis of the 
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expanding pannus, in addition to inducing angiogenesis. Importantly, leptin produced in the 
articular joints of RA patients may also contribute to circulating leptin levels exerting 
systemic effects on the immune system and contributing to increased cardiovascular co-
morbidity observed in RA.  
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7 GENERAL DISCUSSION 
Hypoxia-mediated signalling is critical to normal development and has a strong 
involvement in several pathological conditions such as RA, where deregulation of oxygen-
dependent cellular processes contributes to the destruction of joints. Characterising the 
upstream and downstream events following the onset of tissue hypoxia is critical to our ability 
to understand and therefore treat pathological hypoxia. HIFs are the main transcription factors 
involved in the regulation of genes in hypoxic tissues, and it is therefore necessary to fully 
elucidate the regulatory mechanisms driving HIF induction and consequently the downstream 
changes taking place. In the context of my project, it is vital to understand the regulation of 
the HIF pathway particularly in terms of interactions between hypoxia and inflammation in 
RA disease tissue, to allow conclusions to be drawn regarding possible consequences of 
hypoxia in RA and thereby the potential to design new therapies. 
Recent publications have increased our understanding of the upstream events 
involved in hydroxylation and stabilisation of HIFα protein. However, our understanding of 
other mechanisms regulating HIF levels in disease is very limited and based on a handful of 
publications. When HIF signalling goes unabated it leads to overactivation of large and 
complex gene programmes involved in restoring oxygen tensions back to physiological levels 
and in the case of RA this leads to pathophysiological angiogenesis, inflammation, and joint 
destruction. Thus, several mechanisms controlling the level of HIF transcription factors in 
hypoxic tissues have evolved to counter-balance the dramatic accumulation of HIFα protein 
that occurs with the decline in PHD-mediated hydroxylation and degradation of HIFs as tissue 
hypoxia sets in. The existence of multiple mechanisms providing negative feedback inhibition 
of the HIF system in hypoxic tissue is not surprising when considering the implications of 
overstimulation of the hypoxia-signalling cascade. In addition to the complex antisense HIF 
(aHIF)-mediated auto-negative feedback regulation of HIF-1α mRNA described in Chapter 3, 
HIF-1α is prone to other means of auto-negative feedback inhibition during hypoxia. For 
instance at the protein level, a splicing variant of HIF-1α, sHIF-1α, has been described, which 
encodes a truncated protein that can compete with normal HIF-1α protein for dimerisation 
with HIF-1β protein, hereby decreasing HIF-1 activity (Cayre et al. 2003). In addition, it has 
been reported that PHDs are themselves upregulated by hypoxia (with PHD-2 being regulated 
in a HIF-dependent manner) leading to downregulation of HIFα protein levels in prolonged 
hypoxia through increased hydroxylation and thus decreased protein stability (Vengellur et al. 
2003; Marxsen et al. 2004). As the level of the PHDs increase with exposure to hypoxia, the 
equilibrium between the available oxygen, PHDs, and HIF stabilisation is shifted in favour of 
HIF hydroxylation. However, the increase in available PHDs would only compensate for 
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smaller reductions in available oxygen. Such a feedback loop would limit the expression of, 
for instance, HIF-1α induced ROS and pro-apoptotic genes, giving the cell an alternative to 
programmed cell death in cases of milder or intermittent hypoxia.  
In parallel to these auto-negative feedback mechanisms taking place during hypoxia, 
trans-regulation between the various HIF isoforms has also been reported. Firstly, both HIF-1 
and HIF-2 protein has been shown to bind to HRE in the aHIF which means that in some cell 
types HIF-2 can downregulate HIF-1α levels via the induction of aHIF (Uchida et al. 2004). 
Secondly, an alternatively spliced variant of HIF-3α, HIF-3α4 has been shown to complex 
with both HIF-1α and HIF-2α hereby sequestering the proteins from forming functional 
transcription factors thus curtailing HIF-dependent activity (Maynard et al. 2007). This 
inhibitory variant has been reported to be trans-activated by HIF-1α itself in hypoxia 
(Makino et al. 2007), providing a further level of negative feedback gene regulation in the 
adaptive response to hypoxia. In my study, trans-regulation between HIF-1α and HIF-2α in 
RA FLS was detected as a concomitant downregulation of HIF-1α transcript in FLS 
transfected with siRNA against HIF-2α, indicating that HIF-1α is partly induced by HIF-2 
(Figure 3.19b). It seems therefore that in hypoxic RA FLS HIF-1-driven gene expression is 
reinforced by HIF-2. 
Although very few studies exist, several of these naturally occurring feedback 
mechanisms controlling HIF activity in hypoxia have been reported to have 
pathophysiological roles. For instance, HIF-3α4 has been shown to act as a tumour 
suppressor in VHL-/- CC-RCC in which the oncogenic event is based on stabilisation of HIF-
2α rather than HIF-1α which is not expressed in the cells (Maynard et al. 2007). The 
expression of HIF-3α4 is suppressed in many primary CC-RCC cell lines. However, 
restoration of its expression suppresses the oncogenic progression of CC-RCC in vitro, 
thought to occur through the ability of HIF-3α4 to form a transcriptional complex with HIF-
2α. This prevents its engagement with HRE sites leading to a reduction in expression of target 
genes, including VEGF. Interestingly, HIF-3α4 has been reported to suppress the growth of 
tumour xenografts in SCID mice. Likewise, the murine HIF-3α splice variant termed 
inhibitory PAS domain protein has been shown to act as a dominant-negative regulator of 
HIF-1 and VEGF expression in the mouse cornea under hypoxia (Makino et al. 2001).  
PHD-3, HIF-3α4 and aHIF have been shown to be implicated in human end-stage 
heart failure. In vitro and animal studies have shown that acute activation of HIF is essential 
for maintaining normal cardiac function through appropriate gene expression and that HIF 
exerts a cardio-protective role (Huang et al. 2004; Date et al. 2005). Chronic activation of the 
HIF pathway in transgenic animals on the other hand, has been reported to contribute to 
cardiac degeneration and progression to heart failure (Lei et al. 2008). In a study in human 
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end-stage heart failure, the HIF-1α transcript level was found to be 51% lower in failing 
hearts than in non-failing hearts, whereas HIF-2α levels were unchanged. Interestingly, HIF-
3α4 mRNA levels were 72% higher in failing hearts compared to non-failing hearts. 
Moreover, aHIF was nearly 2-fold higher in failing hearts than donor controls and an inverse 
relationship between HIF-1α and aHIF RNA expression was found (Zolk et al. 2008). The 
level of PHD-2 was unchanged between the two conditions, whereas PHD-3 protein was 
upregulated in failing hearts. Thus it appears that several negative feedback mechanisms 
controlling HIFα protein are activated to prevent excessive activation of hypoxia-mediated 
signalling in chronic human heart failure. 
Finally, the endogenous inhibitors of the HIF system have been associated with breast 
cancer. HIF-1α is considered to be a reliable prognostic and diagnostic marker for an 
increasing number of cancers from various origins where HIF-1α overexpression is correlated 
with poor clinical outcome. Interestingly, one study reported that aHIF is a poor prognostic 
marker in breast carcinomas seen as a significant association between aHIF expression and 
disease-free survival. The expression of aHIF was also found to be higher in larger tumours 
and in those with the highest proliferation rate and a high aHIF expression in tumours was 
linked to a lower 5-year survival rate compared to patients harbouring tumours with low aHIF 
expression (Cayre et al. 2003). These findings are in contrast to what would be expected if 
aHIF functions to destabilise and reduce HIF-1α levels. Perhaps as the tumour grows and 
starts to over-express HIF-1α protein, aHIF expression is also induced in a HIF-1-dependent 
manner via the HRE elements in its promoter. This is supported by the findings of a weak 
positive correlation between HIF-1α and aHIF levels in the study. The aHIF level may not 
reach high enough levels to suppress HIF-1α levels and HIF-1 function. Thus the poor 
prognosis linked to high levels of aHIF transcript may actually reflect high HIF-1α levels. 
Interestingly, there was a strong negative correlation between the ratio of HIF-1α:sHIF-
1α and aHIF levels in the carcinomas which could be explained by aHIF either destabilising 
HIF-1α or alternatively driving the splicing of HIF-1α rendering more of sHIF-1α and less of 
full-length HIF-1α transcript. Unexpectedly, the concentration of the HIF-1α inhibitor, sHIF-
1α, was not associated with a good prognosis or a less aggressive tumour phenotype (Cayre et 
al. 2003). 
The research area on naturally occurring inhibitors of hypoxia-signalling is only 
starting to take off. These emerging endogenous regulatory pathways of HIF-mediated gene 
expression are likely to hold great therapeutic potential for diseases characterised by 
pathological hypoxia and its downstream effects. Targeted delivery of aHIF or one of the 
dominant-negative HIF splice variants to hypoxic tissues such as solid tumours or the RA 
synovium could halt the pathological consequences of excessive HIF expression such as 
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angiogenesis and inflammation. Conversely, in situations with too little HIF expression such 
as that seen in ischemic tissues, the therapeutic strategy would be to deplete endogenous HIF 
inhibitors and thereby boost HIF-mediated transcription.  
The differential regulation of HIF-1α and HIF-2α isoforms in addition to the isoform 
specific regulation of target genes also remains to be fully elucidated. A better understanding 
of this aspect opens up for the possibility of isoform-specific therapeutics. For instance, it has 
been suggested that HIF-1α is the main isoform mediating hypoxic signalling in fibroblasts 
(Vengellur et al. 2003). If this is true of the rheumatoid fibroblast as well, then HIF-2 could 
be the main mediator of other non-hypoxic responses in the RA synovium, such as promotion 
of cell survival and proliferation for instance via inhibition of BNIP-3, as has been reported in 
other cells. In contrast, HIF-1α has been shown to induce BNIP-3 (see Section 1.1.4) (Raval 
et al. 2005). In agreement with this, my studies suggest that HIF-1α is the predominant 
isoform regulating expression of angiogenic genes, particularly in response to DMOG. 
Interestingly, in the present study HIF-2 was shown to be the main isoform regulating leptin 
expression which in turn can induce proliferation of RA FLS and has been shown to have 
anti-apoptotic effects in other cell systems. Thus, in hyperproliferating tissues such as cancer 
and the RA synovium, specific manipulation of HIF-2 via the HIF-2α subunit could reduce 
growth of the hyperplastic tissue leaving the apoptotic effects of HIF-1 intact. Interestingly, 
the present study demonstrated that inflammatory cytokines specifically upregulate HIF-1α 
but not HIF-2α mRNA. Consequently, therapeutic effects of currently used treatments against 
cytokines, such as the TNFα  inhibitors, might reflect a HIF isoform-specific effect with a 
reduction in the activation of HIF-1α but not HIF-2α target genes. 
Besides investigating the regulation of HIFs, the present work was also aimed at 
discovering novel hypoxia/HIF regulated target genes in RA FLS with angiogenic properties 
using gene expression profiling techniques and FLS from RA patients. The results of these 
studies are described in Chapter 5. The expression of leptin, encoded by the OB gene changed 
most dramatically in response to hypoxia on the PCR array. Data described in Chapter 6 
suggest that leptin produced in the articular joints of RA patients in response to hypoxia may 
also contribute to increased circulating leptin levels in patients hereby exerting systemic 
effects on the immune system and contributing to increased cardiovascular co-morbidity 
observed in RA. However, despite the apparent involvement of leptin in other autoimmune 
inflammatory conditions, the involvement of leptin in RA pathology in humans is 
controversial. The existing literature offers a complicated and inconclusive scenario in which 
RA serum leptin levels have been reported to be similar, lower or higher compared to healthy 
subjects, and few publications found a relationship between disease activity and serum leptin 
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levels. Approximately half of the studies measuring serum and synovial fluid leptin have 
shown that RA patients have significantly high synovial fluid and serum leptin levels 
compared to healthy control subjects when these were corrected for BMI (Bokarewa et al. 
2003; Gunaydin et al. 2006; Otero et al. 2006; Seven et al. 2009). In contrast, other studies 
have not detected any difference in serum leptin concentration between RA patients and 
healthy subjects (Grunfeld et al. 1996; Anders et al. 1999; Popa et al. 2005; Hizmetli et al. 
2007; Popa et al. 2009) and Tokarczyk-Knapik suggested that chronic inflammation may 
even lower leptin levels in plasma (Tokarczyk-Knapik et al. 2002), something which was also 
observed in a subgroup of patients in another  study (Popa et al. 2005). 
In addition to the inconsistent findings describing serum leptin levels in RA patients, 
conflicting data exist on the correlation between leptin levels and disease activity in RA. The 
majority of the studies have not uncovered any significant correlation between serum leptin 
levels in RA patients and disease activity score (DAS)28 (Grunfeld et al. 1996; Anders et al. 
1999; Gunaydin et al. 2006; Wislowska et al. 2007; Popa et al. 2009; Seven et al. 2009), an 
established and validated measure for evaluating current RA disease (van der Heijde et al. 
1993), even in the studies where higher RA serum and synovial fluid leptin levels were 
detected compared to healthy controls. For instance, Anders et al. and Gunayidin et al. found 
no statistically significant difference in leptin levels in patient groups divided according to 
high and low DAS28 (Anders et al. 1999; Gunaydin et al. 2006) and Hizmetli et al. found no 
correlation between plasma and synovial fluid leptin and disease duration and erosive or non-
erosive disease (Hizmetli et al. 2007). In agreement with these findings, Guyanadin reported 
that there was no correlation between serum leptin levels and DAS28 in patients grouped 
according to high disease activity, compared to mild and low disease activity (Gunaydin et al. 
2006). Interestingly and in contrast to these studies, Lee et al. found that both serum leptin 
levels and leptin levels adjusted to BMI correlated well and significantly with DAS28 (Lee et 
al. 2007a). In this study, serum leptin was higher in RA patients with high disease activity 
compared to those with low disease activity, correlated well with disease activity and CRP 
levels, and decreased significantly in follow-up studies when disease was well controlled. The 
discrepancies between these various studies are most likely generated by the complex 
regulation of serum leptin by multiple confounding factors such as sex hormones, 
glucocorticoids, menopausal status, BMI, and insulin resistance and other as yet unknown 
factors (Otero et al. 2005; Otero et al. 2006). Moreover, leptin produced in non-adipose 
tissues may also contribute to the leptin plasma pool and interfere with analyses. On the other 
hand, the finding that body fat corrected serum leptin levels are substantially and 
unambiguously increased in mice with bacterial peritonitis (Moshyedi et al. 1998), and in 
humans with sepsis (Bornstein et al. 1998), following major surgery (Stratton et al. 1997) and 
after administration of inflammatory cytokines (Zumbach et al. 1997) may suggest that serum 
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levels are elevated in, and important to, acute but not chronic inflammatory pathogenesis. It is 
possible that the angiogenic and inflammatory potential of leptin is important in early stage 
development of RA rather than later during the chronic stage. For instance, angiogenesis in 
the synovial membrane is considered by many investigators to be an important early step in 
pathogenesis of RA (Walsh 1999; Koch 2003). Moreover, it should be kept in mind that 
angiogenesis is a local process that is not necessarily mirrored by elevated serum leptin levels, 
where local tissue levels of leptin in non-adipose peripheral tissues e.g. intra-articularly 
produced leptin may be of greater importance for articular pathogenesis in RA than 
circulating leptin concentrations. 
The existing data suggest that serum leptin levels may not be used as a serological 
marker to monitor the disease activity of RA or degree of ongoing inflammation and that BMI 
remains the major determinant of plasma leptin concentration. This however does not mean 
that leptin is not involved in RA. Rather than investigating serum leptin levels and its 
correlation with DAS28, it seems more relevant to look at the role of leptin in specific 
pathological intra-articular events such as angiogenesis, inflammation and FLS 
apoptosis/proliferation and correlate the degree of these pathological processes to leptin 
concentration in patient synovial fluid. This would allow for a better evaluation of the 
contribution of leptin to intra-articular changes associated with RA. In this regard, it is 
interesting that Bokarewa et al. reported that in RA patients, synovial fluid leptin levels were 
lower than serum levels and because synovial fluid leptin levels were lower in non-erosive 
disease, they suggested that consumption of intra-articular leptin may be protective against 
the destructive process in RA (Bokarewa et al. 2003). Seven et al. also detected lower 
synovial fluid leptin levels compared to serum levels in both RA patients and controls (Seven 
et al. 2009). On the other hand, two studies in OA patients showed higher synovial fluid 
leptin levels compared to serum levels (Presle et al. 2006; Simopoulou et al. 2007). In 
addition to total leptin concentration, other local parameters must also be taken into account 
such as the ratio of free and bound leptin in the synovium, as the binding of leptin to 
macromolecules in synovial fluid may affect its bioavailability and bioactivity (Sinha et al. 
1996). Furthermore, the soluble leptin receptor isoform, ObRe, may bind leptin and hereby 
function as a decoy receptor and the level of ObRe in the synovial fluid would determine 
leptin bioavailability. In this regard, Presle et al. have shown that the level of this receptor is 
lower in synovial fluid from female OA patients compared to its level in matched serum 
samples (Presle et al. 2006). Thus, a scenario may exist in the RA synovium where a decrease 
in soluble ObRe and a concomitant increase in the production of leptin by hypoxic RA FLS 
lead to a large pool of available and bioactive leptin in the synovium. 
Leptin has been implicated in cardiovascular disease and leptin produced in the 
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synovium could potentially contribute to the increased cardiovascular co-morbidity reported 
in RA patients. Leptin receptors are widely expressed on ECs (Bouloumie et al. 1998; Sierra-
Honigmann et al. 1998), and other arterial wall-subpopulations and in atherosclerotic lesions 
(Kang et al. 2000; Parhami et al. 2001). Several clinical surveys demonstrate that 
hyperleptinemia predicts acute cardiovascular events including restenosis after coronary 
injury such as angioplasty and cerebral stroke (Soderberg et al. 1999a; Wallace et al. 2001; 
Piatti et al. 2003). These findings can be explained by the ability of leptin to promote 
atherogenesis. Leptin has been shown to induce oxidative stress in ECs possibly via its ability 
to upregulate inducible NO synthase generating NO that impair EC function (Bouloumie et 
al. 1999; Naseem 2005). Furthermore, leptin can increase NADPH oxidase expression and 
activity in murine cardiomyocytes (Dong et al. 2006). Leptin can also stimulate VSMC 
proliferation and migration leading to vascular smooth muscle hypertrophy and prolonged 
treatment with leptin has been shown to increase vascular cell calcification (Parhami et al. 
2001; Li et al. 2005a).  
Contrasting data from animal studies indicate that leptin may both induce and protect 
against atherogenesis however. For instance leptin-deficient hyperlipidemic mice (ob/ob; 
apolipoprotein E [apoE ]-/- mice) develop significantly less atherosclerosis than apoE-/- mice 
on a high fat diet and administration of leptin significantly increases the atherosclerotic 
plaques in apoE -/- mice indicating that leptin can accelerate atherosclerosis (Chiba et al. 
2008). Moreover, leptin-deficient and leptin receptor-deficient mice seem protected from 
arterial thrombosis or neointimal hyperplasia induced by arterial injury (Beltowski 2006). In 
contrast, studies carried out in low-density lipoprotein-receptor knock-out mice lacking leptin 
(ob/ob; LDLR-/-) develop more atherosclerosis than in LDLR-/- control mice. Data from 
clinical surveys are likewise controversial in regard to the role of leptin in cardiovascular 
disease. For example, the relationship between serum leptin and intima-media thickness of the 
common carotid artery (a measure of preclinical atherosclerosis) show contrasting results in 
various studies. However, this may just depend on the pathopysiological context of the 
patients studied and the complex regulation of leptin. In addition to atherogenesis, 
hyperleptinemia has also been implicated in both thrombus formation in obese people and 
hypertension. Data surveying the effect of leptin on thrombosis suggests that leptin may 
contribute to platelet hyperactivity and a pathological shift in coagulation-fibrinolysis 
(Soderberg et al. 1999b). In summary, although the existing studies on leptin and its 
involvement with the cardiovascular system seem circumstantial and sometimes 
contradictory, therapeutic intervention targeting the leptin system and its production in 
hypoxic joints may potentially reduce cardiovascular complications in RA patients in addition 
to reducing any pathological intra-articular effects leptin may have. 
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Besides leptin the expression of another adipokine, ANGPTL-4, was also greatly 
induced by hypoxia in RA FLS on the PCR arrays (described in Chapter 5). To date more 
than 50 adipokines have been identified and include conventional cytokines such as IL-1β, 
TNFα or IL-6, and chemokines such as MCP-1, and proteins involved in glucose homeostasis 
such as adiponectin and resistin. The nomenclature adipokine derives from early findings that 
some of the factors were primarily produced and secreted by adipose tissue and had structural 
similarity to cytokines. It is not entirely surprising that the RA FLS can secrete several 
inflammation-related adipokines as fibroblasts derive from the same mesenchymal stem cell 
progenitor as do adipocytes. In fact, much can be learned about the regulation and action of 
leptin from studies in adipocytes and adipose tissue, which is characterised by a state of 
inflammation and hypoxia with concomitant angiogenesis much like that observed in the RA 
synovium (reviewed in (Hausman and Richardson 2004). Dysregulation of the expression and 
secretion of both ANGPTL-4 and leptin has been shown in hypoxic adipocytes using Q-PCR. 
For comparison, in two studies leptin transcript increased 29-fold and 21-fold in adipocytes 
subjected to 24 hours of 1% oxygen which were the same conditions used in my study (Wang 
et al. 2007a; Wang et al. 2008b). This is much lower than the 108-fold observed in RA FLS 
in the present study, but this could be due to adipocytes having a higher basal expression of 
leptin. Nevertheless, it emphasises the dramatic change in leptin production by hypoxic RA 
FLS from very low and often undetectable basal levels. ANGPTL-4 was upregulated 11-fold 
in adipocytes (Wang et al. 2008b) which is similar to that observed in RA FLS in the present 
study (12-fold). In addition to the adipokines ANGPTL-4 and leptin, adipocytes and RA FLS 
seem to share other components of their hypoxic and angiogenic profiles such as upregulation 
of VEGF and downregulation of both HIF-1α and HIF-2α (Wang et al. 2008b). 
The current study revealed that although there are great inter-individual differences in 
the angiogenic profiles of isolated FLS, they have in common a specific angiogenic gene 
expression signature when exposed to hypoxia which appears to be mainly HIF-driven. This 
shared group of angiogenic factors could represent the common players in pathological 
angiogenesis in the hypoxic synovium across patients and either of them or their immediate 
upstream mediators may represent potential therapeutic targets. The identification of common 
changes in hypoxic RA FLS from various patients provides the opportunity to design highly 
specific therapeutic applications with good efficacy across a wide range of RA patients 
irrespective of their otherwise heterogenic gene profiles. Moreover, different expression 
levels of the angiogenic factors highlighted by the present study could be linked to patient 
responsiveness to currently applied therapies, for instance the anti-TNFα treatment, 
infliximab. Pathological angiogenesis is likely to be targeted by current anti-TNFα treatments 
and contribute to alleviation of symptoms in treated patients given that TNFα induces HIF-1α 
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mRNA, protein accumulation, activity and VEGF as presented in this report. A large scale 
gene expression profile study specifically focusing on angiogenic mediators in RA would 
help uncover angiogenic expression profiles of responders versus non-responders to applied 
treatment and will allow in the future the development of novel and individual tailored 
therapies targeting angiogenesis to complement existing approaches, such as cytokine 
inhibitors, for treatment of RA. 
7.1 FUTURE WORK 
7.1.1 Knock-down of aHIF using siRNA 
Final evidence that aHIF is indeed responsible for the downregulation of HIF-1α has 
not yet been provided. Evidence for the role of aHIF in negatively regulating the HIF-1α 
mRNA level in hypoxia may be provided using siRNA technology to transiently knock-down 
aHIF which should result in the abrogation of hypoxia-mediated downregulation of HIF-
1α mRNA and protein in prolonged hypoxia if aHIF is responsible. The siRNA 
oligonucleotide has been designed such that it hybridises to the unique upstream 5’sequence 
in aHIF which is non-complementary to the HIF-1α 3’UTR. The effect of transfecting RA 
FLS with the siRNA against aHIF on HIF-1α mRNA and protein and on the transcription of 
GLUT-1 (as it is a HIF-1 specific target gene in RA FLS) will be monitored using Q-PCR, 
WB, and ELISA. This work is in progress. 
7.1.2 Analysis of the HIF-dependence of hypoxia-regulated genes 
My results presented in this thesis have described the dependence of VEGF and 
ANGPTL-4 on HIF-1, and of leptin on HIF-2. However, many other genes, proteins, and 
thereby phenotypic changes are regulated by hypoxia in RA FLS, including cell proliferation 
and apoptosis, which may involve some of the genes highlighted on the PCR array. A key 
future aim would therefore be to understand the HIF isoform dependence of other hypoxia-
induced genes, using siRNA as described in this thesis. 
For example, HIF-1α and HIF-2α have been described as having distinct effects on 
tumour growth. In endothelial and breast cancer cells, hypoxia-responsive genes were shown 
to be HIF-1α-dependent, in contrast to renal carcinoma cells, where proliferation was shown 
to be HIF-2α-dependent (Sowter et al. 2003). Furthermore, Raval et al. have shown that in 
renal cancer cells, overexpression of HIF-2α promoted tumour growth, whereas HIF-1α 
overexpression inhibited tumour growth (Raval et al. 2005). It has thus become clear that in 
vivo predominance of HIF-2-mediated responses over HIF-1 would allow uncontrolled 
cellular proliferation, with serious consequences in diseases associated with hypoxia, such as 
RA. Little is known about the relative roles of HIF-1α versus HIF-2α in RA, specifically in 
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relation to cell apoptosis/survival and migration. HIF-1-mediated gene transcription would 
promote FLS apoptosis (by induction of genes such as BNIP-3), whereas HIF-2 might 
increase FLS proliferation and migration. It would be of interest to investigate the differential 
roles of HIF-1 versus HIF-2 in the context of FLS proliferation/apoptosis. 
A recent study by our group has demonstrated that FIH-1 selectively inhibits HIF-1 in 
renal cancer, without affecting HIF-2 (Khan et al. 2008). An important property of FIH-1 
which contrasts with that of the PHD is its ability to function even in severe hypoxia 
(Koivunen et al. 2004). Thus, when oxygen levels are low and PHD enzymes can no longer 
function (through lack of O2 substrate), FIH-1 is potentially still able to deactivate HIF-1 and 
hence inhibit HIF-1-induced gene transcription. Although hypoxia is a feature of RA 
(Sivakumar et al. 2008), it is possible that at 1-3% oxygen FIH-1 is still active, and thereby 
limits HIF-1-mediated events such as induction of pro-apoptotic functions. This could also be 
addressed using siRNA. 
7.1.3 Investigation of the angiogenic potential of leptin 
Most importantly the angiogenic potential of leptin secreted by hypoxic RA FLS 
needs to be investigated in vitro and this work is already in progress. Leptin has previously 
been shown to be angiogenic in a growth factor reduced matrigel assay in a preliminary 
collaborative study (with Dr. Elena Garonna, Royal Veterinary College, London; Figure 7.1), 
which is the in vitro assay chosen for measuring the angiogenic potential of leptin in the 
hypoxic supernatants. Recombinant human leptin will be used as a positive control. The 
supernatants from hypoxia and DMOG-stimulated RA FLS have been tested in the matrigel 
assay and were seen to exert pro-angiogenic activity (Figure 7.2), but these findings need to 
be confirmed using a larger population of patient samples. 
The next step would be to inhibit leptin and determine whether there is a reduction in 
the observed HUVEC branch formation induced by the RA FLS supernatants. Several 
inhibitors of leptin are available to be tested, including antibodies against leptin, antibodies 
against ObRb leptin receptor and siRNA oligonucleotides against leptin. It is likely that it will 
be necessary to inhibit RA FLS produced VEGF too in order to see an effect of leptin 
inhibition as VEGF is such a potent angiogenic factor. As shown in the present study, hypoxic 
RA FLS secrete more than twice as much VEGF as normoxic FLS (Figure 3.3). In addition, 
leptin may also have indirect effects on angiogenesis by upregulating VEGF secretion by 
HUVECs so that in order to be able to distinguish between direct and indirect angiogenic 
effects of leptin, inhibition of VEGF is necessary in parallel. 
However, before employing these inhibitors in the matrigel assay their ability to 
inhibit leptin-mediated phosphorylation of STAT3 should obviously be tested. I have already 
shown that HUVECs express both ObRb and ObRa and that STAT3 is phosphorylated in 
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response to leptin (Figure 7.3). The hypoxic supernatants would be incubated with antibodies 
against leptin prior to being added to the wells with plated HUVECs, or in the case of the 
ObRb inhibitors, HUVECs in the 96-well plate will be pre-incubated with the antibodies to 
block ObRb expressed by the HUVECs prior to the addition of the supernatants. Knock-down 
of leptin will be done with siRNA oligonucleotides and then cells will be stimulated overnight 
in hypoxia prior to assaying the supernatants. Some of these studies are ongoing. 
 
CHAPTER 7  General discussion 
 200
Figure  7.1 PRELIMINARY DATA: Leptin and VEGF induce HUVEC branch formation 
in a matrigel assay 
HUVECs were left to settle on a growth factor reduced matrigel in a 96-well plate. (a) Serum-free 
medium, (b) leptin 100ng/mL or (c) VEGF 25ng/mL was added to the wells. Cells were fixed, stained 
with crystal violet solution and the number of branches formed by the HUVECs was counted using a 
Nikon light microscope. 
 
 
 
 
 
 
 
Figure  7.2 PRELIMINARY DATA: Supernatants from hypoxia and DMOG-stimulated 
FLS are angiogenic in vitro 
HUVECs were left to settle on a growth factor-reduced matrigel in a 96-well plate. Supernatants from 
RA FLS incubated in 21%, 1% oxygen (a) or with 0-1mM DMOG (b) for 24 hours were added to the 
wells. Cells were fixed, stained with crystal violet solution and the number of branches formed by the 
HUVECs were counted. The graphs represent one experiment with mean ± SEM of duplicate wells. 
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Figure  7.3 PRELIMINARY DATA: Leptin stimulates phosphorylation of STAT3 via 
ObRb in HUVECs 
HUVECs were incubated with or without leptin 100ng/mL for 30 minutes and total protein lysates 
were assayed by WB for leptin receptors and phosphorylated STAT3. An antibody against total STAT3 
was used as a loading control.  
 
 
 
 
 
 
 
 
 
7.1.4 Autocrine effects of leptin on human RA FLS 
Having detected the expression of the long signalling leptin receptor form ObRb in 
RA FLS (Figure 6.11 and 6.12), the next step would be to try and uncover what autocrine 
effects leptin might have on the RA FLS. The work on IL-6 and IL-8 secretion in response to 
leptin need repeating by ELISA. The ability of leptin to stimulate proliferation and cell 
survival of RA FLS will be further tested with the MTT assay and the more sensitive 3H-
thymidine incorporation assay. Furthermore, Q-PCR and FACS (fluorescence-activated cell 
sorter) analysis will be used to determine the up- or downregulation of apoptotic and anti-
apoptotic factors in response to leptin.  
As leptin has been reported to have various effects on the immunesystem, Human 
Autoimmunity and Inflammation RT2 ProfilerTM PCR Arrays will be employed to screen for 
genes involved in automimmunity and inflammation which may change expression in RA 
FLS in response to leptin. An initial PCR array screen gave rise to some interesting findings. 
First of all, leptin appeared to induce expression of several components of the eotaxin/eotaxin 
receptor system. This system is best known for its involvement in asthma where it induces 
recruitment of eosinophils, neutrophils, basophils and macrophages (Menzies-Gow et al. 
2002). Other chemokine ligands were also induced by leptin, which was in contrast to that 
observed when RA FLS were stimulated with hypoxia. Hypoxia seemed to have an overall 
negative effect on chemokine ligand expression (for genes see Table 5.3). Interestingly, IL-8 
and its receptor appear to be upregulated by leptin on the PCR array, which was in contrast to 
what I observed at the protein level when performing an ELISA on the supernatants of leptin 
stimulated FLS. In addition to these findings, two toll-like receptors (TLR), TLR3 and TLR5, 
were also upregulated by leptin suggesting that leptin can activate components of the innate 
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immune response in RA FLS. RA FLS from an additional four additional patients will be 
screened on the PCR arrays to further investigate these findings. 
7.2 CONCLUSION 
The present work describes the regulation of HIF isoforms HIF-1α and HIF-2α by 
hypoxia and inflammatory cytokines (TNFα, IL-1β and TGFβ) in RA FLS. From the study it 
emerges that HIF-1α is regulated through an auto-negative feedback loop by its natural 
antisense aHIF induced by HIF-1 in hypoxia, as well as by inflammatory cytokines which are 
well documented to play key roles in RA pathogenesis. In contrast, cytokines appear to 
oppose the effect of hypoxia by upregulating HIF-1α mRNA. Nevertheless, HIF-1α protein 
and activity was upregulated by both stimuli. HIF-2α mRNA was negatively regulated by 
both hypoxia and cytokines indicating that other presently unknown negative regulatory 
mechanisms exist to control the level of HIF-2 in RA. These findings suggest that the HIF-1 
transcription factor represents a key convergence point in RA for hypoxia and cytokines. 
Using PCR arrays to obtain the angiogenic expression profile of hypoxic RA FLS, the 
present study has identified two inflammation-related adipokines, leptin and ANGPTL-4, as 
highly hypoxia-inducible genes in RA. Further analyses of their regulation revealed that both 
factors are regulated in a HIF-dependent manner with ANGPTL-4 primarily regulated by 
HIF-1 whereas HIF-2 appeared to be more important in the regulation of leptin. RA FLS were 
shown to express the long signalling form of the leptin receptor and to proliferate in response 
to leptin indicating that local effects of leptin in the hypoxic joint may contribute to synovial 
hyperplasia, inflammation and angiogenesis in an autocrine and paracrine fashion. Leptin has 
been shown to have both immuno-modulatory and cardiovascular effects in addition to its 
angiogenic effects. As circulating leptin levels are increased in RA, and correlate with disease 
activity in a number of studies the current findings indicate that hypoxia-driven intra-articular 
leptin production may exert systemic effects on the immune system and contribute to 
increased cardiovascular co-morbidity in RA. 
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